

# Curriculum Vitae

Place: Rome  
Date: 08 June 2021

## Part II – Education

Type	Year	Institution	Notes
University graduation	1990	Sapienza University of Rome	Graduated cum laude in Medicine and Surgery
Licensure	1990	Sapienza University of Rome	Medical License to practice in Italy-European Union: n. 42674
Specialty	1994	Sapienza University of Rome	Medical Oncology (score 70/70)
PhD	2001	University of Palermo	Immunopharmacology

## Part III – Appointments

### III A – Academic Appointments

Start	End	Institution	Position
2017	Today	Campus Bio-Medico University of Rome	Full Professor in Medical Oncology
2017	Today	Temple University's College of Science and Technology, Philadelphia (USA)	Adjunct Full Professor in Molecular Biology
2013	Today	Campus Bio-Medico University of Rome	Member of Scientific Board of PhD Program "Integrated Biomedical Sciences and Bioethics"
2011	Today	Campus Bio-Medico University of Rome	Vice-director of Residency School in Medical Oncology
2010	Today	Campus Bio-Medico University of Rome	Coordinator of the Integrated Course of Basic, Clinical Oncology and Psychology, Medical Radiology and Radiotherapy Technique Degree
2007	Today	Campus Bio-Medico University of Rome	Co-chair of Oncology Research Unit
2018	2020	Campus Bio-Medico University of Rome	President of Medicine and Surgery Degree Course
2016	2018	Campus Bio-Medico University of Rome	Study Coordinator of Medicine and Surgery Degree Course
2010	2018	Campus Bio-Medico University of Rome	Coordinator of the Integrated Course Genetic and General Pathology, Food Science and Human Nutrition
2015	2017	Temple University's College of Science and Technology, Philadelphia (USA)	Adjunct Associate Professor
2010	2016	Campus Bio-Medico University of Rome	Associate Professor in General Pathology
2007	2012	Campus Bio-Medico University of Rome	Member of Scientific Board of PhD Program "Osteo-Oncology Pathology"

### IIIB – Other Appointments

Start	End	Institution	Position
2009	Today	Campus Bio-Medico University-Hospital of Rome	Chief of Medical Oncology Day Hospital (UOS)
2006	2009	Department of Medical Oncology, Campus Bio-Medico University of Rome	In charge of high specialization professional activities

### Part IV – Teaching experience

Year	Institution	Lecture/Course
2018-Today	Campus Bio-Medico University of Rome	Integrated therapies in Oncology (Medicine and Surgery Degree)
2017-Today	Campus Bio-Medico University of Rome	Medical Oncology (Anatomical Pathology Residency, Geriatrics Residency, Medical Oncology Residency and Radiation Oncology Residency)
2010-Today	Campus Bio-Medico University of Rome	Basic and Clinical Oncology (Bachelor's Degree in Medical Radiology and Radiotherapy Technique)
2009-Today	Campus Bio-Medico University of Rome	Immunology (Medicine and Surgery Degree)
2017-2018	Campus Bio-Medico University of Rome	Medical Oncology (Allergology and Clinical Immunology Residency and Disease of Digestive System Residency)
2016-2018	Campus Bio-Medico University of Rome	General Pathology (Clinical Pathology Residency and Clinical Biochemistry Residency)
2010-2018	Campus Bio-Medico University of Rome	General Pathology (Bachelor's Degree in Food Science and Human Nutrition)
2014-2017	Campus Bio-Medico University of Rome	Clinical Pathology (Endocrinology and Metabolic Disease Residency)
2013-2017	Campus Bio-Medico University of Rome	General Pathology (Anatomical Pathology Residency and Radiation Oncology Residency)
2012-2017	Campus Bio-Medico University of Rome	General Pathology (Disease of Cardiovascular System Residency, Surgery of Digestive System)
2007-2017	Campus Bio-Medico University of Rome	General Pathology (Radiation Oncology Residency and Clinical Pathology Residency)
2015-2016	Campus Bio-Medico University of Rome	General Pathology (Disease of Digestive System Residency)
2014-2016	Campus Bio-Medico University of Rome	General Pathology (Anesthesia, Intensive Care Residency)
2012-2016	Campus Bio-Medico University of Rome	Clinical Pathology (Microbiology and Virology Residency)
2012-2015	Campus Bio-Medico University of Rome	General Pathology (Allergology and Clinical Immunology Residency)
2011-2015	Campus Bio-Medico University of Rome	General Pathology (Bachelor's Degree in Nursing)
2012-2014	Campus Bio-Medico University of Rome	General Pathology (Infectious Disease Residency,

	of Rome	Neurology Residency, Internal Medicine Residency, General Surgery Residency, Plastic Aesthetic and Reconstructive Surgery Residency, Urology Residency and Geriatrics Residency)
2012-2014	Campus Bio-Medico University of Rome	Clinical Pathology (Gastroenterology Residency)
2003-2013	Campus Bio-Medico University of Rome	General Pathology (General Surgery Residency)
2009-2012	Campus Bio-Medico University of Rome	General Pathology (Bachelor's Degree Medical Radiology and Radiotherapy Technique)
2011-2012	Campus Bio-Medico University of Rome	General Pathology and Pathophysiology (Medicine and Surgery Degree)
2005-2012	Campus Bio-Medico University of Rome	Didactic and integrated activities in Oncology (Bachelor's Degree in Nursing)
2005-2009	Campus Bio-Medico University of Rome	Integrated therapies in Oncology (Medicine and Surgery Degree)
2006-2008	Campus Bio-Medico University of Rome	General Immunology and Oncogenesis (Microbiology and Virology Residency)
2003-2008	Campus Bio-Medico University of Rome	Tumor Immunology, Immunosurveillance and Methodology in Cancer Research (Medical Oncology Residency)
2002-2008	Campus Bio-Medico University of Rome	Immunology (Allergology Residency)
		Humoral and Cellular Immunity (Hematology Residency)
2002-2007	Campus Bio-Medico University of Rome	Immunology (Clinical Pathology Residency)
2003-2005	Campus Bio-Medico University of Rome	Immunology (Medicine and Surgery Degree)
2003-2004	Campus Bio-Medico University of Rome	General Pathology and Pathophysiology (Medicine and Surgery Degree)
2002-2004	Campus Bio-Medico University of Rome	Immunology (Microbiology and Virology Residency)
2002-2003	Campus Bio-Medico University of Rome	Integrated therapies in Oncology (Surgery of Digestive System Residency)

## Part V - Society memberships, Awards and Honors

Year	Title
2019	Award "Leone d'Argento di Venezia 2019" for Professional Career
2018	Special Award for Professional Career received in the "Gran Premio Internazionale di Venezia
2021-Today	National Advisor, Italian Network For Research In Urologic-Oncology (Meet-URO)
2020-Today	National Advisor, Network Italiano Cure di Supporto in Oncologia (NICSO)
2014-Today	National Advisor, South Italy Oncology Group (GOIM)
2014-Today	National Advisor, North West Oncology Group (GONO)
2015-2017	National President of Italian Society of Osteoncology (ISO)
2011-2016	Regional Advisor, Italian Association of Medical Oncology (AIOM)

**Part VI - Funding Information [grants as PI-principal investigator or I-investigator]**

Year	Title	Program	Grant value
2019	PI of the project “Biological effects of cyclin-dependent kinase drugs ribociclib, palbociclib and abemaciclib on breast cancer bone microenvironment”	NOVARTIS	60.000 EUR
2018	PI of the project “SELF-ON-A-CHIP”	Bando Interno dell’Università Campus Bio-Medico per progetti di ricerca utili a favorire la formazione di profili interdisciplinari in collaborazione tra l’Istituto FAST e le unità di ricerca dell’Ateneo sul tema dell’embodiment	15.000 EUR
2017	PI of the project “Biological effect of cabozantinib on tumor bone microenvironment”	IPSEN S.P.A	120.000 EUR
2016	PI of the project “Biological effects of lenvatinib on tumour bone microenvironment”	EISAI	60.000 EUR
2015	PI of the project “In vitro study on the impact of abiraterone treatment on bone microenvironment”	JANSSEN-CILAG SpA	45.000 EUR
2014	PI of the project “Understanding the interplay between cancer stem cells and immune system: an innovative cells-on-chip approach”	Bilateral project Italia-USA MAE (Ministero Affari Esteri)	24.000 EUR
2013	PI of the project “Cell-on-chip models for the development of integrated therapies of immunotherapy with the aim to overcome the resistance to conventional treatments in non-small cell lung cancer: the role of interaction between cancer stem cells and macrophage polarization”	Fondazione G. Berlucci for Cancer Research	60.000 EUR
2005	Research Unit PI of the project “ Modulation of Human Gamma/Delta T Lymphocytes and analysis of different biological parameters (Inflammatory cytokines, cytokines related to the immune response, pro-angiogenic factors, bone	PRIN 2005	36.000 EUR

resorption markers) after zoledronic acid administration in patients with solid tumors”
---

## Part VII – Editorial Activity

Year	Title
2016-Today	Associate Editor of "ESMO Open"
2013-Today	Editor in chief of "Expert Opinion on Therapeutic Targets"
2013-Today	Editorial Board member of "Clinical medicine insights: oncology"
2008-Today	Editorial Board member of "Expert Opinion on Biological Therapy" e "Expert Opinion on Emerging Drugs"
2014-2020	Academic Editor of "PLOS ONE"
2014-2017	Editorial Board member of "Oncotarget"
2013-2017	Editorial Board member of "Critical Review in Oncology and Haematology"
2010-2014	Editorial Board member of "Journal of Experimental and Clinical Cancer Research"
2008-2014	Editorial Board member of "Pharmacogenomics", "Recent Patents on Anti-Cancer Drug Discovery", "World Journal Clinical Oncology" e "Onco Targets and Therapy"

## Part VIII – Additional Information

Year	Title
2021-Today	Coordinator of the Oncological Commission of the General Medical Council of Rome
2020-Today	ESMO (European Society of Medical Oncology) Clinical Practice Guidelines “subject editor” for the palliative care
2020-Today	Inventor of patent: “Statistical Methods to identify genomic regions with highly tumor mutation burden” (Publication Number WO/2020/201864; International Application No. PCT/IB2020/052314)
2020-Today	Member of the Ethical Committee at Campus Bio-Medico University of Rome
2018-Today	Coordinator of Guidelines on “Orphan symptoms” for the European Society of Medical Oncology (ESMO)
2018-Today	Co-author of Guidelines “Bone Health” for the European Society of Medical Oncology (ESMO)
2018-Today	Co-author of Guidelines “Skin toxicity” for the European Society of Medical Oncology (ESMO)
2018-Today	Member of the “Genitourinary Faculty (GU)” for the European Society of Medical Oncology (ESMO) Guidelines
2016-Today	Coordinator of the multicentric study: “Impact of cabazitaxel on metastatic bone health in patients with castration resistant prostate cancer previously treated with docetaxel: CaBone Study”
2010-Today	Principal investigator of 34 Clinical Trials on solid tumors including prostate, breast, renal, lung, gastric, bladder, urothelial and colorectal cancer at Campus Bio-Medico University
2008-Today	Coordinator of the National Guidelines on “Bone metastases treatment” for the Italian Association of Medical Oncology (AIOM)
2018 & 2021	Eligibility as “Commissario per la valutazione ASN (Abilitazione Scientifica Nazionale) Hematology, Oncology and Rheumatology - MED 06/D3

2016-2019	Member of the Ethical Committee at National Institute Tumori Regina Elena of Rome
2012- 2015	“Participating scientist” for international “Halifax Project”
2012	Co-author of Guidelines on Management of cancer pain for the European Society of Medical Oncology (ESMO)
2010	Coordinator of the National Guidelines on “Lung Bone metastases treatment” for the Italian Association of Toracic Oncology (AIOT)
2010	Co-author of the National Guidelines on “Prostate bone metastases treatment” for the Italian Society of Urology (SIU)

## Part IX – Research Activities

### Keywords

Translational Oncology
Genitourinary cancer
Osteo-Oncology
Cancer Immunology
Gastro-intestinal cancer

### Brief Description

I am actively involved in clinical and translational research with a particular focus on osteo-oncology and cancer immunology. As scientific Director of Translational Oncology Laboratory at Campus Bio-Medico University of Rome, I coordinated several research projects focused on the crosstalk between cancer cell/bone microenvironment and interactions of cancer stem cells/immune cells obtaining several national and international awards. The principal research topic investigated in our laboratory is the identification of new circulating biomarkers predictive of response to immunotherapies in metastatic solid tumors. Moreover, in the last ten years my research activity is devoted to the evaluation of anticancer drug effects on the bone microenvironment and the identification of novel prognostic and predictive targets for the treatment of solid tumors with special focus on prostate, renal and breast cancers. Finally, I am coordinating several clinical and translational studies focused on colorectal cancer and urothelial cancer.

## Part X – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	591	Scopus	1990	2021
Books [scientific]	12	Scopus	2010	2018

Total Impact factor	8534,4
Impact factor last 10 years	2202,9
Mean Impact factor	14,4
Total Citations (Scopus)	16262
Average Citations per Product	28
Hirsch (H) index (Scopus)	58
Normalized H index*	1,9

\*H index divided by the academic seniority.

## Part XI– Selected Publications

1. Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fernández-Peñas P, Santini D, Jahn F, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆. *Ann Oncol* (**IF 18,274**). 2021 Feb;32(2):157-170. doi: 10.1016/j.annonc.2020.11.005. Epub 2020 Nov 25. PMID: 33248228. **Cit. 2**
2. Citarella F, Russano M, Perrone G, Vincenzi B, Tonini G, Santini D. Response to: Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations. *Thorac Cancer* (**IF 2,61**) 2021 May 11. doi: 10.1111/1759-7714.13997. Epub ahead of print. PMID: 33977646. **Cit. 0**
3. Stellato M, Santini D. ImmuneOncology-tyrosine kinase inhibitors combination, sometimes less is more. *Int Immunopharmacol* (**IF 3,943**) 2021 Apr 29:107673. doi: 10.1016/j.intimp.2021.107673. Epub ahead of print. PMID: 33935023. **Cit. 0**
4. Roberto M, Botticelli A, Panebianco M, Aschelter AM, Gelibter A, Ciccarese C, Minelli M, Nuti M, Santini D, Laghi A, Tomao S, Marchetti P. Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. *Front Oncol.* (**IF 4,25**) 2021 Apr 22;11:657639. doi: 10.3389/fonc.2021.657639. PMID: 33968762; PMCID: PMC8100507. **Cit. 0**
5. Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. *J Immunother Cancer* (**IF 10,252**). 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421. PMID: 33827906; PMCID: PMC8031700. **Cit. 1**
6. Krasniqi E, Pizzuti L, Valerio MR, Capomolla E, Botti C, Sanguineti G, Marchetti P, Anselmi E, Tomao S, Giordano A, Ficorella C, Cannita K, Livi L, Meattini I, Mauri M, Greco F, Veltri EM, Michelotti A, Moschetti L, Giotta F, Lorusso V, Paris I, Tomao F, Santini D, Tonini G, Villa A, Gebbia V, Gamucci T, Ciliberto G, Sperduti I, Mazzotta M, Barba M, Vici P. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. *Int J Med Sci* (**IF 2,399**) 2021 Mar 27;18(10):2245-2250. doi: 10.7150/ijms.54996. PMID: 33859534; PMCID: PMC8040412. **Cit. 0**
7. Santini D, Stellato M, De Giorgi U, Pantano F, De Lisi D, Casadei C, Maruzzo M, Bimbatti D, Naglieri E, Buti S, Bersanelli M, De Vivo R, Di Lorenzo G, Sbrana A, Verzoni E, Soraru' M, Fornarini G, Mucciarini C, Grillone F, Mini E, Vignani F, Attademo L, Pignata S, Procopio G. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). *Am J Clin Oncol* (**IF 3,062**). 2021 Mar 1;44(3):121-125. doi:10.1097/COC.0000000000000791. PMID:33617179. **Cit. 0**
8. Fassan M, Milione M, Maddalena G, Cremolini C, Schirripa M, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Bergamo F, Volante M, Boccaccino A, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calveti L, Aprile G, Salvatore L, Santini D, Salmaso R, Centonze G, Biason P, Borgia C, Lonardi S, Zagonel V, Dei Tos AP, Di Maio M, Loupakis F. Synaptophysin expression in <sup>V600E</sup>BRAF- mutated advanced colorectal cancers identifies a new subgroup of tumours

with worse prognosis. *Eur J Cancer* (**IF 7,275**). 2021 Mar;146:145-154. doi: 10.1016/j.ejca.2021.01.016. Epub 2021 Feb 16. PMID: 33607478. **Cit. 0**

9. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordo T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med* (**IF 74,699**) 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. PMID: 33616314. **Cit. 16**
10. Mallio CA, Napolitano A, Castiello G, Giordano FM, D'Alessio P, Iozzino M, Sun Y, Angeletti S, Russano M, Santini D, Tonini G, Zobel BB, Vincenzi B, Quattrocchi CC. Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis. *Cancers (Basel)* (**IF 6,126**) 2021 Feb 6;13(4):652. doi: 10.3390/cancers13040652. PMID: 33562011; PMCID: PMC7914551. **Cit. 3**
11. Rovesti G, Leone F, Brandi G, Fornaro L, Scartozzi M, Niger M, Yoo C, Caputo F, Filippi R, Casagrande M, Silvestris N, Santini D, Faloppi L, Palloni A, Aglietta M, Vivaldi C, Cho H, Lai E, Fenocchio E, Nichetti F, Pella N, De Lorenzo S, Di Maio M, Vasile E, de Braud F, Jeong JH, Aprile G, Orsi G, Cascinu S, Casadei-Gardini A. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. *J Gastrointest Cancer* (**IF 1,01**) 2021 Feb 5. doi: 10.1007/s12029-021-00596-z. Epub ahead of print. PMID: 33544375. **Cit. 0**
12. Pantano F, Croset M, Driouch K, Bednarz-Knoll N, Iuliani M, Ribelli G, Bonnelye E, Wikman H, Geraci S, Bonin F, Simonetti S, Vincenzi B, Hong SS, Sousa S, Pantel K, Tonini G, Santini D, Clézardin P. Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. *Oncogene* (**IF 7,971**) 2021 Feb;40(7):1284-1299. doi: 10.1038/s41388-020-01603-6. Epub 2021 Jan 8. PMID: 33420367; PMCID: PMC7892344. **Cit. 1**
13. Rossi E, Aieta M, Tartarone A, Pezzuto A, Facchinetti A, Santini D, Ulivi P, Ludovini V, Possidente L, Fiduccia P, Minicuci N, Zamarchi R. A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. *Transl Lung Cancer Res* (**IF 5,132**) 2021 Jan;10(1):80-92. doi: 10.21037/tlcr-20-855. PMID: 33569295; PMCID: PMC7867748. **Cit. 0**
14. Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini A. Effect of concomitant medications with immunomodulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. *Eur J Cancer* (**IF 7,275**). 2021 Jan;142:18-28. doi: 10.1016/j.ejca.2020.09.033. Epub 2020 Nov 16. PMID: 33212418. **Cit. 5**
15. Citarella F, Russano M, Galletti A, Vincenzi B, Tonini G, Santini D. Novel drugs, familiar interactions: ciprofloxacin may increase exposure to the RET inhibitor pralsetinib. *Ann Oncol* (**IF 18,274**) 2021 Jun;32(6):811-813. doi: 10.1016/j.annonc.2021.02.023. Epub 2021 Mar 15. PMID: 33737118. **Cit. 0**
16. Borelli B, Fontana E, Giordano M, Antoniotti C, Lonardi S, Bergamo F, Pietrantonio F, Morano F, Tamburini E, Boccaccino A, Santini D, Zucchelli G, Pella N, Maiello E, Passardi A, Zaniboni A,



- Ugolini C, Fontanini G, Falcone A, Nyamundanda G, Sadanandam A, Cremolini C. Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. *ESMO Open* (**IF 5,329**) 2021 Apr;6(2):100073. doi: 10.1016/j.esmoop.2021.100073. Epub 2021 Mar 3. PMID: 33676295; PMCID: PMC8103536. **Cit. 0**
17. Santini D, Cinieri S, Gasparro D, Bordonaro R, Guglielmini PF, Chiuri VE, D'Angelillo RM, Ceresoli GL, Fagnani D, Acquati M, Mencoboni M, Lanzetta G, Sartori D, Carlini P, Panebianco F, Beccaglia P, Procopio G. Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE. *J Bone Oncol* (**IF 3,066**) Oncol. 2020 Dec 2;26:100341. doi: 10.1016/j.jbo.2020.100341. PMID: 33425672; PMCID: PMC7779770. **Cit. 0**
  18. Ratta R, Verzoni E, Mennitto A, Pantano F, Martinetti A, Raimondi A, Sepe P, Sottotetti E, Mennitto R, Morelli D, Santini D, de Braud FG, Procopio G. Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. *Tumori* (**IF 1,707**). 2020 Nov 5:300891620969817. doi: 10.1177/0300891620969817. Epub ahead of print. PMID: 33153416. **Cit. 0**
  19. Pantano F, Manca P, Armento G, Zeppola T, Onorato A, Iuliani M, Simonetti S, Vincenzi B, Santini D, Mercadante S, Marchetti P, Cuomo A, Caraceni A, Mediati RD, Vellucci R, Mammucari M, Natoli S, Lazzari M, Dauri M, Adile C, Airoidi M, Azzarello G, Blasi L, Chiurazzi B, Degiovanni D, Fusco F, Guardamagna V, Liguori S, Palermo L, Mameli S, Masedu F, Mazzei T, Melotti RM, Menardo V, Miotti D, Moroso S, Pascoletti G, De Santis S, Orsetti R, Papa A, Ricci S, Scelzi E, Sofia M, Aielli F, Valle A, Tonini G. Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. *JCO Precis Oncol* (**NO IF**). 2020 Nov 4;4:PO.20.00158. doi: 10.1200/PO.20.00158. PMID: 33283139; PMCID: PMC7713587. **Cit. 0**
  20. Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petraghani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierio PA. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. *J Immunother Cancer* (**IF 10,252**). 2020 Nov;8(2):e001361. doi: 10.1136/jitc-2020-001361. PMID: 33154150; PMCID: PMC7646355. **Cit. 4**
  21. Procopio G, Chiuri VE, Giordano M, Mantini G, Maisano R, Bordonaro R, Calvani N, Facchini G, De Placido S, Airoidi M, Sbrana A, Gasparro D, Ludovico GM, Guglielmini P, Naglieri E, Fagnani D, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D. Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABITUDE study. *Ther Adv Med Oncol* (**IF 2,304**). 2020 Oct 29;12:1758835920968725. doi: 10.1177/1758835920968725. PMID: 33193831; PMCID: PMC7604981. **Cit. 0**
  22. Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, Proto C, Marinello A, Randon G, Rossi S, Vita E, Sartori G, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, Ciccone LP, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. *Lung Cancer* (**IF 4,702**) 2020 Dec;150:123-131. doi: 10.1016/j.lungcan.2020.10.008. Epub 2020 Oct 22. PMID: 33130353. **Cit. 3**

23. Rossini D, Lonardi S, Antoniotti C, Santini D, Tomasello G, Ermacora P, Germani MM, Bergamo F, Ricci V, Caponnetto S, Moretto R, Zaniboni A, Pietrantonio F, Buonadonna A, Ritorto G, Masi G, Latiano TP, Rapisardi S, Falcone A, Cremolini C. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. *Br J Cancer* (**IF 5,791**). 2021 Jan;124(1):183-190. doi: 10.1038/s41416-020-01089-9. Epub 2020 Oct 7. PMID: 33024268; PMCID: PMC7782547. **Cit. 2**
24. Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, Bracarda S, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. *Target Oncol* (**IF 3,463**) 2020 Oct;15(5):691. doi: 10.1007/s11523-020-00746-6. Erratum for: *Target Oncol* 2020 Aug;15(4):495-501. PMID: 32857328. **Cit. 4**
25. Moretto R, Rossini D, Zucchelli G, Lonardi S, Bergamo F, Santini D, Cupini S, Tomasello G, Caponnetto S, Zaniboni A, Antoniotti C, Pietrantonio F, Buonadonna A, Marmorino F, Bordonaro R, Fea E, Tamburini E, Boccaccino A, Grande R, Aprile G, Falcone A, Cremolini C. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. *Eur J Cancer* (**IF 7,275**). 2020 Nov;139:81-89. doi: 10.1016/j.ejca.2020.08.009. Epub 2020 Sep 23. PMID: 32979645. **Cit. 0**
26. Citarella F, Russano M, Galletti A, Vincenzi B, Tonini G, Santini D. Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer. *Clin Lung Cancer* (**IF 4,2**). 2021 Mar;22(2):e137-e138. doi: 10.1016/j.clcc.2020.09.001. Epub 2020 Sep 18. PMID: 33028500. **Cit. 0**
27. Dell'Aquila E, Armento G, Iuliani M, Simonetti S, D'Onofrio L, Zeppola T, Madaudo C, Russano M, Citarella F, Ribelli G, Pantano F, Vincenzi B, Tonini G, Santini D. Denosumab for cancer-related bone loss. *Expert Opin Biol Ther* (**IF 3,974**). 2020 Nov;20(11):1261-1274. doi: 10.1080/14712598.2020.1814731. Epub 2020 Sep 9. PMID: 32835531. **Cit. 0**
28. Cursano MC, Kopf B, Scarpi E, Menna C, Casadei C, Schepisi G, Lolli C, Altavilla A, Gallà V, Santini D, Tonini G, Chovanec M, Mego M, De Giorgi U. Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy. *Front Oncol*. (**IF 4,25**) 2020 Aug 14;10:1325. doi: 10.3389/fonc.2020.01325. PMID: 32923384; PMCID: PMC7457022. **Cit. 0**
29. Citarella F, Galletti A, Russano M, Gallo P, Vespasiani-Gentilucci U, Picardi A, Tonini G, Vincenzi B, Santini D. Steroid-refractory immune related hepatitis may hide viral re-activation. *Future Sci OA* (**IF 3,25**) 2020 Aug 6;6(9):FSO614. doi: 10.2144/fsoa-2020-0056. PMID: 33235808; PMCID: PMC7668132. **Cit. 0**
30. Dell'Aquila E, Zeppola T, Stellato M, Pantano F, Scartozzi M, Madaudo C, Pietrantonio F, Cremolini C, Aprile G, Vincenzi B, Moretto R, Puzzone M, Garattini SK, Lobefaro R, Tonini G, Santini D. Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? *Clin Med Insights Oncol* (**IF 1,077**) 2020 Aug 4;14:1179554920946693. doi: 10.1177/1179554920946693. PMID: 32821190; PMCID: PMC7412900. **Cit. 1**
31. Stellato M, Guadalupi V, Sepe P, Mennitto A, Claps M, Zattarin E, Verzoni E, Valdagni R, De Braud FG, Santini D, Tonini G, Procopio G. The emerging role of PARP inhibitors in prostate cancer. *Expert Rev Anticancer Ther*. (**IF 3,573**) 2020 Aug;20(8):715-726. doi: 10.1080/14737140.2020.1797497. Epub 2020 Aug 6. PMID: 32758032. **Cit. 0**

32. Napolitano A, Mazzocca A, Spalato Ceruso M, Minelli A, Baldo F, Badalamenti G, Silletta M, Santini D, Tonini G, Incorvaia L, Vincenzi B. Recent Advances in Desmoid Tumor Therapy. *Cancers (Basel)* (**IF 6,126**) 2020 Aug 1;12(8):2135. doi: 10.3390/cancers12082135. PMID: 32752153; PMCID: PMC7463981. **Cit. 0**
33. Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, Bracarda S, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. *Target Oncol* (**IF 3,463**) 2020 Aug;15(4):495-501. doi: 10.1007/s11523-020-00732-y. Erratum in: *Target Oncol* 2020 Oct;15(5):691. PMID: 32671807. **Cit. 4**
34. Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. *BMJ Open* (**IF 2,496**). 2020 Jul 19;10(7):e034393. doi: 10.1136/bmjopen-2019-034393. PMID: 32690499; PMCID: PMC7371236. **Cit. 2**
35. Russano M, Citarella F, Napolitano A, Dell'Aquila E, Cortellini A, Pantano F, Vincenzi B, Tonini G, Santini D. COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. *Expert Opin Biol Ther* (**IF 3,974**). 2020 Sep;20(9):959-964. doi: 10.1080/14712598.2020.1789097. Epub 2020 Jul 2. PMID: 32588674; PMCID: PMC7441753. **Cit. 3**
36. Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, Pantano F, Dell'Aquila E, Anesi C, Silvestris N, Argentiero A, Solimando AG, Vincenzi B, Tonini G, Santini D. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. *J Exp Clin Cancer Res*. 2020 Jun 24;39(1):120. doi: 10.1186/s13046-020-01615-w. Erratum for: *J Exp Clin Cancer Res* (**IF 5,646**). 2020 May 27;39(1):95. PMID: 32580740; PMCID: PMC7313142. **Cit. 13**
37. Conteduca V, Caffo O, Scarpi E, Sepe P, Galli L, Fratino L, Maines F, Chiuri VE, Santoni M, Zanardi E, Massari F, Toma I, Lolli C, Schepisi G, Sbrana A, Kinspergher S, Cursano MC, Casadei C, Modonesi C, Santini D, Procopio G, De Giorgi U. Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. *J Clin Med* (**IF 1,883**) 2020 Jun 22;9(6):1950. doi: 10.3390/jcm9061950. PMID: 32580478; PMCID: PMC7356925. **Cit. 0**
38. Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Russano M, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Gwaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression  $\geq$  50% and Their Relationship With Clinical Outcomes. *Clin Lung Cancer* (**IF 4,2**) 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.clcc.2020.06.010. Epub 2020 Jun 21. PMID: 32680806. **Cit. 11**
39. Iuliani M, Simonetti S, Ribelli G, Napolitano A, Pantano F, Vincenzi B, Tonini G, Santini D. Current and Emerging Biomarkers Predicting Bone Metastasis Development. *Front Oncol*. (**IF 4,25**) 2020 Jun 3;10:789. doi: 10.3389/fonc.2020.00789. PMID: 32582538; PMCID: PMC7283490. **Cit. 1**

40. Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of  $\geq 50$ . *Cancer Immunol Immunother* (**IF 5,422**). 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May 30. PMID: 32474768. **Cit. 14**
41. Citarella F, Russano M, Pantano F, Dell'Aquila E, Vincenzi B, Tonini G, Santini D. Facing SARS-CoV-2 outbreak in immunotherapy era. *Future Oncol* (**IF 2,66**). 2020 Jul;16(20):1475-1485. doi: 10.2217/fo-2020-0340. Epub 2020 May 29. PMID: 32468851; PMCID: PMC7265683. **Cit. 4**
42. Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzutilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, Battelli N, Fagnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. *Eur J Cancer* (**IF 7,275**). 2020 Jul;134:19-28. doi: 10.1016/j.ejca.2020.04.025. Epub 2020 May 23. PMID: 32454395. **Cit. 10**
43. Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari MA, Salvatore L, Tortora G, Rossini D, Germani MM, Boccaccino A, Dell'Aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino PD, Lombardi P, Keränen SR, Álvaro MH, Zurlo IV, Corsi DC, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti MA, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache SD, Porzio G, Ficorella C. Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. *Cancers (Basel)* (**IF 6,126**) 2020 May 16;12(5):1259. doi: 10.3390/cancers12051259. PMID: 32429380; PMCID: PMC7281759. **Cit. 4**
44. Ruzzo A, Graziano F, Bagaloni I, Di Bartolomeo M, Prisciandaro M, Aprile G, Ongaro E, Vincenzi B, Perrone G, Santini D, Fornaro L, Vivaldi C, Tomasello G, Loupakis F, Lonardi S, Fassan M, Valmasoni M, Sarti D, Lorenzini P, Catalano V, Bissoni R, Del Prete M, Collina G, Magnani M. Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. *Gastric Cancer* (**IF 4,828**) 2020 Nov;23(6):1064-1074. doi: 10.1007/s10120-020-01078-0. Epub 2020 May 5. PMID: 32372141; PMCID: PMC7567716. **Cit. 0**
45. Santini D, Tonini G. Brief letter of a doctor to his psychologist in the COVID-19 outbreak era. *ESMO Open* (**IF 5,329**). 2020 May;5(3):e000801. doi: 10.1136/esmooopen-2020-000801. PMID: 32398253; PMCID: PMC7223352. **Cit. 0**
46. Palermo A, Napolitano A, Maggi D, Naciu AM, Tabacco G, Manfrini S, Crescenzi A, Taffon C, Pantano F, Vincenzi B, Tonini G, Santini D. Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer. *Eur Thyroid J* (**IF 1,23**) 2020 May;9(3):157-161. doi: 10.1159/000506107. Epub 2020 Apr 15. PMID: 32523892; PMCID: PMC7265713. **Cit. 0**
47. Rossini D, Germani MM, Pagani F, Pellino A, Dell'Aquila E, Bensi M, Liscia N, Moretto R, Boccaccino A, Prisciandaro M, Manglaviti S, Schirripa M, Vivolo R, Scartozzi M, Santini D, Salvatore L, Pietrantonio F, Loupakis F, Falcone A, Cremolini C. Retreatment With Anti-EGFR

- Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. *Clin Colorectal Cancer* (**IF 2,813**). 2020 Sep;19(3):191-199.e6. doi: 10.1016/j.clcc.2020.03.009. Epub 2020 Apr 11. PMID: 32466976. **Cit. 2**
48. Silipigni S, Ippolito E, Matteucci P, Santo B, Gangemi E, La Cesa A, Santini D, Greco C, Ramella S. Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case report. *Breast J* (**IF 1,991**) 2020 Jul;26(7):1370-1371. doi: 10.1111/tbj.13844. Epub 2020 Apr 11. PMID: 32279411. **Cit. 0**
49. Russano M, Citarella F, Vincenzi B, Tonini G, Santini D. Coronavirus Disease 2019 or Lung Cancer: What Should We Treat? *J Thorac Oncol* (**IF 13,357**) 2020 Jul;15(7):e105-e106. doi: 10.1016/j.jtho.2020.04.001. Epub 2020 Apr 10. PMID: 32283315; PMCID: PMC7151236. **Cit. 6**
50. Dell'Aquila E, Fulgenzi CAM, Minelli A, Citarella F, Stellato M, Pantano F, Russano M, Cursano MC, Napolitano A, Zeppola T, Vincenzi B, Tonini G, Santini D. Prognostic and predictive factors in pancreatic cancer. *Oncotarget* (**IF 3,765**). 2020 Mar 10;11(10):924-941. doi: 10.18632/oncotarget (**IF 3,765**).27518. PMID: 32206189; PMCID: PMC7075465. **Cit. 10**
51. Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol* (**IF 33,752**). 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. PMID: 32164906. **Cit. 48**
52. Santini D, Berruti A, Di Maio M, Procopio G, Bracarda S, Ibrahim T, Bertoldo F. Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. *ESMO Open* (**IF 5,329**). 2020 Mar;5(2):e000652. doi: 10.1136/esmoopen-2019-000652. Erratum in: *ESMO Open* (**IF 5,329**). 2020 Aug;5(4): PMID: 32220946; PMCID: PMC7174015. **Cit. 5**
53. Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. *Eur J Cancer* (**IF 7,275**). 2020 Mar;128:17-26. doi: 10.1016/j.ejca.2019.12.031. Epub 2020 Mar 5. PMID: 32109847. **Cit. 20**
54. Stellato M, Cursano MC, Citarella F, Pantano F, Russano M, Dell' Aquila E, Vincenzi B, Tonini G, Santini D. Response to cabozantinib in renal cell carcinoma with cardiac metastases. *Anticancers Drugs* (**IF 1,784**). 2020 Mar;31(3):314-318. doi: 10.1097/CAD.0000000000000889. PMID: 31929349. **Cit. 2**
55. Pantano F, Russano M, Berruti A, Mansueto G, Migliorino MR, Adamo V, Aprile G, Gelibter A, Ficorella C, Falcone A, Russo A, Aieta M, Maio M, Martelli O, Barni S, Napolitano A, Roca E, Quadri S, Iacono D, Russo A, Calvetti L, Occhipinti MA, Cortellini A, Vasile E, Passiglia F, Imperatori M, Calabrò L, Di Giacomo AM, Petrelli F, Pasquini G, Franchina T, Venditti O, Intagliata S, Galvano A, Fioroni I, Vincenzi B, Tonini G, Santini D. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. *Expert Opin Biol Ther* (**IF**

- 3,974**). 2020 Mar;20(3):319-326. doi: 10.1080/14712598.2020.1724953. Epub 2020 Feb 6. PMID: 32011207. **Cit. 1**
56. Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, Russo A, Barni S, Maio M, Martelli O, Pantano F, Iacono D, Calvetti L, Quadri S, Roca E, Vasile E, Imperatori M, Occhipinti M, Galvano A, Petrelli F, Calabrò L, Pasquini G, Intagliata S, Ricciardi GRR, Tonini G, Santini D, Adamo V. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. *Adv Ther (IF 3,26)*. 2020 Mar;37(3):1145-1155. doi: 10.1007/s12325-020-01229-w. Epub 2020 Jan 30. PMID: 32002809. **Cit. 19**
57. Pantano F, Rossi E, Iuliani M, Facchinetti A, Simonetti S, Ribelli G, Zoccoli A, Vincenzi B, Tonini G, Zamarchi R, Santini D. Dynamic changes of Receptor activator of nuclear factor- $\kappa$ B expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. *Sci Rep (IF 3,998)*. 2020 Jan 28;10(1):1288. doi: 10.1038/s41598-020-58339-2. PMID: 31992773; PMCID: PMC6987166. **Cit. 7**
58. Fusco V, Santini D, Campisi G, Bertoldo F, Lanzetta G, Ibrahim T, Bertetto O, Numico G, Addeo A, Berruti A, Bettini G, Saia G, Bedogni A. Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. *JCO Oncol Pract (IF 3,551)* 2020 Mar;16(3):142-145. doi: 10.1200/JOP.19.00645. Epub 2020 Jan 24. PMID: 32048935. **Cit. 4**
59. Annibaldi O, Petrucci MT, Santini D, Bongarzone V, Russano M, Pisani F, Venditti O, Pantano F, Rago A, Siniscalchi A, Cerchiara E, Franceschini L, De Rosa L, Mariani M, Andriani S, Cudillo L, Garcia M, Cantonetti M, Mohamed S, Anaclerico B, Caravita T, Stocchi F, Cimino G, Gumenyuk S, Vozella F, Avvisati G. Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference? *J Bone Oncol (IF 3,066)*. 2020 Nov 18;26:100338. doi: 10.1016/j.jbo.2020.100338. PMID: 33304804; PMCID: PMC7708946. **Cit. 0**
60. Santini D, Armento G, Giusti R, Ferrara M, Moro C, Fulfaro F, Bossi P, Arena F, Ripamonti CI; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment†. *ESMO Open (IF 5,329)*. 2020 Nov;5(6):e000933. doi: 10.1136/esmoopen-2020-000933. PMID: 33208491; PMCID: PMC7674109. **Cit. 1**
61. Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Bone health in cancer: ESMO Clinical Practice Guidelines. *Ann Oncol (IF 18,274)*. 2020 Dec;31(12):1650-1663. doi: 10.1016/j.annonc.2020.07.019. Epub 2020 Aug 12. PMID: 32801018. **Cit. 19**
62. Cursano MC, Iuliani M, Casadei C, Stellato M, Tonini G, Paganelli G, Santini D, De Giorgi U. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. *Crit Rev Oncol Hematol (IF 5,833)* 2020 Feb;146:102864. doi: 10.1016/j.critrevonc.2020.102864. Epub 2020 Jan 7. PMID: 31986318. **Cit. 6**
63. Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. *Clin Transl Oncol (IF 2,37)* 2020 Jun;22(6):844-851. doi: 10.1007/s12094-019-02193-w. Epub 2019 Aug 7. PMID: 31392645. **Cit. 4**

64. Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, Kayal R, Sanguineti G, Marchetti P, Botticelli A, Marinelli D, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Tonini G, Santini D, Michelotti A, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Cazzaniga M, Moschetti L, Fabbri A, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Garufi C, Di Stefano P, Mirabelli R, Veltri E, Paris I, Giotta F, Lorusso V, Landucci E, Ficorella C, Roselli M, Adamo V, Ricciardi G, Russo A, Valerio MR, Berardi R, Pistelli M, Cannita K, Zamagni C, Garrone O, Baldini E, Livi L, Meattini I, Del Medico P, Generali D, De Maria R, Risi E, Ciliberto G, Villa A, Sperduti I, Mazzotta M, Barba M, Giordano A, Vici P. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. *J Cell Physiol* (**IF 5,546**). 2020 Nov;235(11):7900-7910. doi: 10.1002/jcp.29445. Epub 2020 Jan 15. PMID: 31943171. **Cit. 5**
65. Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fargnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C. Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. *Oncoimmunology* (**5,869**) 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389. PMID: 32002308; PMCID: PMC6959456. **Cit. 2**
66. Napolitano A, Minelli A, Santini D, Tonini G, Vincenzi B. Identification of Aneuploid Circulating Tumor Cells in Soft-Tissue Sarcoma Patients: A Pilot Study. *Oncology* (**IF 2,642**). 2020;98(12):893-896. doi: 10.1159/000509326. Epub 2020 Aug 20. PMID: 32818940. **Cit. 1**
67. Napolitano A, Provenzano S, Colombo C, Vitellaro M, Brunello A, Badalamenti G, Nannini M, Ibrahim T, Hohenberger P, Gasperoni S, Gennatas S, Jones RL, Hindi N, Martin-Broto J, Spalato Ceruso M, Silletta M, Dei Tos AP, Gronchi A, Stacchiotti S, Santini D, Tonini G, Palassini E, Vincenzi B. Familial adenomatous polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. *ESMO Open* (**IF 5,329**). 2020 Jan;5(1):e000604. doi: 10.1136/esmoopen-2019-000604. PMID: 31958289; PMCID: PMC7003390. **Cit. 3**
68. Salati M, Filippi R, Vivaldi C, Caputo F, Leone F, Salani F, Cerma K, Aglietta M, Fornaro L, Sperti E, Di Maio M, Ortega C, Fenocchio E, Lombardi P, Cagnazzo C, Depetris I, Gelsomino F, Spallanzani A, Santini D, Silvestris N, Aprile G, Roviello G, Scartozzi M, Cascinu S, Casadei-Gardini A. The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. *Liver Int* (**IF 5,175**) 2020 Mar;40(3):704-711. doi: 10.1111/liv.14314. Epub 2019 Dec 11. PMID: 31773848. **Cit. 11**
69. Roberto M, Botticelli A, Cecere F, Cognetti F, Giusti R, Gelibter A, Lugini A, Nelli F, Nuti M, Santini D, Marchetti P. L'immunoterapia nel tumore del polmone non a piccole cellule: ritorno al futuro [Immunotherapy in non-small cell lung cancer patients: back to the future.]. *Recenti Prog Med* (**IF 0,32**). 2019 Dec;110(12):587-593. Italian. doi: 10.1701/3278.32517. PMID: 31909761. **Cit. 0**
70. Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Carteni G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and

Prognostic Factors. *Cancers (Basel)* (**IF 6,126**) 2019 Dec 30;12(1):84. doi: 10.3390/cancers12010084. PMID: 31905816; PMCID: PMC7016527. **Cit. 7**

71. Casadei C, Dizman N, Schepisi G, Cursano MC, Basso U, Santini D, Pal SK, De Giorgi U. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. *Ther Adv Med Oncol* (**IF 2,304**). 2019 Nov 25;11:1758835919890285. doi: 10.1177/1758835919890285. PMID: 31803255; PMCID: PMC6878604. **Cit. 21**
72. Cazzaniga ME, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccicarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Fiorentini G, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Melegari E, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V; VICTOR Study Group. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. *Breast* (**IF 3,754**) 2019 Dec;48:7-16. doi: 10.1016/j.breast.2019.07.006. Epub 2019 Aug 22. PMID: 31470257. **Cit. 18**
73. Rinaldi S, Santoni M, Leoni G, Fiordoliva I, Marcantognini G, Meletani T, Armento G, Santini D, Newsom-Davis T, Tiberi M, Morgese F, Torniai M, Bower M, Berardi R. The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases. *Support Care Cancer* (**IF 2,698**). 2019 Apr;27(4):1255-1261. doi: 10.1007/s00520-018-4489-2. Epub 2018 Nov 8. PMID: 30406916. **Cit. 10**
74. Barni S, Livraghi L, Gravina A, Martella F, D'Onofrio L, Morritti M, Michelotti A, Vici P, Mentuccia L, Porcu L, Orditura M, Puglisi F; ESEMPiO Group. Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study. *J Geriatr Oncol* (**IF 2,761**). 2019 Nov;10(6):990-993. doi: 10.1016/j.jgo.2019.05.003. Epub 2019 May 13. PMID: 31097340. **Cit. 3**
75. Cortellini A, Vitale MG, De Galitiis F, Di Pietro FR, Berardi R, Torniai M, De Tursi M, Grassadonia A, Di Marino P, Santini D, Zeppola T, Anesi C, Gelibter A, Occhipinti MA, Botticelli A, Marchetti P, Rastelli F, Pergolesi F, Tudini M, Silva RR, Mallardo D, Vanella V, Ficorella C, Porzio G, Ascierto PA. Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. *J Transl Med* (**IF 4,197**) 2019 Nov 15;17(1):376. doi: 10.1186/s12967-019-02132-x. PMID: 31730009; PMCID: PMC6857130. **Cit. 7**
76. Catalano V, Bergamo F, Cremolini C, Vincenzi B, Negri F, Giordani P, Alessandroni P, Intini R, Stragliotto S, Rossini D, Borelli B, Santini D, Sarti D, Rocchi MBL, Lonardi S, Falcone A, Zagonel V, Mattioli R, Graziano F. Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. *J Cancer Res Clin Oncol* (**3,656**). 2020 Feb;146(2):493-501. doi: 10.1007/s00432-019-03077-w. Epub 2019 Nov 6. PMID: 31691872. **Cit. 2**
77. Schepisi G, Cursano MC, Casadei C, Menna C, Altavilla A, Lolli C, Cerchione C, Paganelli G, Santini D, Tonini G, Martinelli G, De Giorgi U. CAR-T cell therapy: a potential new strategy against prostate cancer. *J Immunother Cancer* (**IF 10,252**). 2019 Oct 16;7(1):258. doi: 10.1186/s40425-019-0741-7. PMID: 31619289; PMCID: PMC6794851. **Cit. 15**
78. Berardi R, Mastroianni C, Lo Russo G, Buosi R, Santini D, Montanino A, Carnaghi C, Tiseo M, Chiari R, Camerini A, Barni S, De Marino V, Ferrari D, Cristofano A, Doni L, Freddari F, Fumagalli D, Portalone L, Sarmiento R, Schinzari G, Sperandi F, Tucci M, Inno A, Ciuffreda L, Mariotti M, Mariani C, Caramanti M, Torniai M, Gallucci R, Bennati C, Bordi P, Buffoni L, Galeassi A, Ghidini M, Grossi E, Morabito A, Vincenzi B, Arvat E. Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. *Ther Adv Med Oncol* (**IF**



- 2,304**). 2019 Sep 27;11:1758835919877725. doi: 10.1177/1758835919877725. PMID: 31632468; PMCID: PMC6767731. **Cit. 4**
79. Schepisi G, Brighi N, Cursano MC, Gurioli G, Ravaglia G, Altavilla A, Burgio SL, Testoni S, Menna C, Farolfi A, Casadei C, Tonini G, Santini D, De Giorgi U. Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. *J Oncol* (**IF 2,206**) 2019 Sep 19;2019:7317964. doi: 10.1155/2019/7317964. PMID: 31641355; PMCID: PMC6770345. **Cit. 3**
80. Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. *Ann Oncol* (**IF 18,274**). 2019 Dec 1;30(12):1959-1968. doi: 10.1093/annonc/mdz406. PMID: 31562758; PMCID: PMC6938600. **Cit. 11**
81. Santini D, Citarella F, Vincenzi B, Russano M, Tonini G, Stellato M. Cabozantinib and apixaban: an hitherto unreported interaction. *Exp Hematol Oncol* (**IF 1,223**) 2019 Sep 11;8:22. doi: 10.1186/s40164-019-0146-9. PMID: 31528502; PMCID: PMC6737677. **Cit. 1**
82. Loupakis F, Biason P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M. CK7 and consensus molecular subtypes as major prognosticators in <sup>V600E</sup>BRAF mutated metastatic colorectal cancer. *Br J Cancer* (**IF 5,791**). 2019 Oct;121(7):593-599. doi: 10.1038/s41416-019-0560-0. Epub 2019 Sep 2. PMID: 31474758; PMCID: PMC6889398. **Cit. 7**
83. Argentiero A, Solimando AG, Brunetti O, Calabrese A, Pantano F, Iuliani M, Santini D, Silvestris N, Vacca A. Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. *Cancers (Basel)* (**IF 6,126**) 2019 Aug 29;11(9):1270. doi: 10.3390/cancers11091270. PMID: 31470608; PMCID: PMC6770264. **Cit. 8**
84. Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. *Int J Cancer* (**IF 5,145**) 2020 Apr 1;146(7):1917-1929. doi: 10.1002/ijc.32583. Epub 2019 Aug 7. PMID: 31330065; PMCID: PMC7027476. **Cit. 1**
85. Lolli C, De Lisi D, Conteduca V, Gurioli G, Scarpi E, Schepisi G, Ravaglia G, Menna C, Farolfi A, Altavilla A, Burgio SL, Tonini G, Santini D, De Giorgi U. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. *Prostate* (**IF 4,47**) 2019 Aug;79(11):1211-1220. doi: 10.1002/pros.23804. PMID: 31251826. **Cit. 6**
86. Santini D, Galvano A, Pantano F, Incorvaia L, Rizzo S, Vincenzi B, Castellana L, Giuliana G, Guadagni F, Toia F, Tonini G, Russo A, Badalamenti G, Bazan V. How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic

- review and a meta- analysis of randomized trials. *Crit Rev Oncol Hematol* (**IF 5,833**). 2019 Oct;142:68-75. doi: 10.1016/j.critrevonc.2019.07.013. Epub 2019 Jul 25. PMID: 31377434. **Cit. 1**
87. Procopio G, Pignata S, Altavilla A, Attademo L, De Lisi D, Verzoni E, De Giorgi U, Santini D. Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. *Future Oncol* (**IF 2,66**). 2019 Aug;15(22):2657-2666. doi: 10.2217/fon-2018-0857. Epub 2019 Jul 24. PMID: 31339065. **Cit. 0**
88. Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Zirano P, Schirripa M, Buggin F, Prete AA, Depetris I, Bion P, Lonardi S, Zagonel V, Fassan M, Di Maio M. A validated prognostic classifier for <sup>V600E</sup>BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. *Eur J Cancer* (**IF 7,275**). 2019 Sep;118:121-130. doi: 10.1016/j.ejca.2019.06.008. Epub 2019 Jul 19. PMID: 31330487. **Cit. 14**
89. Galvano A, Scaturro D, Badalamenti G, Incorvaia L, Rizzo S, Castellana L, Cusenza S, Cutaia S, Santini D, Guadagni F, Roselli M, Gori S, Latteri MA, Bazan V, Giulia LM, Russo A. Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. *J Bone Oncol* (**IF 3,066**) *Oncol*. 2019 Jul 16;18:100252. doi: 10.1016/j.jbo.2019.100252. PMID: 31440444; PMCID: PMC6700425. **Cit. 7**
90. Parisi A, Cortellini A, Roberto M, Venditti O, Santini D, Dell'Aquila E, Stellato M, Marchetti P, Occhipinti MA, Zoratto F, Mazzuca F, Tinari N, De Tursi M, Iezzi L, Natoli C, Ratti M, Pizzo C, Ghidini M, Porzio G, Ficorella C, Cannita K. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. *J Cancer Res Clin Oncol* (**3,656**). 2019 Sep;145(9):2365-2373. doi: 10.1007/s00432-019-02971-7. Epub 2019 Jul 6. PMID: 31280347. **Cit. 4**
91. De Vincentis G, Frantellizzi V, Follacchio GA, Farcomeni A, Pani A, Samaritani R, Schinzari G, Santini D, Cortesi E. No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium. *Eur J Cancer* (**IF 7,275**) *Care (Engl)* (**IF 2,161**) 2019 Sep;28(5):e13112. doi: 10.1111/ecc.13112. Epub 2019 May 31. PMID: 31148330. **Cit. 5**
92. Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G, Vincenzi B. New frontiers in the medical management of gastrointestinal stromal tumours. *Ther Adv Med Oncol* (**IF 2,304**). 2019 May 17;11:1758835919841946. doi: 10.1177/1758835919841946. PMID: 31205499; PMCID: PMC6535752. **Cit. 12**
93. Cursano MC, Santini D, Iuliani M, Paganelli G, De Giorgi U. Early use of abiraterone and radium-223 in metastatic prostate cancer. *Lancet Oncol* (**IF 33,752**). 2019 May;20(5):e228. doi: 10.1016/S1470-2045(19)30226-8. PMID: 31044705. **Cit. 3**
94. Cazzaniga ME, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoidi M, Moretti G, Ficorella C, Gianni L, Michelotti A, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi GV, Artale S, Blasi L, De Laurentiis M, Atzori F, Turletti A, Porpiglia M, Santini D, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Giordano M, Donadio M, Biganzoli L, Del Mastro L, Bisagni G, Livi L, Natoli C, Montemurro F, Riccardi F, Romagnoli E, Marchetti P, Torri V, Pronzato P, Mustacchi G. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2-Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13

- AMBRA Studies. *Breast Care (Basel)* (**IF 0,721**). 2020 Feb;15(1):30-37. doi: 10.1159/000495469. Epub 2019 Apr 17. PMID: 32231495; PMCID: PMC7098305. **Cit. 2**
95. Brunetti O, Luchini C, Argentiero A, Tommasi S, Mangia A, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Santini D, Doglioni C, Maiello E, Lawlor RT, Mazzaferro V, Lonardi S, Giuliante F, Brandi G, Scarpa A, Cascinu S, Silvestris N. The Italian Rare Pancreatic Exocrine Cancer Initiative. *Tumori* (**IF 1,707**). 2019 Aug;105(4):353-358. doi: 10.1177/0300891619839461. Epub 2019 Apr 9. Erratum in: *Tumori*. 2020 Dec;106(6):526. PMID: 30967031. **Cit. 2**
96. Iacovelli R, Galli L, De Giorgi U, Porta C, Nolè F, Zucali P, Sabbatini R, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Buti S, Massari F, Masini C, Ricotta R, Biasco E, Lolli C, Gri N, Verri E, Miggiano C, Vitale MG, Tortora G. The effect of a treatment delay on outcome in metastatic renal cell carcinoma. *Urol Oncol* (**IF 2,882**) 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29. PMID: 30935843. **Cit. 3**
97. Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P. Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study. *Clin Pharmacol Ther* (**IF 7,266**) 2019 Aug;106(2):422-431. doi: 10.1002/cpt.1391. Epub 2019 Mar 28. PMID: 30739312. **Cit. 7**
98. De Matteis S, Scarpi E, Granato AM, Vespasiani-Gentilucci U, La Barba G, Foschi FG, Bandini E, Ghetti M, Marisi G, Cravero P, Gramantieri L, Cucchetti A, Ercolani G, Santini D, Frassinetti GL, Faloppi L, Scartozzi M, Cascinu S, Casadei-Gardini A. Role of SIRT-3, p-mTOR and HIF-1 $\alpha$  in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. *Int J Mol Sci* (**IF 4,566**) 2019 Mar 26;20(6):1503. doi: 10.3390/ijms20061503. PMID: 30917505; PMCID: PMC6470641. **Cit. 8**
99. Neuzillet C, Casadei Gardini A, Brieu B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S, Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues Oncologues); GICO (Italian Group of Cholangiocarcinoma) Investigators; Gustave Roussy Institute Cohort; Barts Cancer Institute Cohort. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. *Eur J Cancer* (**IF 7,275**). 2019 Apr;111:94-106. doi: 10.1016/j.ejca.2019.01.019. Epub 2019 Mar 1. PMID: 30826661. **Cit. 14**
100. Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. *JAMA Oncol* (**IF 24,799**) 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. PMID: 30476968; PMCID: PMC6439839. **Cit. 72**
101. Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierio PA, Ficorella C, Natoli C. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. *J Immunother Cancer* (**IF 10,252**). 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y. PMID: 30813970; PMCID: PMC6391761. **Cit. 96**

102. Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fagnoli MC, Ascierto PA, Ficorella C. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. *Oncologist* (**IF 5,025**). 2019 Jun;24(6):e327-e337. doi: 10.1634/theOncologist.2018-0618. Epub 2019 Feb 22. PMID: 30796151; PMCID: PMC6656514. **Cit. 45**
103. Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. *Clin Lung Cancer* (**IF 4,2**). 2019 Jul;20(4):237-247.e1. doi: 10.1016/j.clcc.2019.02.006. Epub 2019 Feb 21. PMID: 30885550. **Cit. 45**
104. Spalato Ceruso M, Napolitano A, Silletta M, Mazzocca A, Valeri S, Improta L, Santini D, Tonini G, Badalamenti G, Vincenzi B. Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients. *Chemotherapy* (**IF 1,288**) 2019;64(2):105-109. doi: 10.1159/000501195. Epub 2019 Aug 7. PMID: 31390619. **Cit. 4**
105. Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, Melisi D, Vasile E, Gerrata L, Aprile G. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. *J Geriatr Oncol* (**IF 2,761**) 2019 Jul;10(4):591-597. doi: 10.1016/j.jgo.2018.11.009. Epub 2018 Dec 11. PMID: 30551958. **Cit. 1**
106. Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Aroldi F, Orlandi A, Moschetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D,
107. Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. *J Cell Physiol* (**IF 5,546**). 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10. PMID: 30536609. **Cit. 6**
108. Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moschetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P. A multicenter RETrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. *Cancer Biol Ther* (**IF 3,659**) (**IF 3,659**). 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7. PMID: 30403909; PMCID: PMC6343690. **Cit. 9**

109. Cortellini A, Cocciolone V, Irelli A, Pavese F, Sidoni T, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Bonfili P, Franzese P, Zugaro L, Verna L, Porzio G, Santini D, Cannita K, Ficorella C. The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis- generator' study from clinical practice. *Oncol Lett* (**IF 1,554**) 2018 Dec;16(6):7195-7203. doi: 10.3892/ol.2018.9561. Epub 2018 Oct 10. PMID: 30546457; PMCID: PMC6256706. **Cit. 1**
110. Santoni M, Piva F, De Giorgi U, Mosca A, Basso U, Santini D, Buti S, Lolli C, Terrone C, Maruzzo M, Iuliani M, Bersanelli M, Conti A, Mazzucchelli R, Montironi R, Burattini L, Berardi R. Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. *Anticancer Res* (**IF 1,994**). 2018 Oct;38(10):5773-5782. doi: 10.21873/anticancer.12916. PMID: 30275199. **Cit. 5**
111. Vincenzi B, Russo A, Terenzio A, Galvano A, Santini D, Vorini F, Antonelli-Incalzi R, Vespasiani-Gentilucci U, Tonini G. The use of SAME in chemotherapy-induced liver injury. *Crit Rev Oncol Hematol* (**IF 5,833**) 2018 Oct;130:70-77. doi: 10.1016/j.critrevonc.2018.06.019. Epub 2018 Jul 31. PMID: 30196914. **Cit. 7**
112. Santini D, Brandi G, Aprile G, Russano M, Cereda S, Leone F, Lonardi S, Fornaro L, Scartozzi M, Silvestris N, Barni S, Pantano F, Vincenzi B, Palloni A, Frega G, Casagrande M, Ferrari L, Dadduzio V, Intini R, Filippi R, Vasile E, Vivaldi C, Faloppi L, Brunetti O, Reni M, Aglietta M, Tonini G. Bone metastases in biliary cancers: A multicenter retrospective survey. *J Bone Oncol* (**IF 3,066**). 2018 Apr 7;12:33-37. doi: 10.1016/j.jbo.2017.11.006. PMID: 30042924; PMCID: PMC6054714. **Cit. 1**
113. Fioramonti M, Fausti V, Pantano F, Iuliani M, Ribelli G, Lotti F, Pignochino Y, Grignani G, Santini D, Tonini G, Vincenzi B. Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. *Sci Rep* (**IF 3,998**). 2018 Mar 8;8(1):4177. doi: 10.1038/s41598-018-22469-5. PMID: 29520051; PMCID: PMC5843583. **Cit. 18**
114. Dell'Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, Stellato M, Marmorino F, Schirripa M, Urbano F, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Fea E, Di Donato S, Chiara S, Tonini G, Tomcikova D, Boni L, Falcone A, Santini D. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. *Ann Oncol* (**IF 18,274**). 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004. PMID: 29324972. **Cit. 36**
115. Cazzato RL, Arrigoni F, Boatta E, Bruno F, Chiang JB, Garnon J, Zugaro L, Giordano AV, Carducci S, Varrassi M, Beomonte Zobel B, Bazzocchi A, Aliprandi A, Basile A, Marcia S, Masala S, Grasso RF, Squarza S, Floridi C, Ierardi AM, Burdi N, Cioni R, Napoli A, Niola R, Rossi G, Rossi UG, Venturini M, De Cobelli F, Carotti M, Gravina GL, Di Staso M, Zoccali C, Biagini R, Tonini G, Santini D, Carrafiello G, Cariati M, Silvestri E, Sconfienza LM, Giovagnoni A, Masciocchi C, Gangi A, Barile A. Percutaneous management of bone metastases: state of the art, interventional strategies and joint position statement of the Italian College of MSK Radiology (ICoMSKR) and the Italian College of Interventional Radiology (ICIR). *Radiol Med* (**IF 2**) 2019 Jan;124(1):34-49. doi: 10.1007/s11547-018-0938-8. Epub 2018 Sep 6. PMID: 30191448. **Cit. 28**
116. Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. *Ther Adv Med Oncol* (**IF 2,304**). 2018 Aug 29;10:1758835918794623. doi: 10.1177/1758835918794623. PMID: 30181783; PMCID: PMC6116078. **Cit. 9**
117. Sbrana A, Biasco E, Paolieri F, Palesandro E, Caserta C, Iacovelli R, Detti B, Santini D, Mosca A, Morelli F, Fornarini G, De Giorgi U, Masini C, Galli L. Long-term Response to First-line

- Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. *Anticancer Res* (**IF 1,994**). 2018 Aug;38(8):4913-4918. doi: 10.21873/anticancer.12807. PMID: 30061269. **Cit. 3**
118. Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. *Anticancer Drugs* (**IF 1,784**). 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632. PMID: 29846246. **Cit. 1**
119. Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, Carbognin L, Ciccarese M, La Verde N, Arpino G, Cannita K, Paris I, Santini D, Montemurro F, Russillo M, Ferretti G, Filippelli G, Rossello R, Fabbri A, Zambelli A, Leonardi V, D'Ottavio AM, Nisticò C, Stani S, Giampaglia M, Scandurra G, Catania G, Malaguti P, Giannarelli D, Cognetti F. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. *Breast* (**IF 3,754**) 2018 Oct;41:137-143. doi: 10.1016/j.breast.2018.07.004. Epub 2018 Jul 12. PMID: 30092500. **Cit. 15**
120. Vitale MG, Scagliarini S, Galli L, Pignata S, Lo Re G, Berruti A, Defferrari C, Spada M, Masini C, Santini D, Ciuffreda L, Ruggeri EM, Bengala C, Livi L, Fagnani D, Bonetti A, Giustini L, Hamzaj A, Procopio G, Caserta C, Sabbatini R. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy. *PLoS One* (**IF 2,74**). 2018 Jul 6;13(7):e0199642. doi: 10.1371/journal.pone.0199642. PMID: 29979712; PMCID: PMC6034807. **Cit. 13**
121. Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Scarpa A, Basile D, Mazza F, Graziano G, Argentiero A, Santini D, Reni M, Cascinu S, Silvestris N. Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. *Pancreas* (**IF 2,92**) 2018 Jul;47(6):759-771. doi: 10.1097/MPA.0000000000001063. PMID: 29771769. **Cit. 15**
122. Davies AN, Elsner F, Filbet MJ, Porta-Sales J, Ripamonti C, Santini D, Webber K. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines. *BMJ Support Palliat Care* (**IF 0,779**) 2018 Sep;8(3):241-249. doi: 10.1136/bmjspcare-2017-001467. Epub 2018 Jun 6. PMID: 29875184. **Cit. 13**
123. Gardini AC, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calveti L, Cascinu S, Frassineti GL, Scartozzi M. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. *Tumori* (**1,707**). 2018 Dec;104(6):476-479. doi: 10.5301/tj.5000704. Epub 2018 May 9. PMID: 29739298. **Cit. 11**
124. Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Pasini F, Masini C, Massari F, Buti S, Sava T, Sacco C, Ricotta R, Sperduti I, Tortora G, Porta C. Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? *Clin Genitourin Cancer* (**IF 2,45**). 2018 Oct;16(5):355-359.e1. doi: 10.1016/j.clgc.2018.04.007. Epub 2018 May 7. PMID: 29803346. **Cit. 18**
125. Goldberg RM, Montagut C, Wainberg ZA, Ronga P, Audhuy F, Taieb J, Stintzing S, Siena S, Santini D. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. *ESMO Open* (**IF 5,329**). 2018 May 5;3(4):e000353. doi: 10.1136/esmoopen-2018-000353. PMID: 29765773; PMCID: PMC5950648. **Cit. 24**

126. Rauh S, Antonuzzo A, Bossi P, Eckert R, Fallon M, Fröbe A, Gonella S, Giusti R, Lakatos G, Santini D, Villarini A. Nutrition in patients with cancer: a new area for medical oncologists? A practising oncologist's interdisciplinary position paper. *ESMO Open* (**IF 5,329**). 2018 May 5;3(4):e000345. doi: 10.1136/esmoopen-2018-000345. PMID: 29765772; PMCID: PMC5950635. **Cit. 13**
127. Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Carteni G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zstovitch F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clin Genitourin Cancer* (**IF 2,45**). 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19. PMID: 29753637. **Cit. 18**
128. Camilli M, Papadimitriou K, Nogueira A, Incorvaia L, Galvano A, D'Antonio F, Ferri J, Santini D, Silvestris N, Russo A, Peeters M, Rolfo C. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. *Expert Rev Gastroenterol Hepatol*. (**IF 2,991**) 2018 May;12(5):471-478. doi: 10.1080/17474124.2018.1463157. Epub 2018 Apr 18. PMID: 29629846. **Cit. 3**
129. De Lisi D, De Giorgi U, Lolli C, Schepisi G, Conteduca V, Menna C, Tonini G, Santini D, Farolfi A. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? *Expert Opin Drug Metab Toxicol* (**IF 3,487**) 2018 Apr;14(4):461-467. doi: 10.1080/17425255.2018.1455826. Epub 2018 Mar 23. PMID: 29557694. **Cit. 7**
130. Fiore M, D'Apos Angelillo RM, Greco C, Fioroni I, Ippolito E, Santini D, Ramella S. Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer. *Chemotherapy* (**IF 1,288**) 2018 Mar 19;63(2):83-89. doi: 10.1159/000488252. Epub ahead of print. PMID: 29554654. **Cit. 5**
131. Del Re M, Crucitta S, Restante G, Rofi E, Arrigoni E, Biasco E, Sbrana A, Coppi E, Galli L, Bracarda S, Santini D, Danesi R. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. *Crit Rev Oncol Hematol* (**IF 5,833**). 2018 May;125:51-59. doi: 10.1016/j.critrevonc.2018.03.002. Epub 2018 Mar 6. PMID: 29650277. **Cit. 4**
132. Conteduca V, Caffo O, Galli L, Maugeri A, Scarpi E, Maines F, Chiuri VE, Lolli C, Kinspergher S, Schepisi G, Santoni M, Santini D, Fratino L, Burgio SL, Salvi S, Menna C, De Giorgi U. Association among metabolic syndrome, inflammation, and survival in prostate cancer. *Urol Oncol* (**IF 2,882**) 2018 May;36(5):240.e1-240.e11. doi: 10.1016/j.urolonc.2018.01.007. Epub 2018 Mar 2. PMID: 29402534. **Cit. 6**
133. Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. *Oncologist* (**IF 5,025**). 2018 Feb;23(2):272. doi: 10.1634/theoncologist.2017-0158erratum. Erratum for: *Oncologist*. 2017 Dec;22(12):1463-1469. PMID: 29449512; PMCID: PMC5813760. **Cit. 14**
134. Pietrantonio F, Barretta F, Fanotto V, Park SH, Morano F, Fucà G, Nigam M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G. Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. *Oncology* (**IF 2,642**). 2018;95(6):344-352. doi: 10.1159/000491753. Epub 2018 Aug 21. PMID: 30130791. **Cit. 6**

135. Vincenzi B, Badalamenti G, Armento G, Silletta M, Spalato Ceruso M, Catania G, Napolitano A, Maltese G, Valeri S, Incorvaia L, Santini D, Tonini G. Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. *Oncology (IF 2,642)*. 2018;95(1):1-7. doi: 10.1159/000487266. Epub 2018 Mar 6. PMID: 29510410. **Cit. 3**
136. Calabrese V, Menna P, Annibali O, Armento G, Carpino A, Cerchiara E, Greco C, Marchesi F, Spallarossa P, Toglia G, Reggiardo G, Minotti G; Collaborators. Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study. *Chemotherapy (IF 1,288)* 2018;63(2):55-63. doi: 10.1159/000486761. Epub 2018 Feb 9. Erratum in: *Chemotherapy*. 2018 Apr 10;63(2):64. PMID: 29428939. **Cit 11**
137. Fabi A, Giannarelli D, Moscetti L, Santini D, Zambelli A, Laurentiis M, Caruso M, Generali D, Valle E, Leonardi V, Cannita K, Arpino G, Filippelli G, Ferretti G, Giampaglia M, Montemurro F, Nisticò C, Gasparro S, Cognetti F. Ado- trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? *Future Oncol (IF 2,66)*. 2017 Dec;13(30):2791-2797. doi: 10.2217/fon-2017-0336. Epub 2017 Nov 28. PMID: 29182361. **Cit. 13**
138. Longo V, Gnoni A, Casadei Gardini A, Pisconti S, Licchetta A, Scartozzi M, Memeo R, Palmieri VO, Aprile G, Santini D, Nardulli P, Silvestris N, Brunetti O. Immunotherapeutic approaches for hepatocellular carcinoma. *Oncotarget (IF 3,765)* 2017 May 16;8(20):33897-33910. doi: 10.18632/oncotarget.15406. PMID: 28420805; PMCID: PMC5464921. **Cit. 34**
139. Antonella S, Flavia V, Daniela T, Giuseppe T, Daniele S. The 'Charter of Rights for Family Caregivers'. The role and importance of the caregiver: an Italian proposal. *ESMO Open (IF 5,329)*. 2017 Nov 4;2(5):e000256. doi: 10.1136/esmoopen-2017-000256. PMID: 29177096; PMCID: PMC5687533. **Cit. 3**
140. Rizzo S, Galvano A, Pantano F, Iuliani M, Vincenzi B, Passiglia F, Spoto S, Tonini G, Bazan V, Russo A, Santini D. The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. *Crit Rev Oncol Hematol (IF 5,833)*. 2017 Dec;120:227-233. doi: 10.1016/j.critrevonc.2017.09.008. Epub 2017 Oct 16. PMID: 29110971. **Cit. 9**
141. Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassinetti GL, Scartozzi M. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. *Eur J Cancer (IF 7,275)*. 2017 Nov;86:106-114. doi: 10.1016/j.ejca.2017.09.003. Epub 2017 Oct 3. PMID: 28985579. **Cit. 45**
142. Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G. Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. *Future Oncol (IF 2,66)*. 2017 Oct;13(25):2265-2275. doi: 10.2217/fon-2017-0246. Epub 2017 Oct 4. Erratum in: *Future Oncol*. 2018 Mar;14 (6):577. PMID: 28976226. **Cit. 5**
143. Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, Sanguineti G, Di Filippo S, di Lauro L, Sergi D, Catenaro T, Tomao S, Giordano A, Maugeri-Saccà M, Barba M, Vici P. Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with



- everolimus-exemestane: The EverExt study. *Sci Rep* (**IF 3,998**). 2017 Sep 6;7(1):10597. doi: 10.1038/s41598-017-10061-2. PMID: 28878375; PMCID: PMC5587713. **Cit. 6**
144. Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca LM, Gori S, Tonini G, Barone C. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. *Br J Cancer* (**IF 5,791**) 2017 May 9;116(10):1279-1286. doi: 10.1038/bjc.2017.109. Epub 2017 Apr 20. PMID: 28427088; PMCID: PMC5482728. **Cit. 25**
145. Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. *Oncologist*. 2017 Dec;22(12):1463-1469. doi: 10.1634/theoncologist.2017-0158. Epub 2017 Aug 31. Erratum in: *Oncologist* (**IF 5,025**). 2018 Feb;23 (2):272. PMID: 28860412; PMCID: PMC5728025. **Cit. 0**
146. Lucchesi M, Lanzetta G, Antonuzzo A, Rozzi A, Sardi I, Favre C, Ripamonti CI, Santini D, Armento G. Developing drugs in cancer-related bone pain. *Crit Rev Oncol Hematol* (**IF 5,833**) 2017 Nov;119:66-74. doi: 10.1016/j.critrevonc.2017.08.005. Epub 2017 Aug 25. PMID: 28893462. **Cit. 7**
147. Bertani FR, Mozetic P, Fioramonti M, Iuliani M, Ribelli G, Pantano F, Santini D, Tonini G, Trombetta M, Businaro L, Selci S, Rainer A. Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis. *Sci Rep* (**IF 3,998**). 2017 Aug 21;7(1):8965. doi: 10.1038/s41598-017-08121-8. PMID: 28827726; PMCID: PMC5566322. **Cit. 54**
148. Santini D, Ratta R, Pantano F, De Lisi D, Maruzzo M, Galli L, Biasco E, Farnesi A, Buti S, Sternberg CN, Cerbone L, Di Lorenzo G, Spoto S, Sterpi M, De Giorgi U, Berardi R, Torniai M, Camerini A, Massari F, Procopio G, Tonini G. Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. *Oncotarget* (**IF 3,765**). 2017 Aug 7;8(59):100708-100716. doi: 10.18632/oncotarget.20022. PMID: 29246014; PMCID: PMC5725056. **Cit. 11**
149. Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG, Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzone M, Silletta M, Brunetti O, Cardellino GG, Frassinetti GL, Scartozzi M. Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. *Oncotarget* (**IF 3,765**). 2017 Jul 22;8(39):66699-66708. doi: 10.18632/oncotarget.19449. PMID: 29029548; PMCID: PMC5630448. **Cit. 7**
150. Vincenzi B, Badalamenti G, Napolitano A, Spalato Ceruso M, Pantano F, Grignani G, Russo A, Santini D, Aglietta M, Tonini G. Olaratumab: PDGFR- $\alpha$  inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. *Crit Rev Oncol Hematol* (**IF 5,833**). 2017 Oct;118:1-6. doi: 10.1016/j.critrevonc.2017.06.006. Epub 2017 Jul 15. PMID: 28917265. **Cit. 11**
151. Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. *Br J Cancer* (**IF 5,791**). 2017 Jul 25;117(3):340-346. doi: 10.1038/bjc.2017.187. Epub 2017 Jun 22. PMID: 28641307; PMCID: PMC5537497. **Cit. 9**
152. Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A; all the investigators of the Gruppo Oncologico del Nord Ovest. TRIBE-2: a phase III, randomized, open-label, strategy trial

- in unresectable metastatic colorectal cancer patients by the GONO group. *BMC Cancer* (**IF 3,15**) 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z. PMID: 28599628; PMCID: PMC5466800. **Cit. 15**
153. Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. *Oncotarget* (**IF 3,765**). 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. PMID: 28915642; PMCID: PMC5593613. **Cit. 27**
154. De Matteis S, Granato AM, Napolitano R, Molinari C, Valgiusti M, Santini D, Foschi FG, Ercolani G, Vespasiani Gentilucci U, Faloppi L, Scartozzi M, Frassinetti GL, Casadei Gardini A. Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. *Dig Dis Sci* (**IF 2,937**) 2017 Aug;62(8):1872-1880. doi: 10.1007/s10620-017-4615-x. Epub 2017 May 19. PMID: 28527050. **Cit. 8**
155. Longo V, Gnoni A, Casadei Gardini A, Pisconti S, Licchetta A, Scartozzi M, Memeo R, Palmieri VO, Aprile G, Santini D, Nardulli P, Silvestris N, Brunetti O. Immunotherapeutic approaches for hepatocellular carcinoma. *Oncotarget* (**IF 3,765**). 2017 May 16;8(20):33897-33910. doi: 10.18632/oncotarget.15406. PMID: 28420805; PMCID: PMC5464921. **Cit. 0**
156. Manca P, Russano M, Pantano F, Tonini G, Santini D. Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib. *Oncotarget* (**IF 3,765**). 2017 May 4;8(35):59986-59990. doi: 10.18632/oncotarget.17607. PMID: 28938699; PMCID: PMC5601795. **Cit. 8**
157. Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzone M, Scartozzi M. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? *Crit Rev Oncol Hematol* (**IF 5,833**). 2017 Jul;115:1-12. doi: 10.1016/j.critrevonc.2017.03.025. Epub 2017 Apr 20. PMID: 28602164. **Cit. 17**
158. Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M, Brunetti O, Scartozzi M, Santini D, Silvestris N, Casadei Gardini A, Puzzone M, Calvetti L, Cardarelli N, Aprile G. Immunotherapy for colorectal cancer: where are we heading? *Expert Opin Biol Ther* (**IF 3,974**). 2017 Jun;17(6):709-721. doi: 10.1080/14712598.2017.1315405. Epub 2017 Apr 13. Erratum in: *Expert Opin Biol Ther*. 2017 Jun;17(6):791. PMID: 28375039. **Cit. 59**
159. Fioramonti M\*, Santini D\*, Iuliani M, Ribelli G, Manca P, Papapietro N, Spiezia F, Vincenzi B, Denaro V, Russo A, Tonini G, Pantano F. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. *Oncotarget* (**IF 3,765**). 2017 Mar 21;8(12):20113-20121. doi: 10.18632/oncotarget.15390. PMID: 28223547; PMCID: PMC5386748. **Cit. 19 \*Co-first authors**
160. Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F. Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study. *Oncotarget* (**IF 3,765**). 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. PMID: 28969087; PMCID: PMC5610019. **Cit. 9**

161. Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, Bracarda S, Santini D, Danesi R. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. *Cancer Treat Rev* (**IF 8,885**) 2017 Apr;55:71-82. doi: 10.1016/j.ctrv.2017.03.001. Epub 2017 Mar 9. PMID: 28340451. **Cit. 26**
162. Baldari S, Boni G, Bortolus R, Caffo O, Conti G, De Vincentis G, Monari F, Procopio G, Santini D, Seregini E, Valdagni R. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. *Crit Rev Oncol Hematol* (**IF 5,833**). 2017 May;113:43-51. doi: 10.1016/j.critrevonc.2017.03.001. Epub 2017 Mar 6. PMID: 28427521. **Cit. 18**
163. Manca P, Pantano F, Iuliani M, Ribelli G, De Lisi D, Danesi R, Del Re M, Vincenzi B, Tonini G, Santini D. Determinants of bone specific metastasis in prostate cancer. *Crit Rev Oncol Hematol* (**IF 5,833**). 2017 Apr;112:59-66. doi: 10.1016/j.critrevonc.2017.02.013. Epub 2017 Feb 16. PMID: 28325265. **Cit. 14**
164. Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Torri V, Aprile G. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. *Gastric Cancer* (**IF 4,828**) 2017 Sep;20(5):825-833. doi: 10.1007/s10120-016-0681-6. Epub 2016 Dec 27. PMID: 28028664. **Cit. 19**
165. von Moos R, Costa L, Ripamonti CI, Niepel D, Santini D. Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. *Eur J Cancer* (**IF 7,275**) 2017 Jan;71:80-94. doi: 10.1016/j.ejca.2016.10.021. Epub 2016 Dec 14. PMID: 27984770. **Cit. 31**
166. Mercadante S, Marchetti P, Cuomo A, Caraceni A, Mediati RD, Mammucari M, Natoli S, Lazzari M, Dauri M, Airoidi M, Azzarello G, Bandera M, Blasi L, Carteni G, Chiurazzi B, Costanzo BVP, Degiovanni D, Fusco F, Guardamagna V, Iaffaioli V, Liguori S, Lorusso V, Mameli S, Mattioli R, Mazzei T, Melotti RM, Menardo V, Miotti D, Moroso S, De Santis S, Orsetti R, Papa A, Ricci S, Sabato AF, Scelzi E, Sofia M, Tonini G, Aielli F, Valle A; IOPS MS study group. Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). *Adv Ther* (**IF 3,26**) (**IF 3,26**). 2017 Jan;34(1):120-135. doi: 10.1007/s12325-016-0440-4. Epub 2016 Nov 21. PMID: 27873235; PMCID: PMC5216057. **Cit. 12**
167. Sartore-Bianchi A, Siena S, Tonini G, Bardelli A, Santini D. Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. *Cancer Treat Rev* (**IF 8,885**) 2016 Dec;51:54-62. doi: 10.1016/j.ctrv.2016.10.006. Epub 2016 Oct 29. PMID: 27865140. **Cit. 18**
168. Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. *Oncotarget* (**IF 3,765**). 2016 Oct 25;7(43):69412-69419. doi: 10.18632/oncotarget.5136. PMID: 26416414; PMCID: PMC5342487. **Cit. 7**
169. Moscetti L, Vici P, Gamucci T, Natoli C, Cortesi E, Marchetti P, Santini D, Giuliani R, Sperduti I, Mauri M, Pizzuti L, Mancini ML, Fabbri MA, Magri V, Iezzi L, Sini V, D'Onofrio L, Mentuccia L, Vaccaro A, Ramponi S, Roma CL, Ruggeri EM. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. *Breast* (**IF 3,754**) 2016 Oct;29:96-101. doi: 10.1016/j.breast.2016.07.005. Epub 2016 Jul 29. PMID: 27476084. **Cit. 7**

170. Vincenzi B, Fioroni I, Pantano F, Angeletti S, Dicuonzo G, Zoccoli A, Santini D, Tonini G. Procalcitonin as diagnostic marker of infection in solid tumors patients with fever. *Sci Rep* (**IF 3,998**). 2016 Jun 17;6:28090. doi: 10.1038/srep28090. PMID: 27312877; PMCID: PMC4911581. **Cit. 15**
171. Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. *Ann Oncol* (**IF 18,274**). 2016 Mar;27(3):379-90. doi: 10.1093/annonc/mdv617. Epub 2015 Dec 17. PMID: 26681681. **Cit. 105**
172. Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, Mosconi S, Vasile E, Santini D, Belli C, Auriemma A, Novarino A, Vaccaro V, Martines C, Marino D, Lutrino SE, Palazzo V, Reinach B, Aldrighetti L, Reni M. Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. *Cancer Chemother Pharmacol* (**IF 2,737**) 2016 Jan;77(1):109-14. doi: 10.1007/s00280-015-2919-0. Epub 2015 Dec 10. PMID: 26659366. **Cit. 6**
173. Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, Licitra L, Montironi R, Tortora G, Massari F. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. *Expert Opin Drug Metab Toxicol* (**IF 3,487**) 2016;12(1):57-75. doi: 10.1517/17425255.2016.1120287. Epub 2015 Dec 8. PMID: 26565919. **Cit. 35**
174. Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G, Frassinetti GL. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. *Oncotarget* (**IF 3,765**). 2016 Oct 11;7(41):67142-67149. doi: 10.18632/oncotarget.11565. PMID: 27613839; PMCID: PMC5341863. **Cit. 60**
175. Puzzoni M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell'Aquila E, Marino D, Brunetti O, Garattini SK, Ongaro E, Astara G, Orgiano L, Aprile G, Santini D, Scartozzi M. The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? *Target Oncol* (**IF 3,463**) 2016 Oct;11(5):593-603. doi: 10.1007/s11523-016-0437-6. PMID: 27184491. **Cit. 11**
176. Maugeri-Saccà M, Barba M, Vici P, Pizzuti L, Sergi D, Catenaro T, Di Lauro L, Mottolese M, Santini D, Milella M, De Maria R. Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. *Crit Rev Oncol Hematol* (**IF 5,833**). 2016 Oct;106:132-42. doi: 10.1016/j.critrevonc.2016.08.004. Epub 2016 Aug 21. PMID: 27637358. **Cit. 6**
177. Fusco V, Campisi G, Numico G, Migliorati CA, Santini D, Bedogni A. RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw. *J Natl Cancer Inst* (**IF 12,589**). 2016 Jul 7;108(9):djw155. doi: 10.1093/jnci/djw155. PMID: 27390045. **Cit. 3**
178. Amato M, Perrone G, Righi D, Pellegrini C, Rabitti C, Di Matteo F, Crucitti P, Caputo D, Coppola R, Tonini G, Santini D, Onetti Muda A. HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease. *Pathol Oncol Res* (**IF 2,826**) 2017 Jan;23(1):55-61. doi: 10.1007/s12253-016-0082-5. Epub 2016 Jun 30. PMID: 27363700. **Cit. 7**
179. Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G. Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. *Oncotarget* (**IF 3,765**). 2016 Jun

- 28;7(26):40085-40094. doi: 10.18632/oncotarget.9485. PMID: 27223078; PMCID: PMC5129994. **Cit. 13**
180. Vincenzi B, Armento G, Spalato Ceruso M, Catania G, Leakos M, Santini D, Minotti G, Tonini G. Drug-induced hepatotoxicity in cancer patients - implication for treatment. *Expert Opin Drug Saf* (**IF 3,156**) 2016 Sep;15(9):1219-38. doi: 10.1080/14740338.2016.1194824. Epub 2016 Jun 14. PMID: 27232067. **Cit. 27**
181. Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. *Oncotarget* (**IF 3,765**). 2016 May 31;7(22):33381-90. doi: 10.18632/oncotarget.8302. PMID: 27027342; PMCID: PMC5078103. **Cit. 11**
182. Gori S, Inno A, Rossi V, Turazza M, Fiorio E, Fabi A, Bisagni G, Foglietta J, Santini D, Pavese I, Pellegrino A, Zambelli A, Vici P, Leonardi V, Barni S, Saracchini S, Bogina G, Marchetti F, Duranti S, Lunardi G, Montemurro F. Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. *PLoS One* (**IF 2,74**). 2016 May 25;11(5):e0156221. doi: 10.1371/journal.pone.0156221. PMID: 27224517; PMCID: PMC4880338. **Cit. 2**
183. Fanale D, Amodeo V, Bazan V, Insalaco L, Incurvaia L, Barraco N, Castiglia M, Rizzo S, Santini D, Giordano A, Castorina S, Russo A. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer? *Oncotarget* (**IF 3,765**). 2016 May 17;7(20):29321-32. doi: 10.18632/oncotarget.8722. PMID: 27081088; PMCID: PMC5045398. **Cit. 17**
184. Fusco V, Santini D, Armento G, Tonini G, Campisi G. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. *Expert Opin Drug Saf* (**IF 3,156**) 2016 Jul;15(7):925-35. doi: 10.1080/14740338.2016.1177021. Epub 2016 May 3. PMID: 27074901. **Cit. 39**
185. Santini D, Barni S, Intagliata S, Falcone A, Ferrà F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G. Corrigendum: Natural History of Non- Small-Cell Lung Cancer with Bone Metastases. *Sci Rep* (**IF 3,998**). 2016 Apr 15;6:22205. doi: 10.1038/srep22205. Erratum for: *Sci Rep* (**IF 3,998**). 2015;5:18670. multiple author names corrected. PMID: 27079142; PMCID: PMC4832177. **Cit. 47**
186. Passiglia F, Bronte G, Bazan V, Natoli C, Rizzo S, Galvano A, Listì A, Cicero G, Rolfo C, Santini D, Russo A. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. *Oncotarget* (**IF 3,765**). 2016 Apr 12;7(15):19738-47. doi: 10.18632/oncotarget.7582. PMID: 26918451; PMCID: PMC4991415. **Cit. 101**
187. Faloppi L, Del Prete M, Casadei Gardini A, Santini D, Silvestris N, Bianconi M, Giampieri R, Valgiusti M, Brunetti O, Bittoni A, Andrikou K, Lai E, Dessì A, Cascinu S, Scartozzi M. The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. *Sci Rep* (**IF 3,998**). 2016 Apr 11;6:24136. doi: 10.1038/srep24136. PMID: 27063994; PMCID: PMC4827080. **Cit. 15**
188. Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC,

- Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F. "Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. *Oncotarget* (**IF 3,765**). 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480. PMID: 26910921; PMCID: PMC4951261. **Cit. 23**
189. Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, de Lorenzo S, Garajova I, Di Marco M, Pinna AD, Cescon M, Cucchetti A, Ercolani G, D'Errico-Grigioni A, Pantaleo MA, Biasco G, Tavolari S; G.I.CO. (Gruppo Italiano Colangiocarcinoma). Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. *Oncologist* (**IF 5,025**). 2016 May;21(5):600-7. doi: 10.1634/theoncologist.2015-0356. Epub 2016 Mar 31. PMID: 27032872; PMCID: PMC4861359. **Cit. 20**
190. Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L, Gamucci T, Natoli C, Marchetti P, Barba M, Maugeri-Saccà M, Sergi D, Tomao F, Vizza E, Di Filippo S, Paolini F, Curzio G, Corrado G, Michelotti A, Sanguineti G, Giordano A, De Maria R, Venuti A. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. *Expert Rev Vaccines*. (**IF 4,684**) 2016 Oct;15(10):1327-36. doi: 10.1080/14760584.2016.1176533. Epub 2016 May 9. PMID: 27063030; PMCID: PMC5152541. **Cit. 45**
191. Santini D, Tonini G. Treatment of Advanced Renal-Cell Carcinoma. *N Engl J Med* (**IF 74,699**) 2016 Mar 3;374(9):888-9. doi: 10.1056/NEJMc1515613. PMID: 26962913. **Cit. 3**
192. Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D'Angelo A, Spizzo G, Bortolus R, Donini M, Lo Re G, Massari F, Vicario G, Zucali PA, Alesini D, Bonetti A, Mucciarini C, Nicodemo M, Berruti A, Fratino L, Lodde M, Messina C, Perin A, Santini D, Sava T, Tucci M, Basso U, Maines F, Burgio LS, Galligioni E. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. *Future Oncol* (**IF 2,66**). 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18. PMID: 26776493. **Cit. 8**
193. Borro M, Simmaco M, Aceti A, Barni S, De Luca A, Fineschi V, Frati P, Girardi P, Miozzo M, Nati G, Nicoletti F, Santini D, Marchetti P. H2020 and Beyond: Skip Discrepancy between Theory and Practice of Personalized Medicine. A Position Paper by the Italian Society of Personalized Medicine. *Curr Pharm Biotechnol* (**IF 1,49**) 2016;17(10):926-9. doi: 10.2174/1389201017666160519112850. PMID: 27194357. **Cit. 7**
194. Fornaro L, Vivaldi C, Cereda S, Leone F, Aprile G, Lonardi S, Silvestris N, Santini D, Milella M, Caparello C, Musettini G, Pasquini G, Falcone A, Brandi G, Sperduti I, Vasile E; GICO group (Gruppo Italiano COLangiocarcinoma). Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum- gemcitabine combination: a multicenter survey and pooled analysis with published data. *J Exp Clin Cancer Res* (**IF 5,646**). 2015 Dec 23;34:156. doi: 10.1186/s13046-015-0267-x. PMID: 26693938; PMCID: PMC4689003. **Cit. 31**
195. Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M; Early Strong Opioid Treatment Study (ESOT) Investigators. Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. *J Clin Oncol*. 2016 Feb 10;34(5):436-42. doi: 10.1200/JCO.2015.61.0733. Epub 2015 Dec 7. Erratum in: *J Clin Oncol* (**IF 32,956**). 2017 May 20;35(15):1753. PMID: 26644526. **Cit. 69**
196. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARM, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M,

- Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Nicolai E, Newsheem S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. *Semin Cancer Biol* (**IF 11,09**) 2015 Dec;35 Suppl(Suppl):S276-S304. doi: 10.1016/j.semcancer.2015.09.007. PMID: 26590477; PMCID: PMC4819002. **Cit 174**
197. Santoni M, Piva F, Scarpelli M, Cheng L, Lopez-Beltran A, Massari F, Iacovelli R, Berardi R, Santini D, Montironi R. The origin of prostate metastases: emerging insights. *Cancer Metastasis Rev* (**IF 6,667**). 2015 Dec;34(4):765-73. doi: 10.1007/s10555-015-9597-6. PMID: 26363603. **Cit. 25**
198. Brandi G, Venturi M, Pantaleo MA, Ercolani G; GICO. Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. *Dig Liver Dis* (**IF 3,57**) 2016 Mar;48(3):231-41. doi: 10.1016/j.dld.2015.11.017. Epub 2015 Nov 28. PMID: 26769568. **Cit. 53**
199. Silvestris N, Longo V, Cellini F, Reni M, Bittoni A, Cataldo I, Partelli S, Falconi M, Scarpa A, Brunetti O, Lorusso V, Santini D, Morganti A, Valentini V, Cascinu S. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. *Crit Rev Oncol Hematol* (**IF 5,833**). 2016 Feb;98:309-24. doi: 10.1016/j.critrevonc.2015.11.016. Epub 2015 Nov 23. PMID: 26653573. **Cit. 25**
200. Massari F, Modena A, Ciccarese C, Pilotto S, Maines F, Bracarda S, Sperduti I, Giannarelli D, Carlini P, Santini D, Tortora G, Porta C, Bria E. Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. *Crit Rev Oncol Hematol* (**IF 5,833**). 2016 Feb;98:254-63. doi: 10.1016/j.critrevonc.2015.11.009. Epub 2015 Nov 17. PMID: 26638863. **Cit. 0**
201. Santoni M, Conti A, Piva F, Massari F, Ciccarese C, Burattini L, Cheng L, Lopez-Beltran A, Scarpelli M, Santini D, Tortora G, Cascinu S, Montironi R. Role of STAT3 pathway in genitourinary tumors. *Future Sci OA* (**IF 3,25**) 2015 Nov 1;1(3):FSO15. doi: 10.4155/fso.15.13. PMID: 28031890; PMCID: PMC5137995. **Cit. 28**
202. Piva F, Giulietti M, Occhipinti G, Santoni M, Massari F, Sotte V, Iacovelli R, Burattini L, Santini D, Montironi R, Cascinu S, Principato G. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. *Oncotarget* (**IF 3,765**). 2015 Oct 13;6(31):32161-8. doi: 10.18632/oncotarget.5147. PMID: 26452128; PMCID: PMC4741666. **Cit. 21**

203. Vincenzi B, Cremonini C, Sartore-Bianchi A, Russo A, Mannavola F, Perrone G, Pantano F, Loupakis F, Rossini D, Ongaro E, Bonazzina E, Dell'Aquila E, Imperatori M, Zoccoli A, Bronte G, De Maglio G, Fontanini G, Natoli C, Falcone A, Santini D, Onetti-Muda A, Siena S, Tonini G, Aprile G. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. *Oncotarget* (**IF 3,765**). 2015 Oct 13;6(31):31604-12. doi: 10.18632/oncotarget.5231. PMID: 26384309; PMCID: PMC4741627. **Cit. 24**
204. Santoni M, Scarpelli M, Lopez-Beltran A, Cheng L, Briganti A, Montorsi F, Montironi R, Santini D. Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. *Eur Urol* (IF 17,581) 2015;68:542-3. *Eur Urol* (**IF 17,581**). 2016 Sep;70(3):e69-70. doi: 10.1016/j.eururo.2015.09.022. Epub 2015 Oct 1. PMID: 26431914. **Cit. 0**
205. Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, Azzariti A, Aprile G, Delcuratolo S, Signorile M, Gnani A, Palermo L, Lorusso V, Cascinu S, Silvestris N. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? *Oncotarget* (**IF 3,765**). 2015 Sep 15;6(27):23323-41. doi: 10.18632/oncotarget.4492. PMID: 26259238; PMCID: PMC4695121. **Cit. 51**
206. Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini MG, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. *PLoS One* (IF 2,74). 2015 Sep 4;10(9):e0136731. doi: 10.1371/journal.pone.0136731. Erratum in: *PLoS One* (**IF 2,74**). 2015;10(9):e0139650. PMID: 26340098; PMCID: PMC4560419. **Cit. 6**
207. Santini D, Stumbo L, Spoto C, D'Onofrio L, Pantano F, Iuliani M, Fioramonti M, Zoccoli A, Ribelli G, Virzì V, Vincenzi B, Tonini G. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence. *Breast Cancer Res* (**IF 4,988**). 2015 Sep 2;17(1):121. doi: 10.1186/s13058-015-0634-8. PMID: 26328589; PMCID: PMC4557314. **Cit. 21**
208. Di Lauro L, Barba M, Pizzuti L, Vici P, Sergi D, Di Benedetto A, Mottolese M, Speirs V, Santini D, De Maria R, Maugeri-Saccà M. Androgen receptor and antiandrogen therapy in male breast cancer. *Cancer Lett* (**IF 7,36**). 2015 Nov 1;368(1):20-25. doi: 10.1016/j.canlet.2015.07.040. Epub 2015 Aug 11. PMID: 26276719. **Cit. 18**
209. Vincenzi B, Stumbo L, Maltese G, Cerbone L, Spalato Ceruso M, Badalamenti G, Santini D, Tonini G, Frezza AM, De Lisi D, Silletta M. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. *Sci Rep* (**IF 3,998**). 2015 Aug 3;5:12077. doi:10.1038/srep12077. PMID: 26235506; PMCID: PMC4522670. **Cit. 1**
210. Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. *PLoS One* (**IF 2,74**). 2015 Jul 31;10(7):e0133488. doi: 10.1371/journal.pone.0133488. PMID: 26230853; PMCID: PMC4521926. **Cit. 62**
211. Cazzato RL, Buy X, Grasso RF, Luppi G, Faiella E, Quattrocchi CC, Pantano F, Beomonte Zobel B, Tonini G, Santini D, Palussiere J. Interventional Radiologist's perspective on the management of bone metastatic disease. *Eur J Surg Oncol* (**IF 3,959**) 2015 Aug;41(8):967-74. doi: 10.1016/j.ejso.2015.05.010. Epub 2015 Jun 3. PMID: 26072701. **Cit. 23**



212. Grimaldi A, Santini D, Zappavigna S, Lombardi A, Misso G, Boccellino M, Desiderio V, Vitiello PP, Di Lorenzo G, Zoccoli A, Pantano F, Caraglia M. Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. *Cancer Biol Ther* (**IF 3,659**) 2015;16(4):567-79. doi: 10.1080/15384047.2015.1018494. Epub 2015 Apr 11. PMID: 25866016; PMCID: PMC4622435. **Cit. 41**
213. Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P, Sliva D, Subbarayan PR, Sarkar M, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Ye L, Helferich WG, Yang X, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Nowsheen S, Pantano F, Santini D. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. *Semin Cancer Biol* (**IF 11,09**) 2015 Dec;35 Suppl:S244-S275. doi: 10.1016/j.semcancer.2015.03.008. Epub 2015 Apr 10. PMID: 25865774. **Cit 234**
214. Lastraioli E, Perrone G, Sette A, Fiore A, Crociani O, Manoli S, D'Amico M, Masselli M, Iorio J, Callea M, Borzomati D, Nappo G, Bartolozzi F, Santini D, Bencini L, Farsi M, Boni L, Di Costanzo F, Schwab A, Onetti Muda A, Coppola R, Arcangeli A. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. *Br J Cancer* (**IF 5,791**) 2015 Mar 17;112(6):1076-87. doi: 10.1038/bjc.2015.28. PMID: 25719829; PMCID: PMC4366888. **Cit. 24**
215. Massari F, Santoni M, Ciccicarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. *Cancer Treat Rev* (**IF 8,885**) 2015 Feb;41(2):114-21. doi: 10.1016/j.ctrv.2014.12.013. Epub 2015 Jan 6. PMID: 25586601. **Cit 121**
216. Berardi R, Rinaldi S, Santini D, Vincenzi B, Giampieri R, Maccaroni E, Marcucci F, Francoletti M, Onofri A, Lucarelli A, Pierantoni C, Tonini G, Cascinu S. Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. *Support Care Cancer* (**IF 2,698**). 2015 May;23(5):1295-302. doi: 10.1007/s00520-014-2466-y. Epub 2014 Oct 19. PMID: 25326782. **Cit. 7**
217. Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. *Ann Oncol* (**IF 18,274**). 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27. Erratum in: *Ann Oncol*. 2016 Feb;27(2):366. PMID: 26216384. **Cit. 59**
218. Massari F, Ciccicarese C, Santoni M, Brunelli M, Piva F, Modena A, Bimbatti D, Fantinel E, Santini D, Cheng L, Cascinu S, Montironi R, Tortora G. Metabolic alterations in renal cell carcinoma. *Cancer Treat Rev* (**IF 8,885**). 2015 Nov;41(9):767-76. doi: 10.1016/j.ctrv.2015.07.002. Epub 2015 Jul 9. PMID: 26169313. **Cit. 45**
219. Iacovelli R, Santini D, Rizzo M, Felici A, Santoni M, Verzoni E, Masini C, Massari F, Calvani N, Mosca A, Procopio G. Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. *Can Urol Assoc J* (**IF 1,419**) 2015 Jul-Aug;9(7-8):263-7. doi: 10.5489/cuaj.2377. PMID: 26316911; PMCID: PMC4537338. **Cit. 6**
220. Massari F, Santoni M, Ciccicarese C, Santini D. The immun checkpoints in modern oncology: the next 15 years. *Expert Opin Biol Ther* (**IF 3,974**). 2015 Jul;15(7):917-21. doi: 10.1517/14712598.2015.1035251. PMID: 26063384. **Cit. 17**
221. Santoni M, Conti A, Andrikou K, Bittoni A, Lanese A, Pistelli M, Pantano F, Vincenzi B, Armento G, Massari F, Tonini G, Cascinu S, Santini D. Risk of pruritus in cancer patients treated

- with biological therapies: A systematic review and meta-analysis of clinical trials. *Crit Rev Oncol Hematol* (**IF 5,833**). 2015 Nov;96(2):206-19. doi: 10.1016/j.critrevonc.2015.05.007. Epub 2015 Jun 10. PMID: 26070625. **Cit. 15**
222. Cappelletti MR, Gnetti L, Santini D, Spada D, Fox SB, Generali D. Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? *Oncoscience* (**IF 3,16**) 2015 Jun 5;2(6):567-9. doi: 10.18632/oncoscience.168. PMID: 26244161; PMCID: PMC4506357. **Cit. 1**
223. Vincenzi B, Imperatori M, Silletta M, Marrucci E, Santini D, Tonini G. Emerging kinase inhibitors of the treatment of gastric cancer. *Expert Opin Emerg Drugs* (**IF 3,058**) 2015 Sep;20(3):479-93. doi: 10.1517/14728214.2015.1051467. Epub 2015 Jun 1. PMID: 26021342. **Cit. 8**
224. Iuliani M, Pantano F, Buttigliero C, Fioramonti M, Bertaglia V, Vincenzi B, Zoccoli A, Ribelli G, Tucci M, Vignani F, Berruti A, Scagliotti GV, Tonini G, Santini D. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. *Oncotarget* (**IF 3,765**). 2015 May 20;6(14):12520-8. doi: 10.18632/oncotarget.3724. PMID: 25904051; PMCID: PMC4494955. **Cit. 33**
225. Di Lauro L, Pizzuti L, Barba M, Sergi D, Sperduti I, Mottolese M, Amoreo CA, Belli F, Vici P, Speirs V, Santini D, De Maria R, Maugeri-Saccà M. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. *J Hematol Oncol* (**IF 10,743**). 2015 May 17;8:53. doi: 10.1186/s13045-015-0147-z. PMID: 25980944; PMCID: PMC4440498. **Cit. 22**
226. Massari F, Santoni M, Ciccarese C, Brunelli M, Conti A, Santini D, Montironi R, Cascinu S, Tortora G. Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. *Crit Rev Oncol Hematol* (**IF 5,833**). 2015 Oct;96(1):81-90. doi: 10.1016/j.critrevonc.2015.05.005. Epub 2015 May 15. PMID: 26022449. **Cit. 40**
227. Conteduca V, Caffo O, Derosa L, Veccia A, Petracci E, Chiuri VE, Santoni M, Santini D, Fratino L, Maines F, Testoni S, De Giorgi U. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. *Prostate* (**IF 4,47**) 2015 Sep;75(12):1329-38. doi: 10.1002/pros.23014. Epub 2015 May 15. PMID: 25982919. **Cit. 15**
228. Russano M, Vincenzi B, Venditti O, D'Onofrio L, Ratta R, Guida FM, Tonini G, Santini D. Pazopanib and pancreatic toxicity: a case report. *BMC Res Notes* (**IF 1,34**). 2015 May 14;8:196. doi: 10.1186/s13104-015-1154-4. PMID: 25967382; PMCID: PMC4434851. **Cit. 3**
229. Vincenzi B, Iuliani M, Zoccoli A, Pantano F, Fioramonti M, De Lisi D, Frezza AM, Rabitti C, Perrone G, Onetti Muda A, Russo A, Giordano A, Santini D, Dei Tos AP, Tonini G. Deregulation of dicer and mir-155 expression in liposarcoma. *Oncotarget* (**IF 3,765**). 2015 Apr 30;6(12):10586-91. doi: 10.18632/oncotarget.3201. PMID: 25888631; PMCID: PMC4496377. **Cit. 14**
230. Garon EB, Rizvi NA, Hui R, Leigh N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Luceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med* (**IF 74,699**) 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19. PMID: 25891174. **Cit. 3388**
231. Pantano F, Santoni M, Procopio G, Rizzo M, Iacovelli R, Porta C, Conti A, Lugini A, Milella M, Galli L, Ortega C, Guida FM, Silletta M, Schinzari G, Verzoni E, Modica D, Crucitti P, Rauco A, Felici A, Ballatore V, Cascinu S, Tonini G, Carteni G, Russo A, Santini D. The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new

- pharmacodynamic marker? *PLoS One* (**IF 2,74**). 2015 Apr 17;10(4):e0120427. doi: 10.1371/journal.pone.0120427. PMID: 25885920; PMCID: PMC4401714. **Cit. 9**
232. Fioroni I, Dell'Aquila E, Pantano F, Intagliata S, Caricato M, Vincenzi B, Coppola R, Santini D, Tonini G. Role of c-mesenchymal-epithelial transition pathway in gastric cancer. *Expert Opin Pharmacother* (**IF 3,894**) 2015 Jun;16(8):1195-207. doi: 10.1517/14656566.2015.1037739. Epub 2015 Apr 16. PMID: 25881479. **Cit. 8**
233. Bronte G, Rolfo C, Passiglia F, Rizzo S, Gil-Bazo I, Fiorentino E, Cajozzo M, Van Meerbeeck JP, Lequaglie C, Santini D, Pauwels P, Russo A. What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. *Crit Rev Oncol Hematol* (**IF 5,833**). 2015 Sep;95(3):306-17. doi: 10.1016/j.critrevonc.2015.03.010. Epub 2015 Apr 11. PMID: 25922216. **Cit. 20**
234. Vincenzi B, D'Onofrio L, Frezza AM, Grasso RF, Fausti V, Santini D, Dei Tos AP, Tonini G. Classic Kaposi Sarcoma: to treat or not to treat? *BMC Res Notes* (**IF 1,34**). 2015 Apr 10;8:138. doi: 10.1186/s13104-015-1076-1. PMID: 25889316; PMCID: PMC4395989. **Cit. 10**
235. Cazzato RL, Palussière J, Buy X, Denaro V, Santini D, Tonini G, Grasso RF, Zobel BB, Poretti D, Pedicini V, Balzarini L, Lanza E. Percutaneous Long Bone Cementoplasty for Palliation of Malignant Lesions of the Limbs: A Systematic Review. *Cardiovasc Intervent Radiol* (**IF 1,928**) 2015 Dec;38(6):1563-72. doi: 10.1007/s00270-015-1082-7. Epub 2015 Mar 24. PMID: 25799950. **Cit. 31**
236. Santoni M, Massari F, Del Re M, Ciccarese C, Piva F, Principato G, Montironi R, Santini D, Danesi R, Tortora G, Cascinu S. Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. *Expert Opin Investig Drugs* (**IF 5,528**) 2015 Jun;24(6):809-24. doi: 10.1517/13543784.2015.1020370. Epub 2015 Mar 7. PMID: 25746129. **Cit. 33**
237. Venditti O, De Lisi D, Caricato M, Caputo D, Capolupo GT, Taffon C, Pagliara E, Battisi S, Frezza AM, Onetti Muda A, Tonini G, Santini D. Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. *BMC Cancer* (**IF 3,15**). 2015 Mar 1;15:87. doi: 10.1186/s12885-015-1074-7. PMID: 25885696; PMCID: PMC4350587. **Cit. 20**
238. Palmer C, Santini D. A key opinion leader interview with Prof D Santini: insight into cancer research. *Expert Opin Ther Targets* (**IF 4,598**) 2015 Mar;19(3):443-5. doi: 10.1517/14728222.2015.1015227. PMID: 25685935. **Cit. 0**
239. Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, Bracarda S, Tonini G, Cascinu S, Santini D. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? *J Exp Clin Cancer Res* (**IF 5,646**). 2015 Feb 5;34(1):10. doi: 10.1186/s13046-015-0122-0. PMID: 25651794; PMCID: PMC4328067. **Cit. 42**
240. Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A, Montironi R, Santini D, Cheng L, Martignoni G, Cascinu S, Tortora G. The route to personalized medicine in bladder cancer: where do we stand? *Target Oncol* (**IF 3,463**) 2015 Sep;10(3):325-36. doi: 10.1007/s11523-015-0357-x. Epub 2015 Jan 30. PMID: 25634607. **Cit. 13**
241. Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, Pisconti S, Petrelli F, Vacca A, Lorusso V. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? *Crit Rev Oncol Hematol* (**IF 5,833**). 2015 Jul;95(1):46-61. doi: 10.1016/j.critrevonc.2015.01.008. Epub 2015 Jan 20. PMID: 25656744. **Cit. 46**

242. Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. *Target Oncol* (**IF 3,463**) 2015 Dec;10(4):517-22. doi: 10.1007/s11523-014-0356-3. Epub 2015 Jan 6. PMID: 25559290. **Cit. 29**
243. Gnoni A, Santini D, Scartozzi M, Russo A, Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V, Angarano G, Brunetti O, Guarini A, Pisconti S, Lorusso V, Silvestris N. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? *Expert Opin Ther Targets* (**IF 4,598**) 2015;19(12):1623-35. doi: 10.1517/14728222.2015.1071354. Epub 2015 Jul 27. PMID: 26212068. **Cit. 45**
244. Gori M, Trombetta M, Santini D, Rainer A. Tissue engineering and microRNAs: future perspectives in regenerative medicine. *Expert Opin Biol Ther* (**IF 3,974**). 2015;15(11):1601-22. doi: 10.1517/14712598.2015.1071349. Epub 2015 Jul 22. PMID: 26200765. **Cit. 15**
245. Mangia A, Caldarola L, Dell'Endice S, Scarpi E, Saragoni L, Monti M, Santini D, Brunetti O, Simone G, Silvestris N. The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. *Cancer Biol Ther* (**IF 3,659**). 2015;16(8):1140-7. doi: 10.1080/15384047.2015.1056414. Epub 2015 Jun 30. PMID: 26126066; PMCID: PMC4622862. **Cit. 12**
246. Pantano F, Iuliani M, Zoccoli A, Fioramonti M, De Lisi D, Fioroni I, Ribelli G, Santoni M, Vincenzi B, Tonini G, Santini D. Emerging drugs for the treatment of bone metastasis. *Expert Opin Emerg Drugs* (**IF 3,058**) 2015;20(4):637-51. doi: 10.1517/14728214.2015.1062876. Epub 2015 Jun 25. PMID: 26113304. **Cit. 3**
247. Vincenzi B, Imperatori M, Picardi A, Vespasiani Gentilucci U, Gallo P, Fausti V, Spalato Ceruso M, Santini D, Tonini G. Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. *Expert Rev Anticancer Ther.* (**IF 3,573**) 2015;15(8):971-6. doi: 10.1586/14737140.2015.1061937. Epub 2015 Jun 25. PMID: 26112080. **Cit. 8**
248. Scartozzi M, Giampieri R, Aprile G, Iacono D, Santini D, dell'Aquila E, Silvestris N, Gnoni A, Bonotto M, Puzzone M, Demurtas L, Cascinu S. The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. *Expert Rev Mol Diagn.* (**IF 4,096**) 2015;15(8):979-87. doi: 10.1586/14737159.2015.1047346. Epub 2015 May 15. PMID: 25975986. **Cit. 11**
249. Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. *Cancer Treat Rev* (**IF 8,885**). 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. PMID: 25573350. **Cit. 56**
250. Valeri S, Borzomati D, Nappo G, Perrone G, Santini D, Coppola R. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature. *Pancreatology* (**IF 3,628**) 2014 Sep-Oct;14(5):425-30. doi: 10.1016/j.pan.2014.07.002. Epub 2014 Jul 19. PMID: 25278312. **Cit. 15**
251. Vivaldi C, Fornaro L, Cereda S, Aprile G, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Brandi G, Vasile E. Second-line chemotherapy in advanced biliary cancer: the present now will later be past. *Ann Oncol* (**IF 18,274**). 2014 Dec;25(12):2443-2444. doi: 10.1093/annonc/mdu379. Epub 2014 Aug 13. PMID: 25122694. **Cit. 2**

252. Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, Belli C, Bergamo F, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, Brandi G. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. *Br J Cancer* (**IF 5,791**) 2014 Apr 29;110(9):2165-9. doi: 10.1038/bjc.2014.190. Epub 2014 Apr 8. PMID: 24714745; PMCID: PMC4007244. **Cit. 49**
253. Ripamonti CI, Bossi P, Santini D, Fallon M. Pain related to cancer treatments and diagnostic procedures: a no man's land? *Ann Oncol* (**IF 18,274**). 2014 Jun;25(6):1097-106. doi: 10.1093/annonc/mdu011. Epub 2014 Mar 13. PMID: 24625453. **Cit. 16**
254. Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. *Ann Surg Oncol* (**IF 4,179**). 2015;22(6):2094-100. doi: 10.1245/s10434-014-4256-7. Epub 2014 Dec 4. PMID: 25472645. **Cit. 43**
255. Silvestris N, Scartozzi M, Graziano G, Santini D, Lorusso V, Maiello E, Barni S, Cinieri S, Loupakis F, Pisconti S, Brunetti AE, Palasciano G, Palmieri VO, Del Prete M, Dell'Aquila E, Latiano TP, Petrelli F, Lutrino S, Rossini D, Giampieri R, Lotesoriere C, Cascinu S. Basal and bevacizumab-based therapy- induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. *Expert Opin Biol Ther* (**IF 3,974**). 2015 Feb;15(2):155-62. doi: 10.1517/14712598.2015.986452. Epub 2014 Nov 19. PMID: 25411089. **Cit. 20**
256. Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. *Eur Urol* (**IF 17,581**). 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25. PMID: 25457020. **Cit. 67**
257. Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F, Carreca AP, Taverna S, Vento R, Santini D, Peeters M, Russo A, Pauwels P. Liquid biopsies in lung cancer: the new ambrosia of researchers. *Biochim Biophys Acta* (**IF 3,422**). 2014 Dec;1846(2):539-46. doi: 10.1016/j.bbcan.2014.10.001. Epub 2014 Oct 16. Erratum in: *Biochim Biophys Acta* (**IF 3,422**). 2015 Jan; 1855(1):17. Santini, Daniele [added]. PMID: 25444714. **Cit. 111**
258. Vici P, Pizzuti L, Natoli C, Moscetti L, Mentuccia L, Vaccaro A, Sergi D, Di Lauro L, Trenta P, Seminara P, Santini D, Iezzi L, Tinari N, Bertolini I, Sini V, Mottolese M, Giannarelli D, Giotto F, Maugeri-Saccà M, Barba M, Marchetti P, Michelotti A, Sperduti I, Gamucci T. Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. *Breast Cancer Res Treat* (**IF 3,94**). 2014 Oct;147(3):599-607. doi: 10.1007/s10549-014-3133-1. Epub 2014 Sep 19. PMID: 25234842; PMCID: PMC4174332. **Cit. 27**
259. Silvestris N, Vincenzi B, Brunetti AE, Loupakis F, Dell'Aquila E, Russo A, Scartozzi M, Giampieri R, Cascinu S, Lorusso V, Tonini G, Falcone A, Santini D. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. *Pharmacogenomics* (**IF 2,35**) 2014 Sep;15(13):1701-15. doi: 10.2217/pgs.14.124. PMID: 25410895. **Cit. 4**

260. Santini D, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri VO, Infante G, Aieta M, Trogu A, Gadaleta CD, Brunetti AE, Lorusso V, Silvestris N. Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. *PLoS One* (**IF 2,74**). 2014 Aug 29;9(8):e105268. doi: 10.1371/journal.pone.0105268. PMID: 25170882; PMCID: PMC4149423. **Cit. 24**
261. Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M. Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. *Crit Rev Oncol Hematol* (**IF 5,833**). 2015 Jan;93(1):50-9. doi: 10.1016/j.critrevonc.2014.08.001. Epub 2014 Aug 18. PMID: 25195095. **Cit. 10**
262. Guida FM, Santoni M, Conti A, Burattini L, Savini A, Zeppola T, Caricato M, Cascinu S, Tonini G, Santini D. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. *Crit Rev Oncol Hematol* (**IF 5,833**) 2014 Dec;92(3):208-17. doi: 10.1016/j.critrevonc.2014.07.006. Epub 2014 Aug 6. PMID: 25151214. **Cit. 21**
263. Quattrocchi CC, Errante Y, Mallio CA, Carideo L, Scarciolla L, Santini D, Tonini G, Zobel BB. Inverse spatial distribution of brain metastases and white matter hyperintensities in advanced lung and non-lung cancer patients. *J Neurooncol* (**IF 3,267**). 2014 Nov;120(2):321-30. doi: 10.1007/s11060-014-1554-7. Epub 2014 Jul 22. PMID: 25048530. **Cit. 6**
264. Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. *J Urol* (**IF 5,157**) 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18. PMID: 25046616. **Cit. 38**
265. Croset M, Santini D, Iuliani M, Fioramonti M, Zoccoli A, Vincenzi B, Tonini G, Pantano F. MicroRNAs and bone metastasis: a new challenge. *Molecules* (**3,267**). 2014 Jul 11;19(7):10115-28. doi: 10.3390/molecules190710115. PMID: 25019555; PMCID: PMC6271587. **Cit. 16**
266. D'Onofrio L, Tonini G, Santini D. Clinical features of male breast cancer and multimodal treatment: a comment to retrospective survey analysis at Italian centers. *Tumori* (**IF 1,707**). 2014 Jul-Aug;100(4):169e-70e. doi: 10.1700/1636.17944. PMID: 25296612. **Cit. 1**
267. Battisti S, Guida FM, Pagliara E, Tonini G, Zobel BB, Santini D. Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view. *Clin Colorectal Cancer* (**IF 2,813**). 2014 Sep;13(3):e13-5. doi: 10.1016/j.clcc.2014.06.003. Epub 2014 Jun 26. PMID: 25085312. **Cit. 12**
268. Ruzzo A, Catalano V, Canestrari E, Giacomini E, Santini D, Tonini G, Vincenzi B, Fiorentini G, Magnani M, Graziano F. Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy. *BMC Cancer* (**IF 3,15**). 2014 May 22;14:357. doi: 10.1186/1471-2407-14-357. PMID: 24886605; PMCID: PMC4046495. **Cit. 22**
269. Fanale D, Iovanna JL, Calvo EL, Berthezene P, Belleau P, Dagorn JC, Bronte G, Cicero G, Bazan V, Rolfo C, Santini D, Russo A. Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma

- susceptibility? *Expert Opin Ther Targets* (**IF 4,598**) 2014 Aug;18(8):841-50. doi: 10.1517/14728222.2014.920324. Epub 2014 May 16. PMID: 24834797. **Cit. 15**
270. Battisti S, Guida FM, Coppa F, Vaccaro DM, Santini D, Tonini G, Zobel BB, Semelka RC. Modification of abdominal fat distribution after aromatase inhibitor therapy in breast cancer patients visualized using 3-D computed tomography volumetry. *Clin Breast Cancer* (**IF 2,703**) 2014 Oct;14(5):365-70. doi: 10.1016/j.clbc.2014.02.003. Epub 2014 Mar 6. PMID: 24850544. **Cit. 8**
271. Ratta R, Santini D. Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib. *Tumori* (**IF 1,707**). 2014 Mar-Apr;100(2):e59-62. doi: 10.1700/1491.16441. PMID: 24852879. **Cit. 0**
272. Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. *Cancer Metastasis Rev* (**IF 6,667**). 2014 Mar;33(1):321-31. doi: 10.1007/s10555-013-9453-5. PMID: 24337954. **Cit. 22**
273. Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D. Targeting bone metastatic cancer: Role of the mTOR pathway. *Biochim Biophys Acta* (**IF 3,422**) 2014 Apr;1845(2):248-54. doi: 10.1016/j.bbcan.2014.01.009. Epub 2014 Feb 5. PMID: 24508774. **Cit. 20**
274. Foroni C, Milan M, Strina C, Cappelletti M, Fumarola C, Bonelli M, Bertoni R, Ferrero G, Maldotti M, Takano E, Andreis D, Venturini S, Brugnoli G, Petronini PG, Zanoni V, Pritzker L, Pritzker K, Parissenti A, Santini D, Fox SB, Bottini A, Generali D. Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy". *Breast Cancer Res Treat* (**IF 3,94**). 2014 Feb;144(1):113-21. doi: 10.1007/s10549-014-2840-y. Epub 2014 Jan 28. PMID: 24469643. **Cit. 12**
275. Santoni M, Pantano F, Amantini C, Nabissi M, Conti A, Burattini L, Zoccoli A, Berardi R, Santoni G, Tonini G, Santini D, Cascinu S. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. *Biochim Biophys Acta* (**IF 3,422**). 2014 Apr;1845(2):221-31. doi: 10.1016/j.bbcan.2014.01.007. Epub 2014 Jan 27. PMID: 24480319. **Cit. 48**
276. Passiglia F, Van Der Steen N, Raez L, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, Cappuzzo F, Rolfo C. The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target? *Curr Drug Targets* (**IF 3,522**) 2014;15(14):1284-92. doi: 10.2174/138945011514141216092739. PMID: 25511614. **Cit. 9**
277. Silvestris N, Gnoni A, Brunetti AE, Vincenti L, Santini D, Tonini G, Merchionne F, Maiello E, Lorusso V, Nardulli P, Azzariti A, Reni M. Target therapies in pancreatic carcinoma. *Curr Med Chem* (**IF 4,184**) 2014;21(8):948-65. doi: 10.2174/09298673113209990238. PMID: 23992319. **Cit. 42**
278. Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, Fontana A, Berruti A, Berardi R, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, Virzi V, Santoni M, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Fedeli SL, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Tonini G, Bracarda S. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. *PLoS One* (**IF 2,74**). 2013 Dec 30;8(12):e83026. doi: 10.1371/journal.pone.0083026. PMID: 24386138; PMCID: PMC3875424. **Cit. 42**
279. Santini D, Vincenzi B, Venditti O, Dell'Aquila E, Frezza AM, Silletta M, Guida FM, Grasso RF, Silvestris N, Lanzetta G, Tonini G. Sunitinib in malignant melanoma: a treatment option only

- for KIT-mutated patients? *Future Oncol* (**IF 2,66**). 2013 Dec;9(12):1809-11. doi: 10.2217/fo.13.170. PMID: 24295410. **Cit. 3**
280. Scartozzi M, Giampieri R, Del Prete M, Faloppi L, Bianconi M, Vincenzi B, Tonini G, Santini D, Cascinu S. Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. *Expert Opin Pharmacother* (**IF 3,894**) 2014 Jan;15(1):143-50. doi: 10.1517/14656566.2014.860964. Epub 2013 Nov 28. PMID: 24283747. **Cit. 8**
281. Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. *J Exp Clin Cancer Res* (**IF 5,646**). 2013 Nov 18;32(1):92. doi: 10.1186/1756-9966-32-92. PMID: 24245912; PMCID: PMC3874688. **Cit. 56**
282. Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D, Cascinu S. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. *Int J Cancer* (**IF 5,145**). 2014 Aug 15;135(4):763-73. doi: 10.1002/ijc.28544. Epub 2013 Nov 18. PMID: 24127298. **Cit. 35**
283. Santoni M, Berardi R, Amantini C, Burattini L, Santini D, Santoni G, Cascinu S. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. *Int J Cancer* (**IF 5,145**). 2014 Jun 15;134(12):2772-7. doi: 10.1002/ijc.28503. Epub 2013 Nov 18. PMID: 24114790. **Cit. 48**
284. Grimaldi A, Balestrieri ML, D'Onofrio N, Di Domenico G, Nocera C, Lamberti M, Tonini G, Zoccoli A, Santini D, Caraglia M, Pantano F. The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence. *PLoS One* (**IF 2,74**). 2013 Nov 11;8(11):e79658. doi: 10.1371/journal.pone.0079658. PMID: 24244540; PMCID: PMC3823580. **Cit. 18**
285. Suriano F, Santini D, Perrone G, Amato M, Vincenzi B, Tonini G, Muda A, Boggia S, Buscarini M, Pantano F. Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer. *J Exp Clin Cancer Res* (**IF 5,646**). 2013 Nov 5;32(1):87. doi: 10.1186/1756-9966-32-87. PMID: 24423367; PMCID: PMC4029537. **Cit. 24**
286. Pantano F, Berti P, Guida FM, Perrone G, Vincenzi B, Amato MM, Righi D, Dell'aquila E, Graziano F, Catalano V, Caricato M, Rizzo S, Muda AO, Russo A, Tonini G, Santini D. The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients. *J Cell Mol Med* (**IF 4,658**) 2013 Nov;17(11):1415-21. doi: 10.1111/jcmm.12109. Epub 2013 Nov 27. PMID: 24283947; PMCID: PMC4117554. **Cit. 42**
287. Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Pedrazzoli P, Barni S, Bernardo A, Febbraro A, Satolli MA, Bertocchi P, Catalano V, Giommoni E, Comandone A, Maiello E, Riccardi F, Ferrara R, Trogu A, Berardi R, Leo S, Bertolini A, Angelini F, Cinieri S, Russo A, Pisconti S, Brunetti AE, Azzariti A, Santini D. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. *PLoS One* (**IF 2,74**). 2013 Oct 28;8(10):e74402. doi: 10.1371/journal.pone.0074402. PMID: 24204569; PMCID: PMC3810275. **Cit. 37**
288. Pantano F, Vincenzi B, Santini D, Tonini G. Magnesium: are we better off without it? *Anticancers Drugs* (**IF 1,784**). 2013 Oct;24(9):879-80. doi: 10.1097/CAD.0b013e32836452d6. PMID: 23884107. **Cit. 0**
289. Gnoni A, Licchetta A, Scarpa A, Azzariti A, Brunetti AE, Simone G, Nardulli P, Santini D, Aieta M, Delcuratolo S, Silvestris N. Carcinogenesis of pancreatic adenocarcinoma: precursor



- lesions. *Int J Mol Sci* (**IF 4,566**) 2013 Sep 30;14(10):19731-62. doi: 10.3390/ijms141019731. PMID: 24084722; PMCID: PMC3821583. **Cit. 41**
290. Amodeo V, Bazan V, Fanale D, Insalaco L, Caruso S, Cicero G, Bronte G, Rolfo C, Santini D, Russo A. Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? *Expert Opin Ther Targets* (**IF 4,598**) 2013 Nov;17(11):1249-61. doi: 10.1517/14728222.2013.832206. Epub 2013 Sep 22. PMID: 24053448. **Cit. 27**
291. Amadori D, Mercatali L, Nanni O, Aglietta M, Alessi B, Gianni L, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI, Ibrahim T. What can we learn from the ZOOM trial?--Authors' reply. *Lancet Oncol* (**IF 33,752**). 2013 Sep;14(10):e388-90. doi: 10.1016/S1470-2045(13)70295-X. PMID: 23993381. **Cit. 1**
292. Rolfo C, Russo A, Santini D, Bronte G, Peeters M. Dilemma in metastatic colorectal cancer: VEGF versus EGFR targeting. *Expert Opin Ther Targets* (**IF 4,598**) 2013 Aug;17(8):869-71. doi: 10.1517/14728222.2013.818135. Epub 2013 Jul 15. PMID: 23848525. **Cit. 8**
293. Santoni M, De Tursi M, Felici A, Lo Re G, Ricotta R, Ruggeri EM, Sabbatini R, Santini D, Vaccaro V, Milella M. Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. *Expert Rev Anticancer Ther.* (**IF 3,573**) 2013 Jun;13(6):697-709. doi: 10.1586/era.13.52. PMID: 23773104. **Cit. 12**
294. Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, Rocco M, Di Gennaro E, Leone A, Luciano A, Arra C, Santini D, Caraglia M, Budillon A. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. *Cell Death Dis* (**IF 6,304**) 2013 Oct 24;4(10):e878. doi: 10.1038/cddis.2013.406. PMID: 24157872; PMCID: PMC3920938. **Cit. 37**
295. Santini D, Vincenzi B, Pantano F, Schiavon G, Tonini G. 'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer. *Ann Oncol* (**IF 18,274**). 2013 Jul;24(7):1715-1717. doi: 10.1093/annonc/mdt172. Epub 2013 May 12. PMID: 23670095. **Cit. 3**
296. Pantano F, Guida FM, Vivaldi C, Vincenzi B, Grande E, Garrote MR, Caraglia M, Silvestris N, Vasile E, Masi G, Falcone A, Tonini G, Santini D. Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. *Cancer Biol Ther* (**IF 3,659**) 2013 Jun;14(6):467-8. doi: 10.4161/cbt.24346. PMID: 23760487; PMCID: PMC3813561. **Cit. 5**
297. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. *Lancet Oncol* (**IF 33,752**). 2013 Jun;14(7):663-70. doi: 10.1016/S1470-2045(13)70174-8. Epub 2013 May 16. PMID: 23684411. **Cit 120**
298. Quattrocchi CC, Errante Y, Mallio CA, Santini D, Tonini G, Zobel BB. Brain metastatic volume and white matter lesions in advanced cancer patients. *J Neurooncol* (**IF 3,267**). 2013 Jul;113(3):451-8. doi: 10.1007/s11060-013-1137-z. Epub 2013 May 12. PMID: 23666234. **Cit. 7**
299. Vincenzi B, Frezza AM, Schiavon G, Santini D, Dileo P, Silletta M, Delisi D, Bertoldo F, Badalamenti G, Baldi GG, Zovato S, Berardi R, Tucci M, Silvestris F, Dei Tos AP, Tirabosco R, Whelan JS, Tonini G. Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. *Clin Sarcoma Res* (**NO IF**). 2013 Apr 17;3(1):6. doi: 10.1186/2045-3329-3-6. PMID: 23594799; PMCID: PMC3637638. **Cit. 0**

300. Santini D, Lanzetta G, Dell'Aquila E, Vincenzi B, Venditti O, Russano M, Papapietro N, Denaro V, Tonini G, Ripamonti C. 'Old' and 'new' drugs for the treatment of cancer pain. *Expert Opin Pharmacother* (**IF 3,894**) 2013 Mar;14(4):425-33. doi: 10.1517/14656566.2013.774375. PMID: 23438421. **Cit. 6**
301. Santini D, Frezza AM, Venditti O, Intagliata S, dell'Aquila E, Guida F, Vincenzi B, Tonini G. Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. *Expert Opin Ther Targets* (**IF 4,598**) 2013 Apr;17(4):473-4. doi: 10.1517/14728222.2013.773269. Epub 2013 Feb 28. PMID: 23445337. **Cit. 0**
302. Rozzi A, Santini D, Salerno M, Bordin F, Mancuso A, Minniti G, Nardoni C, Corona M, Falbo PT, Recine F, Lanzetta G. Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study. *Med Oncol* (**IF 2,834**) 2013 Mar;30(1):407. doi: 10.1007/s12032-012-0407-5. Epub 2013 Jan 10. PMID: 23307245. **Cit. 13**
303. Santini D, Zoccoli A, Gregorj C, Di Cerbo M, Iuliani M, Pantano F, Zamarchi R, Sergi F, Flammia G, Buscarini M, Rizzo S, Cicero G, Russo A, Vincenzi B, Avvisati G, Tonini G. Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting. *Oncology* (**IF 2,642**). 2013;85(6):342-7. doi: 10.1159/000347226. Epub 2013 Dec 3. PMID: 24335337. **Cit. 9**
304. Morini S, Perrone G, Borzomati D, Vincenzi B, Rabitti C, Righi D, Castri F, Manazza AD, Santini D, Tonini G, Coppola R, Onetti Muda A. Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival. *Pancreas* (**IF 2,92**) 2013 Jan;42(1):60-6. doi: 10.1097/MPA.0b013e318258fda8. PMID: 22889982. **Cit. 37**
305. Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell'aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, Loupakis F, Falcone A, Santini D, Tonini G. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. *Eur J Cancer* (**IF 7,275**). 2013 Apr;49(6):1501-8. doi: 10.1016/j.ejca.2012.11.014. Epub 2012 Dec 22. PMID: 23266047. **Cit. 18**
306. Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfex IV. *Support Care Cancer* (**IF 2,698**). 2013 May;21(5):1313-9. doi: 10.1007/s00520-012-1667-5. Epub 2012 Nov 30. Erratum in: *Support Care Cancer*. 2013 Apr;21(4):1209. Silvestris, Nicola [added]. PMID: 23196819. **Cit. 33**
307. Pantano F, Clézardin P, Santini D. RANK/RANKL pathway in cancer: Biological activity beyond bone? *J Bone Oncol* (**IF 3,066**) *Oncol*. 2012 Nov 29;1(3):67-8. doi: 10.1016/j.jbo.2012.11.001. PMID: 26909258; PMCID: PMC4723344. **Cit. 1**
308. Vincenzi B, Silletta M, Schiavon G, Frezza AM, Del Vescovo R, Zobel BB, Santini D, Dei Tos AP, Tonini G. Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. *Expert Opin Investig Drugs* (**IF 5,528**) 2013 Jan;22(1):1-7. doi: 10.1517/13543784.2013.742886. Epub 2012 Nov 16. PMID: 23157681. **Cit. 8**
309. Santini D, Addeo R, Vincenzi B, Calvieri A, Montella L, Silletta M, Caraglia M, Vespasiani U, Picardi A, Del Prete S, Tonini G. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. *Expert Rev Anticancer Ther*. (**IF 3,573**) 2012 Oct;12(10):1283-8. doi: 10.1586/era.12.102. Epub 2012 Oct 24. PMID: 23094801. **Cit. 7**
310. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G. Aprepitant for management of severe pruritus related to biological cancer treatments: a

- pilot study. *Lancet Oncol* (**IF 33,752**). 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18. PMID: 22995650. **Cit. 78**
311. Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, Santini D, Caraglia M. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. *Cancer Biol Ther* (**IF 3,659**). 2012 Dec;13(14):1491-500. doi: 10.4161/cbt.22274. Epub 2012 Sep 18. PMID: 22990205; PMCID: PMC3542241. **Cit. 45**
312. Vincenzi B, Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, Denaro V, Santini D, Tonini G. Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. *J Hematol Oncol* (**IF 10,743**). 2012 Sep 17;5:56. doi: 10.1186/1756-8722-5-56. PMID: 22986334; PMCID: PMC3472182. **Cit. 27**
313. Insalaco L, Di Gaudio F, Terrasi M, Amodeo V, Caruso S, Corsini LR, Fanale D, Margarese N, Santini D, Bazan V, Russo A. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. *J Cell Mol Med* (**IF 4,658**). 2012 Sep;16(9):2186-95. doi: 10.1111/j.1582-4934.2012.01527.x. PMID: 22260151; PMCID: PMC3822988. **Cit. 25**
314. Santini D, Bertoldo F, Dell'Aquila E, Cecchini I, Fregosi S, Bortolussi P; ZeTa study group. The Italian cross-sectional survey of the management of bone metastasis: ZeTa study. *J Bone Oncol* (**IF 3,066**) *Oncol*. 2012 Jul 21;1(2):35-9. doi: 10.1016/j.jbo.2012.04.005. PMID: 26909253; PMCID: PMC4723326. **Cit. 1**
315. Quattrocchi CC, Errante Y, Gaudino C, Mallio CA, Giona A, Santini D, Tonini G, Zobel BB. Spatial brain distribution of intra-axial metastatic lesions in breast and lung cancer patients. *J Neurooncol* (**IF 3,267**). 2012 Oct;110(1):79-87. doi: 10.1007/s11060-012-0937-x. Epub 2012 Jul 18. PMID: 22802020. **Cit. 28**
316. Minoia C, Giannoccaro M, Iacobazzi A, Santini D, Silvestris N, Fioretti A, Oliva S, Guarini A. Antineoplastic drug-induced bradyarrhythmias. *Expert Opin Drug Saf* (**IF 3,156**) 2012 Sep;11(5):739-51. doi: 10.1517/14740338.2012.705826. Epub 2012 Jul 13. PMID: 22788850. **Cit. 3**
317. Vincenzi B, Napolitano A, Santini D, Maiello E, Torri V, Tonini G. Evidence-based guidelines: Improving AGREEMENT on consistence evaluation. *J Bone Oncol* (**IF 3,066**) *Oncol*. 2012 Apr 30;1(1):30-4. doi: 10.1016/j.jbo.2012.04.001. PMID: 26909252; PMCID: PMC4723325. **Cit. 2**
318. Vincenzi B, Santini D, Schiavon G, Frezza AM, Silletta M, Crucitti P, Casali P, Dei Tos AP, Rossi S, Rizzo S, Badalamenti G, Tomasino RM, Russo A, Butrynski JE, Tonini G. PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy. *J Cell Physiol* (**IF 5,546**) 2012 Apr;227(4):1657-62. doi: 10.1002/jcp.22889. PMID: 21678421. **Cit. 3**
319. Quattrocchi CC, Dell'Aia P, Errante Y, Occhicone F, Longo D, Virzì V, Tonini G, Napoli N, Santini D, Beomonte Zobel B. Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases. *J Bone Oncol* (**IF 3,066**) *Oncol*. 2012 Mar 23;1(1):24-9. doi: 10.1016/j.jbo.2012.02.001. PMID: 26909251; PMCID: PMC4723329. **Cit. 2**
320. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F; ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. *Ann Oncol* (**IF 18,274**). 2012 Oct;23 Suppl 7:vii139-54. doi: 10.1093/annonc/mds233. PMID: 22997447. **Cit 301**
321. Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? *Ann Oncol* (**IF 18,274**). 2012 Sep;23(9):2313-2318. doi:

- 10.1093/annonc/mdr623. Epub 2012 Mar 5. Erratum in: *Ann Oncol* (IF 18,274). 2017 Nov 1;28(11):2906. Erratum in: *Ann Oncol* (IF 18,274). 2017 Nov;28(11):2906. PMID: 22396447. **Cit 118**
322. Caraglia M, De Rosa G, Salzano G, Santini D, Lamberti M, Sperlongano P, Lombardi A, Abbruzzese A, Addeo R. Nanotech revolution for the anti-cancer drug delivery through blood-brain barrier. *Curr Cancer Drug Targets* (IF 3,522) 2012 Mar;12(3):186-96. doi: 10.2174/156800912799277421. PMID: 22268384. **Cit. 45**
323. Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. *Ann Oncol* (IF 18,274). 2012 Aug;23(8):2072-2077. doi: 10.1093/annonc/mdr572. Epub 2012 Jan 4. PMID: 22219016. **Cit. 70**
324. Catalano V, Loupakis F, Graziano F, Bissoni R, Torresi U, Vincenzi B, Mari D, Giordani P, Alessandrini P, Salvatore L, Fornaro L, Santini D, Baldelli AM, Rossi D, Giustini L, Silva RR, Falcone A, D'Emidio S, Rocchi M, Luzi Fedeli S. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. *Ann Oncol* (IF 18,274). 2012 Jan;23(1):135-141. doi: 10.1093/annonc/mdr062. Epub 2011 Apr 29. PMID: 21531784. **Cit. 50**
325. Zoccoli A, Iuliani M, Pantano F, Imperatori M, Intagliata S, Vincenzi B, Marchetti P, Papapietro N, Denaro V, Tonini G, Santini D. Premetastatic niche: ready for new therapeutic interventions? *Expert Opin Ther Targets* (IF 4,598) 2012 Apr;16 Suppl 2:S119-29. doi: 10.1517/14728222.2012.656092. Epub 2012 Mar 23. PMID: 22443277. **Cit. 23**
326. Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis F, Schiavon G, Frezza AM, Ruzzo AM, Rizzo S, Crucitti P, Galluzzo S, Zoccoli A, Rabitti C, Muda AO, Russo A, Falcone A, Tonini G. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. *J Cell Physiol* (IF 5,546). 2012 Mar;227(3):927-33. doi: 10.1002/jcp.22801. PMID: 21503888. **Cit. 6**
327. Catalano V, Vincenzi B, Giordani P, Graziano F, Santini D, Baldelli AM, Alessandrini P, Schiavon G, Rossi D, Casadei V, D'Emidio S, Luzi Fedeli S, Tonini G, Fiorentini G. Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study. *Gastric Cancer*. (IF 4,828) 2012 Oct;15(4):419-26. doi: 10.1007/s10120-011-0134-1. Epub 2012 Jan 12. PMID: 22237659. **Cit. 2**
328. Perrone G, Gaeta LM, Zagami M, Nasorri F, Coppola R, Borzomati D, Bartolozzi F, Altomare V, Trodella L, Tonini G, Santini D, Cavani A, Muda AO. In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas. *PLoS One* (IF 2,74). 2012;7(9):e43110. doi: 10.1371/journal.pone.0043110. Epub 2012 Sep 13. PMID: 23028444; PMCID: PMC3441535. **Cit. 26**
329. Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, Catalano V, Loupakis F, Rabitti C, Santini D, Tonini G, Fiorentini G, Rossi D, Falcone A, Magnani M. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy- refractory metastatic disease. *Oncologist* (IF 5,025). 2012;17(6):823-9. doi: 10.1634/theoncologist.2012-0081. Epub 2012 May 14. PMID: 22584434; PMCID: PMC3380881. **Cit. 63**
330. Santini D, Virzi V, Vasile E, Vincenzi B, Catalano V, Graziano F, Masi G, Bronte G, Russo A, Falcone A, Tonini G. A phase II trial of fixed-dose rate gemcitabine plus capecitabine in

- metastatic/advanced biliary tract cancer patients. *Oncology* (**IF 2,642**). 2012;82(2):75-82. doi: 10.1159/000329079. Epub 2012 Feb 7. PMID: 22327844. **Cit. 10**
331. Santini D, Fratto ME, Aapro M. Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumab. *Recent Results Cancer Res* (**IF 6,27**) 2012;192:171-85. doi: 10.1007/978-3-642-21892-7\_8. PMID: 22307375. **Cit. 3**
332. Santini D, Pantano F, Vincenzi B, Tonini G, Bertoldo F. The role of bone microenvironment, vitamin D and calcium. *Recent Results Cancer Res* (**IF 6,27**) 2012;192:33-64. doi: 10.1007/978-3-642-21892-7\_2. PMID: 22307369. **Cit. 9**
333. Caraglia M, Santini D, Bronte G, Rizzo S, Sortino G, Rini GB, Di Fede G, Russo A. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules. *Curr Drug Metab* (**IF 2,976**) 2011 Dec;12(10):944-55. doi: 10.2174/138920011798062346. PMID: 21787268. **Cit. 14**
334. Vincenzi B, Napolitano A, D'Onofrio L, Frezza AM, Silletta M, Venditti O, Santini D, Tonini G. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. *Expert Opin Investig Drugs* (**IF 5,528**) 2011 Dec;20(12):1685-705. doi: 10.1517/13543784.2011.628984. Epub 2011 Oct 20. PMID: 22010859. **Cit. 3**
335. Santini D, Vincenzi B, Pantano F, Tonini G, Bertoldo F. Targeting bone metastases starting from the preneoplastic niche: home sweet home. *Breast Cancer Res* (**IF 4,988**) 2011 Aug 16;13(4):111. doi: 10.1186/bcr2911. PMID: 21892970; PMCID: PMC3236332. **Cit. 7**
336. Tommasi S, Pinto R, Petriella D, Pilato B, Lacalamita R, Santini D, Zito F, Colucci G, Paradiso A, Silvestris N. Oncosuppressor methylation: a possible key role in colon metastatic progression. *J Cell Physiol* (**IF 5,546**). 2011 Jul;226(7):1934-9. doi: 10.1002/jcp.22524. PMID: 21506124. **Cit. 20**
337. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. *BMC Cancer* (**IF 3,15**) 2011 Jun 14;11:247. doi: 10.1186/1471-2407-11-247. PMID: 21669012; PMCID: PMC3125285. **Cit. 53**
338. Tonini G, Fratto ME, Imperatori M, Pantano F, Vincenzi B, Santini D. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. *Expert Rev Anticancer Ther.* (**IF 3,573**) 2011 Jun;11(6):921-30. doi: 10.1586/era.11.63. PMID: 21707289. **Cit. 10**
339. Pantano F, Zoccoli A, Iuliani M, Lanzetta G, Vincenzi B, Tonini G, Santini D. New targets, new drugs for metastatic bone pain: a new philosophy. *Expert Opin Emerg Drugs* (**IF 3,058**) 2011 Sep;16(3):403-5. doi: 10.1517/14728214.2011.588600. Epub 2011 May 31. PMID: 21623686. **Cit. 9**
340. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G. Receptor activator of NF-Kb (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. *PLoS One* (**IF 2,74**). 2011 Apr 29;6(4):e19234. doi: 10.1371/journal.pone.0019234. PMID: 21559440; PMCID: PMC3084800. **Cit 132**
341. Vitale G, Dicitore A, Sciortino G, Abbruzzese A, Persani L, Santini D. Role of GPR30 in testicular germ cell tumors: a potential new anticancer target. *Cancer Biol Ther* (**IF 3,659**). 2011 Apr 15;11(8):773-5. doi: 10.4161/cbt.11.8.15272. Epub 2011 Apr 15. PMID: 21372633. **Cit. 7**

342. Catalano V, Mellone P, d'Avino A, Shridhar V, Staccioli MP, Graziano F, Giordani P, Rossi D, Baldelli AM, Alessandrini P, Santini D, Lorenzon L, Testa E, D'Emidio S, De Nictolis M, Muretto P, Fedeli SL, Baldi A. HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer. *Histopathology* (**IF 3,626**) 2011 Apr;58(5):669-78. doi: 10.1111/j.1365-2559.2011.03818.x. Epub 2011 Mar 30. PMID: 21447133. **Cit. 20**
343. Santini D, Vincenzi B, Adamo V, Addeo R, Fusco V, Russo A, Montemurro F, Roato I, Redana S, Lanzetta G, Satolli MA, Berruti A, Leoni V, Galluzzo S, Antimi M, Ferraro G, Rossi M, Del Prete S, Valerio MR, Marra M, Caraglia M, Tonini G. Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. *Oncol Rep* (**IF 3,417**). 2011 Jun;25(6):1545-8. doi: 10.3892/or.2011.1235. Epub 2011 Mar 28. PMID: 21455582. **Cit. 6**
344. Vincenzi B, Santini D, Frezza AM, Berti P, Vespasiani U, Picardi A, Tonini G. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. *Expert Opin Drug Saf* (**IF 3,156**) 2011 May;10(3):345-9. doi: 10.1517/14740338.2011.562888. Epub 2011 Mar 15. PMID: 21406026. **Cit. 9**
345. Fratto ME, Imperatori M, Vincenzi B, Tomao F, Santini D, Tonini G. New perspectives: role of Sunitinib in breast cancer. *Clin Ter* (**IF 3,119**) 2011;162(3):251-7. PMID: 21717054. **Cit. 11**
346. Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. *Ann Oncol* (**IF 18,274**) 2011 May;22(5):1141-1146. doi: 10.1093/annonc/mdq550. Epub 2010 Nov 29. PMID: 21115601. **Cit. 52**
347. Ruzzo A, Canestrari E, Galluccio N, Santini D, Vincenzi B, Tonini G, Magnani M, Graziano F. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients. *Ann Oncol* (**IF 18,274**) 2011 Jan;22(1):234-235. doi: 10.1093/annonc/mdq472. Epub 2010 Oct 6. PMID: 20926546. **Cit. 12**
348. Tonini G, Vincenzi B, Santini D. Bisphosphonate anticancer activity. *Expert Opin Pharmacother* (**IF 3,894**) 2011 Apr;12(5):681-3. doi: 10.1517/14656566.2011.543279. Epub 2011 Mar 9. PMID: 21385151. **Cit. 1**
349. Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. *J Cell Physiol* (**IF 5,546**). 2011 Mar;226(3):780-4. doi: 10.1002/jcp.22402. PMID: 20857484. **Cit. 91**
350. Santini D, Galluzzo S, Gaeta L, Zoccoli A, Riva E, Ruzzo A, Vincenzi B, Graziano F, Loupakis F, Falcone A, Muda AO, Tonini G. Should oncologists be aware in their clinical practice of KRAS molecular analysis? *J Clin Oncol* (**IF 32,956**). 2011 Mar 10;29(8):e206-7; author reply e208-9. doi: 10.1200/JCO.2010.32.7700. Epub 2011 Jan 24. PMID: 21263083. **Cit. 16**
351. Vincenzi B, Daniele S, Frezza AM, Berti P, Vespasiani U, Picardi A, Tonini G. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. *Support Care Cancer* (**IF 2,698**). 2012 Jan;20(1):135-9. doi: 10.1007/s00520-010-1078-4. Epub 2011 Jan 14. PMID: 21229271. **Cit 18**

352. Santini D, Pantano F, Vincenzi B, Tonini G. Emerging therapeutic targets in osteoncology. *Oncology* (**IF 2,642**). 2011;80(3-4):223-4. doi: 10.1159/000327573. Epub 2011 Jul 4. PMID: 21734412. **Cit. 1**
353. Fratto ME, Santini D, Vincenzi B, Silvestris N, Azzariti A, Tommasi S, Zoccoli A, Galluzzo S, Maiello E, Colucci G, Tonini G. Targeting EGFR in bilio-pancreatic and liver carcinoma. *Front Biosci (Schol Ed)*. (**IF 2,747**) 2011 Jan 1;3:16-22. doi: 10.2741/s128. PMID: 21196353. **Cit. 6**
354. Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). *Curr Cancer Drug Targets* (**IF 3,522**) 2011 Jan;11(1):123-9. doi: 10.2174/156800911793743600. PMID: 20578980. **Cit. 36**
355. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? *Cancer Treat Rev* (**IF 8,885**). 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9. PMID: 21129611. **Cit. 84**
356. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N, Russo A. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. *Cancer Treat Rev* (**IF 8,885**). 2010 Nov;36 Suppl 3:S21-9. doi: 10.1016/S0305-7372(10)70016-5. PMID: 21129606. **Cit 106**
357. Tonini G, Intagliata S, Cagli B, Segreto F, Perrone G, Onetti Muda A, Santini D, Persichetti P. Recurrent scrotal hemangiomas during treatment with sunitinib. *J Clin Oncol* (**IF 32,956**). 2010 Dec 10;28(35):e737-8. doi: 10.1200/JCO.2010.30.4865. Epub 2010 Sep 7. PMID: 20823408. **Cit. 8**
358. Graziano F, Ruzzo A, Canestrari E, Catalano V, Santini D, Galluccio N, Loupakis F, Alessandrini P, Spada D, Ficarelli R, Bissoni R, D'Emidio S, Vincenzi B, Angeletti S, Salvatore L, Cremolini C, Tonini G, Falcone A, Magnani M. Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. *Pharmacogenomics* (**IF 2,35**). 2010 Sep;11(9):1247-56. doi: 10.2217/pgs.10.92. PMID: 20860465. **Cit. 6**
359. Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G. PML down-regulation in soft tissue sarcomas. *J Cell Physiol* (**IF 5,546**). 2010 Sep;224(3):644-8. doi: 10.1002/jcp.22161. PMID: 20578240. **Cit. 5**
360. Santini D, Galluzzo S, Zoccoli A, Pantano F, Fratto ME, Vincenzi B, Lombardi L, Gucciardino C, Silvestris N, Riva E, Rizzo S, Russo A, Maiello E, Colucci G, Tonini G. New molecular targets in bone metastases. *Cancer Treat Rev* (**IF 8,885**) 2010 Nov;36 Suppl 3:S6-S10. doi: 10.1016/S0305-7372(10)70013-X. PMID: 21129612. **Cit. 44**
361. Silvestris N, Maiello E, De Vita F, Cinieri S, Santini D, Russo A, Tommasi S, Azzariti A, Numico G, Pisconti S, Petriella D, Lorusso V, Millaku A, Colucci G. Update on capecitabine alone and in combination regimens in colorectal cancer patients. *Cancer Treat Rev* (**IF 8,885**) 2010 Nov;36 Suppl 3:S46-55. doi: 10.1016/S0305-7372(10)70020-7. PMID: 21129610. **Cit. 14**
362. Lombardi L, Morelli F, Cinieri S, Santini D, Silvestris N, Fazio N, Orlando L, Tonini G, Colucci G, Maiello E. Adjuvant colon cancer chemotherapy: where we are and where we'll go. *Cancer Treat Rev* (**IF 8,885**) 2010 Nov;36 Suppl 3:S34-41. doi: 10.1016/S0305-7372(10)70018-9. PMID: 21129608. **Cit. 57**

363. Santini D, Fratto ME, Spoto C, Russo A, Galluzzo S, Zoccoli A, Vincenzi B, Tonini G. Cetuximab in small bowel adenocarcinoma: a new friend? *Br J Cancer* (**IF 5,791**) 2010 Oct 12;103(8):1305; author reply 1306. doi: 10.1038/sj.bjc.6605898. Epub 2010 Sep 14. PMID: 20842127; PMCID: PMC2967067. **Cit. 30**
364. Perrone G, Morini S, Santini D, Rabitti C, Vincenzi B, Alloni R, Antinori A, Magistrelli P, Lai R, Cass C, Mackey JR, Coppola R, Tonini G, Onetti Muda A. Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes. *Eur J Histochem* (**IF 2,172**) 2010;54(3):e38. doi: 10.4081/ejh.2010.e38. PMID: 20839414; PMCID: PMC3167316. **Cit. 7**
365. Santini D, Spoto C, Loupakis F, Vincenzi B, Silvestris N, Cremolini C, Canestrari E, Graziano F, Galluccio N, Salvatore L, Caraglia M, Zito FA, Colucci G, Falcone A, Tonini G, Ruzzo A. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. *Ann Oncol* (**IF 18,274**). 2010 Jul;21(7):1565. doi: 10.1093/annonc/mdq318. PMID: 20573852. **Cit. 36**
366. Tonini G, Frato ME, Vincenzi B, Santini D. Chemotherapy in biliary tract cancer. *Eur Rev Med Pharmacol* (**IF 3,024**) Sci. 2010 Apr;14(4):371-4. PMID: 20496551. **Cit. 1**
367. Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D'Emidio S, Giordani P, Tonini G, Falcone A, Magnani M. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. *Pharmacogenomics J* (**IF 2,35**) 2010 Oct;10(5):458-64. doi: 10.1038/tpj.2010.9. Epub 2010 Feb 23. PMID: 20177422. **Cit. 97**
368. Pantano F, Santini D, Guida F, Vincenzi B, Tonini G. Potential role of everolimus in inducing cholestasis. *Ann Oncol* (**IF 18,274**) 2010 Feb;21(2):433. doi: 10.1093/annonc/mdp558. Epub 2009 Dec 2. PMID: 19955336. **Cit. 5**
369. Santini D, Galluzzo S, Vincenzi B, Zoccoli A, Ferraro E, Lippi C, Altomare V, Tonini G, Bertoldo F. Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. *Ann Oncol* (**IF 18,274**) 2010 Jan;21(1):185-6. doi: 10.1093/annonc/mdp497. Epub 2009 Nov 5. PMID: 19892747. **Cit. 28**
370. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. *N Engl J Med* (**IF 74,699**) 2010 Jul 22;363(4):397-8. doi: 10.1056/NEJMc1003937. PMID: 20660413. **Cit. 60**
371. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilias G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* (**IF 33,752**). 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8. PMID: 20619739 **Cit. 1543**.
372. Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. *Crit Rev Oncol Hematol* (**IF 5,833**). 2011 Jun;78(3):243-51. doi: 10.1016/j.critrevonc.2010.06.003. Epub 2010 Jul 8. PMID: 20619672. **Cit. 25**



373. Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. *Support Care Cancer* (**IF 2,698**). 2010 Sep;18(9):1229-30. doi: 10.1007/s00520-010-0895-9. Epub 2010 Jun 11. PMID: 20544226. **Cit. 41**
374. Vincenzi B, Napolitano A, Frezza AM, Schiavon G, Santini D, Tonini G. Wide- spectrum characterization of trabectedin: biology, clinical activity and future perspectives. *Pharmacogenomics* (**IF 2,35**). 2010 Jun;11(6):865-78. doi: 10.2217/pgs.10.69. PMID: 20504257. **Cit. 21**
375. Vincenzi B, Frezza AM, Santini D, Tonini G. New therapies in soft tissue sarcoma. *Expert Opin Emerg Drugs* (**IF 3,058**) 2010 Jun;15(2):237-48. doi: 10.1517/14728211003592108. PMID: 20465449. **Cit. 25**
376. Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G, Graziano F. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. *J Cell Physiol* (**IF 5,546**). 2010 May;223(2):384-8. doi: 10.1002/jcp.22045. PMID: 20082300. **Cit. 31**
377. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. *Endocr Relat Cancer* (**IF 4,8**) 2010 Apr 21;17(2):445-53. doi: 10.1677/ERC-09-0281. PMID: 20410174. **Cit. 96**
378. Santini D, Virzi V, Fratto ME, Bertoldo F, Sabbatini R, Berardi R, Calipari N, Ottaviani D, Ibrahim T. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. *Curr Cancer Drug Targets* (**IF 3,522**) 2010 Feb;10(1):46-54. doi: 10.2174/156800910790980223. PMID: 20088792. **Cit. 22**
379. Vincenzi B, Frezza AM, Santini D, Tonini G. Target therapy in gastrointestinal tract sarcoma: What is new? *World J Gastrointest Oncol* (**IF 2,22**) 2010 Jan 15;2(1):1-4. doi: 10.4251/wjgo.v2.i1.1. PMID: 21160809; PMCID: PMC2999157. **Cit. 0**
380. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. *Oncologist* (**IF 5,025**). 2010;15(1):85-92. doi: 10.1634/theoncologist.2009-0143. Epub 2010 Jan 5. PMID: 20051477; PMCID: PMC3227883. **Cit 133**
381. Tonini G, Virzi V, Fratto ME, Vincenzi B, Santini D. Targeted therapy in biliary tract cancer: 2009 update. *Future Oncol* (**IF 2,66**). 2009 Dec;5(10):1675-84. doi: 10.2217/fon.09.130. PMID: 20001803. **Cit. 10**
382. Caraglia M, Santini D. Target therapy of bone metastases and tumours. *Curr Cancer Drug Targets* (**IF 3,522**). 2009 Nov;9(7):789-90. doi: 10.2174/156800909789760429. PMID: 20025566. **Cit. 0**
383. Santini D, Fratto ME, Vincenzi B, Napoli N, Galluzzo S, Tantardini M, Abbruzzese A, Caraglia M, Tonini G. Denosumab: the era of targeted therapies in bone metastatic diseases. *Curr Cancer Drug Targets* (**IF 3,522**) 2009 Nov;9(7):834-42. doi: 10.2174/156800909789760375. PMID: 20025571. **Cit. 15**
384. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, Tagliaferri P, Santini D, Caraglia M. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. *Curr Cancer Drug Targets* (**IF 3,522**) 2009 Nov;9(7):791-800. doi: 10.2174/156800909789760285. PMID: 20025567. **Cit. 38**

385. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. *Br J Cancer* (**IF 5,791**) 2009 Aug 18;101(4):715-21. doi: 10.1038/sj.bjc.6605177. Epub 2009 Jul 14. PMID: 19603018; PMCID: PMC2736831 **Cit. 442.**
386. Floriani I, Santini D, Torri V, Cremolini C, Falcone A, Loupakis F. Do we need biopsies of metastases for colorectal cancer patients? *Br J Cancer* (**IF 5,791**) 2009 Jul 21;101(2):374-5; author reply 376. doi: 10.1038/sj.bjc.6605131. Epub 2009 Jul 7. PMID: 19584870; PMCID: PMC2720216. **Cit. 1**
387. Tonini G, Fratto ME, Vincenzi B, Santini D. Classification of biliary tract cancer (BTC): evaluation of all entities. *Ann Oncol* (**IF 18,274**) 2009 Jun;20(6):1148-9; author reply 1149. doi: 10.1093/annonc/mdp275. PMID: 19465430. **Cit. 3**
388. Graziano F, Ruzzo A, Canestrari E, Loupakis F, Santini D, Rulli E, Humar B, Galluccio N, Bissoni R, Floriani I, Maltese P, Falcone A, Tonini G, Catalano V, Fontana A, Giustini L, Masi G, Vincenzi B, Alessandroni P, Magnani M. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. *Pharmacogenomics J* (**IF 2,35**) 2009 Feb;9(1):78-84. doi: 10.1038/tpj.2008.16. Epub 2008 Dec 23. PMID: 19104506. **Cit. 17**
389. Spugnini EP, Vincenzi B, Caruso G, Baldi A, Citro G, Santini D, Tonini G. Zoledronic acid for the treatment of appendicular osteosarcoma in a dog. *J Small Anim Pract* (**IF 0,7**) 2009 Jan;50(1):44-6. doi: 10.1111/j.1748-5827.2008.00635.x. Epub 2008 Sep 12. PMID: 18793253. **Cit. 16**
390. Vincenzi B, Santini D, Perrone G, Russo A, Adamo V, Rizzo S, Castri F, Antinori A, Alloni R, Crucitti PF, Morini S, Rabitti C, Vecchio FM, Magistrelli P, Coppola R, Tonini G. Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients. *Ann Oncol* (**IF 18,274**) 2009 Jan;20(1):78-83. doi: 10.1093/annonc/mdn558. Epub 2008 Aug 9. PMID: 18689862. **Cit. 11**
391. Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, Addeo SR, Abbruzzese A, Budillon A, Caraglia M. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. *Int J Cancer* (**IF 5,145**). 2009 Nov 1;125(9):2004-13. doi: 10.1002/ijc.24648. PMID: 19530242. **Cit. 32**
392. Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, Caricato M, Valeri S, Coppola R, Tonini G. Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-,irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. *Cancer* (**IF 5,742**) 2009 Oct 15;115(20):4849-56. doi: 10.1002/cncr.24540. PMID: 19626652. **Cit. 29**
393. Vincenzi B, Santini D, Loupakis F, Addeo R, Rojas Llimpe FL, Baldi GG, Di Fabio F, Del Prete S, Pinto C, Falcone A, Tonini G. Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. *Expert Opin Biol Ther* (**IF 3,974**). 2009 Aug;9(8):945-9. doi 10.1517/14712590903081694. PMID: 19534585. **Cit. 15**
394. Pantano F, Baldi A, Santini D, Vincenzi B, Borzomati D, Vecchio FM, Castri F, Antinori A, Caraglia M, Magistrelli P, Coppola R, Tonini G. MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients. *Cancer Biol Ther* (**IF 3,659**). 2009 Jun;8(11):996-9. doi: 10.4161/cbt.8.11.8537. PMID: 19587537. **Cit. 9**

395. Angeletti S, Galluzzo S, Santini D, Ruzzo A, Vincenzi B, Ferraro E, Spoto C, Lorino G, Graziano N, Calvieri A, Magnani M, Graziano F, Pantano F, Tonini G, Dicuonzo G. NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population. *Hum Immunol* (**IF 2,412**) 2009 Sep;70(9):729-32. doi: 10.1016/j.humimm.2009.04.026. Epub 2009 May 4. PMID: 19397946. **Cit. 22**
396. Silvestris N, Tommasi S, Santini D, Russo A, Simone G, Petriella D, Maiello E, Tonini G, Colucci G. KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. *Expert Opin Biol Ther* (**IF 3,974**) 2009 May;9(5):565-77. doi: 10.1517/14712590902870394. PMID: 19368524. **Cit. 11**
397. Russo A, Rizzo S, Fulfarò F, Adamo V, Santini D, Vincenzi B, Gebbia N, Carreca I. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. *Cancer* (**5,742**) 2009 May 1;115(9):1924-31. doi: 10.1002/cncr.24207. PMID: 19235250. **Cit. 22**
398. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *J Clin Oncol* (**IF 32,956**). 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27. PMID: 19398573. **Cit. 368**.
399. Bertoldo F, Tonini G, Vincenzi B, Santini D. Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer. *Nat Rev Clin Oncol* (**IF 53,276**) 2009 Apr;6(4):191-2. doi: 10.1038/nrclinonc.2009.24. PMID: 19333223. **Cit. 6**
400. Vitale G, Abbruzzese A, Tonini G, Santini D. Chemo-immunotherapy: a new option for non-small cell lung cancer. *Cancer Biol Ther* (**IF 3,659**). 2009 Mar 15;8(6):503-4. doi: 10.4161/cbt.8.6.7770. Epub 2009 Mar 15. PMID: 19242127. **Cit. 1**
401. Pantano F, Silletta M, Iovieno A, Vincenzi B, Santini D, Galluzzo S, Bonini S, Tonini G. Stevens-Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitumumab. *Int J Int J Int J Colorectal Dis* (**IF 2,108**). 2009 Oct;24(10):1247-8. doi: 10.1007/s00384-009-0676-4. Epub 2009 Feb 19. PMID: 19225787. **Cit. 5**
402. Tonini G, Calvieri A, Vincenzi B, Santini D. First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. *Onco Targets Ther* (**IF 3,046**) 2009 Feb 18;2:73-82. doi: 10.2147/ott.s3465. PMID: 20616896; PMCID: PMC2886322. **Cit. 2**
403. Di Martino A, Vincenzi B, Denaro L, Barnaba SA, Papalia R, Santini D, Tonini G, Denaro V. 'Internal bracing' surgery in the management of solid tumor metastases of the thoracic and lumbar spine. *Oncol Rep* (**IF 3,417**). 2009 Feb;21(2):431-5. PMID: 19148519. **Cit. 10**
404. Silvestris N, Tommasi S, Petriella D, Santini D, Fistola E, Russo A, Numico G, Tonini G, Maiello E, Colucci G. The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma. *Oncology* (**IF 2,642**). 2009;77 Suppl 1:69-74. doi: 10.1159/000258498. Epub 2010 Feb 2. PMID: 20130434. **Cit. 15**
405. Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, Graziano F, Baldi GG, Salvatore L, Russo A, Perrone G, Tommasino MR, Magnani M, Falcone A, Tonini G, Ruzzo A. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. *Oncologist* (**IF 5,025**). 2008 Dec;13(12):1270-5. doi: 10.1634/theoncologist.2008-0181. Epub 2008 Dec 4. PMID: 19056857. **Cit. 200**

406. Vincenzi B, Patti G, Galluzzo S, Pantano F, Venditti O, Santini D, Ruzzo A, Schiavon G, Caraglia M, Marra M, Graziano F, Tonini G. Interleukin 1beta-511T gene (IL1beta) polymorphism is correlated with gastric cancer in the Caucasian population: results from a meta-analysis. *Oncol Rep* (**IF 3,417**). 2008 Nov;20(5):1213-20. PMID: 18949424. **Cit. 41**
407. Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? *Br J Cancer* (**IF 5,791**) 2008 Nov 4;99(9):1402-7. doi: 10.1038/sj.bjc.6604732. PMID: 18971936; PMCID: PMC2579675. **Cit. 84**
408. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, Calvieri A, Pizzagalli F, Graziano N, Ferraro E, Lorino G, Altomare A, Magnani M, Graziano F, Tonini G. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. *Clin Exp Immunol* (**IF 3,532**) 2008 Dec;154(3):360-4. doi: 10.1111/j.1365-2249.2008.03776.x. Epub 2008 Sep 29. PMID: 18826495; PMCID: PMC2633233. **Cit. 79**
409. Graziano F, Ruzzo A, Loupakis F, Santini D, Catalano V, Canestrari E, Maltese P, Bissoni R, Fornaro L, Baldi G, Masi G, Falcone A, Tonini G, Giordani P, Alessandroni P, Giustini L, Vincenzi B, Magnani M. Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. *Br J Cancer* (**IF 5,791**) 2008 Sep 2;99(5):716-21. doi: 10.1038/sj.bjc.6604555. Epub 2008 Aug 12. PMID: 18728661; PMCID: PMC2528158. **Cit. 28**
410. Casale M, Rinaldi V, Quattrocchi C, Bressi F, Vincenzi B, Santini D, Tonini G, Salvinelli F. Atypical chronic head and neck pain: don't forget Eagle's syndrome. *Eur Rev Med Pharmacol Sci* (**IF 3,024**) 2008 Mar-Apr;12(2):131-3. PMID: 18575165. **Cit. 5**
411. Santini D, Perrone G, Vincenzi B, Lai R, Cass C, Alloni R, Rabitti C, Antinori A, Vecchio F, Morini S, Magistrelli P, Coppola R, Mackey JR, Tonini G. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. *Ann Oncol* (**IF 18,274**) 2008 Apr;19(4):724-8. doi: 10.1093/annonc/mdm576. Epub 2008 Jan 10. PMID: 18187485. **Cit. 35**
412. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bissoni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandroni P, Giustini L, Maltese P, Testa E, Menichetti ET, Magnani M. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. *Pharmacogenomics J* (**IF 2,35**) 2008 Aug;8(4):278-88. doi: 10.1038/sj.tpj.6500463. Epub 2007 Jun 5. PMID: 17549067. **Cit 93**
413. Maltese P, Canestrari E, Ruzzo A, Graziano F, Falcone A, Loupakis F, Tonini G, Santini D, Magnani M. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. *Int J Colorectal Dis* (**IF 2,108**). 2009 Feb;24(2):165-70. doi: 10.1007/s00384-008-0586-x. Epub 2008 Oct 2. PMID: 18830612. **Cit. 42**
414. Zardi EM, Di Matteo F, Santini D, Uwechie V, Crucitti P, Carassiti M, Picardi A, Perrella E, Caricato M, Tonini G, Coppola R, Afeltra A. Pancreatitis after percutaneous ethanol injection into HCC: a minireview of the literature. *J Exp Clin Cancer Res* (**IF 5,646**) 2008 Aug 14;27(1):28. doi: 10.1186/1756-9966-27-28. PMID: 18702805; PMCID: PMC2531081. **Cit. 3**
415. Santini D, Fratto ME, Galluzzo S, Vincenzi B, Tonini G. Are bisphosphonates the suitable anticancer drugs for the elderly? *Crit Rev Oncol Hematol* (**IF 5,833**). 2009 Jan;69(1):83-94. doi: 10.1016/j.critrevonc.2008.07.008. Epub 2008 Aug 8. PMID: 18692400. **Cit. 11**

416. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. *Crit Rev Oncol Hematol* (**IF 5,833**). 2008 Nov;68(2):93-106. doi: 10.1016/j.critrevonc.2008.07.006. Epub 2008 Aug 3. PMID: 18676156. **Cit. 89**
417. Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V, Alessandroni P, Giordani P, Cicetti A, D'Emidio S, Morini S, Ruzzo A, Magnani M, Tonini G, Rabitti C, Graziano F. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. *Eur J Cancer* (**IF 7,275**). 2008 Sep;44(13):1875-82. doi: 10.1016/j.ejca.2008.05.017. Epub 2008 Jul 9. PMID: 18617393. **Cit 148**
418. Borzomati D, Valeri S, Grasso F, Rabitti C, Vitolo D, Santini D, Vincenzi B, Garberini A, La Vaccara V, Coppola R. Pancreatic intraductal papillary mucinous neoplasms: a paradigmatic case. A case report and review of the literature. *Chir Ital* (**IF 0,588**) 2008 Jul-Aug;60(4):567-72. PMID: 18837259. **Cit. 0**
419. Vincenzi B, Santini D, Galluzzo S, Russo A, Fulfarò F, Silletta M, Battistoni F, Rocci L, Zobel BB, Adamo V, Dicuonzo G, Tonini G. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. *Clin Cancer Res* (**IF 10,107**) 2008 Jul 1;14(13):4219-24. doi: 10.1158/1078-0432.CCR-08-0077. PMID: 18594003. **Cit. 46**
420. Caccamo N, Meraviglia S, Scarpa F, La Mendola C, Santini D, Bonanno CT, Misiano G, Dieli F, Salerno A. Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more. *Expert Opin Biol Ther* (**IF 3,974**). 2008 Jul;8(7):875-83. doi: 10.1517/14712598.8.7.875. PMID: 18549319. **Cit. 42**
421. Vincenzi B, Schiavon G, Pantano F, Santini D, Tonini G. Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. *Nat Clin Pract Oncol*. 2008 Aug;5(8):455-65. doi: 10.1038/nponc1137. Epub 2008 Jun 10. PMID: 18542119. **Cit. 14**
422. Adamo V, Caristi N, Saccà MM, Ferraro G, Arcanà C, Maisano R, Santini D, Tonini G. Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. *Expert Opin Pharmacother* (**IF 3,894**) 2008 Jun;9(8):1351-61. doi: 10.1517/14656566.9.8.1351. PMID: 18473709. **Cit. 13**
423. Vincenzi B, Santini D, Tonini G. Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesium. *Expert Opin Pharmacother* (**IF 3,894**) 2008 Jun;9(8):1267-9. doi: 10.1517/14656566.9.8.1267. PMID: 18473701. **Cit. 16**
424. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, Turchi F, Piacentini P, Rocci L, Manavalan JS, Tonini G, Poccia F. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. *Cancer Immunol Immunother* (**IF 5,422**). 2009 Jan;58(1):31-8. doi: 10.1007/s00262-008-0521-6. Epub 2008 May 6. PMID: 18458903. **Cit. 87**
425. Santini D, Vincenzi B, Tonini G. Updated follow-up of patients treated with bortezomib for relapsed multiple myeloma. *Nat Clin Pract Oncol* (**NO IF**). 2008 Jun;5(6):304-5. doi: 10.1038/nponc1127. Epub 2008 Apr 29. PMID: 18446143. **Cit. 0**
426. Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Bissonni R, Torresi U, Floriani I, Schiavon G, Andreoni F, Maltese P, Rulli E, Humar B, Falcone A, Giustini L, Tonini G, Fontana A, Masi G, Magnani M. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. *J Clin Oncol* (**IF 32,956**). 2008 Mar 20;26(9):1427-34. doi: 10.1200/JCO.2007.12.4602. PMID: 18349392. **Cit 107**

427. Tonini G, Schiavon G, Fratto ME, Vincenzi B, Santini D. Hormono-biological therapy in metastatic breast cancer: preclinical evidence, clinical studies and future directions. *Expert Opin Biol Ther* (**IF 3,974**). 2008 Feb;8(2):221-34. doi: 10.1517/14712598.8.2.221. PMID: 18194078. **Cit. 8**
428. Loupakis F, Vasile E, Santini D, Masi G, Falcone A, Graziano F. EGF- receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. *Pharmacogenomics* (**IF 2,35**). 2008 Jan;9(1):55-69. doi: 10.2217/14622416.9.1.55. PMID: 18154448. **Cit. 13**
429. Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. *Nat Clin Pract Oncol*. 2007 Dec;4(12):711-21. doi: 10.1038/nponc1000. PMID: 18037875. **Cit. 74**
430. Russo A, Fratto ME, Bazan V, Schiró V, Agnese V, Cicero G, Vincenzi B, Tonini G, Santini D. Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. *Expert Opin Ther Targets* (**IF 4,598**) 2007 Dec;11(12):1571-86. doi: 10.1517/14728222.11.12.1571. PMID: 18020979. **Cit. 14**
431. Tonini G, Pantano F, Vincenzi B, Gabbrielli A, Coppola R, Santini D. Molecular prognostic factors in patients with pancreatic cancer. *Expert Opin Ther Targets* (**IF 4,598**) 2007 Dec;11(12):1553-69. doi: 10.1517/14728222.11.12.1553. PMID: 18020978. **Cit. 26**
432. Quattrocchi CC, Santini D, Dell'aia P, Piciucchi S, Leoncini E, Vincenzi B, Grasso RF, Tonini G, Zobel BB. A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid. *Skeletal Radiol* (**IF 1,737**) 2007 Dec;36(12):1121-7. doi: 10.1007/s00256-007-0388-1. Epub 2007 Oct 3. PMID: 17912514. **Cit. 21**
433. Vincenzi B, Santini D, Tonini G. Cetuximab: from biology to the care of colorectal cancer patients. *Future Oncol* (**IF 2,66**). 2007 Oct;3(5):497-9. doi: 10.2217/14796694.3.5.497. PMID: 17927513. **Cit. 0**
434. Spugnini EP, Vincenzi B, Citro G, Santini D, Dotsinsky I, Mudrov N, Montesarchio V, Laieta MT, Esposito V, Baldi A. Adjuvant electrochemotherapy for the treatment of incompletely excised spontaneous canine sarcomas. *In Vivo* (**IF 1,541**) 2007 Sep-Oct;21(5):819-22. PMID: 18019417. **Cit. 26**
435. Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, Guarrasi R, Rossi E, Cennamo G, Tonini G, Capasso E, Santini D, Caraglia M, Del Prete S. Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. *Support Care Cancer* (**IF 2,698**). 2008 Feb;16(2):209-14. doi: 10.1007/s00520-007-0315-y. Epub 2007 Aug 14. PMID: 17701225. **Cit. 11**
436. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. *Clin Cancer Res* (**IF 10,107**) 2007 Aug 1;13(15 Pt 1):4482-6. doi: 10.1158/1078-0432.CCR-07-0551. PMID: 17671133. **Cit 163**
437. Giorgio CG, Pappalardo A, Russo A, Santini D, Di Rosa C, Di Salvo C, Castorina S, Marletta F, Bellissima G, Palermo N, Scuderi C, Bordonaro R. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. *Anticancers Drugs* (**IF 1,784**). 2007 Jul;18(6):713-9. doi: 10.1097/CAD.0b013e328082558a. PMID: 17762402. **Cit. 9**
438. Vincenzi B, Santini D, Frezza AM, Rocci L, Tonini G. Docetaxel induced pericardial effusion. *J Exp Clin Cancer Res* (**IF 5,646**) 2007 Sep;26(3):417-20. PMID: 17987805. **Cit. 8**

439. Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). *J Exp Clin Cancer Res* (**IF 5,646**) 2007 Sep;26(3):307-12. PMID: 17987788. **Cit. 26**
440. Quattrocchi CC, Piciocchi S, Sammarra M, Santini D, Vincenzi B, Tonini G, Grasso RF, Zobel BB. Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. *Radiol Med* (**IF 2**) 2007 Oct;112(7):1049-59. English, Italian. doi: 10.1007/s11547-007-0205-x. Epub 2007 Oct 21. PMID: 17952675. **Cit. 26**
441. Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, Adamo V, Santini D, Russo A. The role of Aurora-A inhibitors in cancer therapy. *Ann Oncol* (**IF 18,274**) 2007 Jun;18 Suppl 6:vi47-52. doi: 10.1093/annonc/mdm224. PMID: 17591831. **Cit. 61**
442. Santini D, Galluzzo S, Vincenzi B, Schiavon G, Fratto E, Pantano F, Tonini G. New developments of aminobisphosphonates: the double face of Janus. *Ann Oncol* (**IF 18,274**) 2007 Jun;18 Suppl 6:vi164-7. doi: 10.1093/annonc/mdm249. PMID: 17591815. **Cit. 20**
443. Santini D, Baldi A, Vincenzi B, Mellone P, Campioni M, Antinori A, Borzomati D, Coppola R, Magistrelli P, Tonini G. Mucin 2 (MUC2) and mucin 5 (MUC5) expression is not associated with prognosis in patients with radically resected ampullary carcinoma. *J Clin Pathol* (**IF 2,894**) 2007 Sep;60(9):1069-70. doi: 10.1136/jcp.2005.035832. PMID: 17761747; PMCID: PMC1972431. **Cit. 4**
444. Vincenzi B, Calvieri A, Santini D, Altomare V, Tonini G. Occasional FDG PET recognition of in situ breast cancer. *Ann Oncol* (**IF 18,274**) 2007 Sep;18(9):1584-5. doi: 10.1093/annonc/mdm418. PMID: 17761715. **Cit. 1**
445. Galluzzo S, Santini D, Vincenzi B, Caccamo N, Meraviglia F, Salerno A, Dieli F, Tonini G. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. *Expert Opin Ther Targets* (**IF 4,598**) 2007 Jul;11(7):941-54. doi: 10.1517/14728222.11.7.941. PMID: 17614762. **Cit. 23**
446. Perrone G, Zagami M, Santini D, Vincenzi B, Gullotta G, Morini S, Battista C, Guerriero G, Altomare V, Tonini G, Rabitti C. COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification. *Histopathology* (**IF 3,626**) 2007 Jul;51(1):33-9. doi: 10.1111/j.1365-2559.2007.02731.x. Epub 2007 Jun 1. PMID: 17542993. **Cit. 9**
447. Santini D, Virzì V, Vincenzi B, Rocci L, Leoni V, Tonini G. A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients. *Ann Oncol* (**IF 18,274**). 2007 Mar;18(3):576-80. doi: 10.1093/annonc/mdl440. Epub 2006 Dec 8. PMID: 17158771. **Cit. 9**
448. Santini D, Vincenzi B, Caraglia M, Tonini G. A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. *Ann Oncol* (**IF 18,274**) 2007 Jan;18(1):201-202. doi: 10.1093/annonc/mdl298. Epub 2006 Oct 4. PMID: 17021272. **Cit. 6**
449. Tonini G, Schiavon G, Vincenzi B, Santini D. New target agents in the treatment of colorectal cancer patients. *Expert Opin Drug Discov* (**IF 3,846**) 2007 Jun;2(6):861-71. doi: 10.1517/17460441.2.6.861. PMID: 23489003. **Cit. 1**
450. Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and

- reduced Bcl-2 and bad phosphorylation. *J Cell Physiol* (**IF 5,546**). 2007 May;211(2):533-43. doi: 10.1002/jcp.20960. PMID: 17192846. **Cit. 64**
451. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bissoni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. *J Clin Oncol* (**IF 32,956**). 2007 Apr 1;25(10):1247-54. doi: 10.1200/JCO.2006.08.1844. Erratum in: *J Clin Oncol* (IF 32,956). 2009 Jul 1;27(19):3262. PMID: 17401013. **Cit. 244**
452. Vincenzi B, Santini D, Russo A, Gavasci M, Battistoni F, Dicuonzo G, Rocci L, Rosaria VM, Gebbia N, Tonini G. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. *Pharmacogenomics* (**IF 2,35**). 2007 Apr;8(4):319-27. doi: 10.2217/14622416.8.4.319. PMID: 17391070. **Cit. 34**
453. Tonini G, Schiavon G, Silletta M, Vincenzi B, Santini D. Antiangiogenic properties of metronomic chemotherapy in breast cancer. *Future Oncol* (**IF 2,66**). 2007 Apr;3(2):183-90. doi: 10.2217/14796694.3.2.183. PMID: 17381418. **Cit. 20**
454. Perrone G, Vincenzi B, Zagami M, Santini D, Panteri R, Flammia G, Verzì A, Lepanto D, Morini S, Russo A, Bazan V, Tomasino RM, Morello V, Tonini G, Rabitti C. Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. *Mod Pathol* (**IF 3,267**) 2007 Mar;20(3):344-51. doi: 10.1038/modpathol.3800743. Epub 2007 Feb 2. PMID: 17277764. **Cit. 30**
455. Schiavon G, Santini D, Vincenzi B, Tonini G. European Society for Medical Oncology 2006: meeting highlights on targeted therapies. Istanbul, Turkey, 29 September-3 October 2006. *Expert Opin Biol Ther* (**IF 3,974**). 2007 Feb;7(2):269-78. doi: 10.1517/14712598.7.2.269. PMID: 17250464. **Cit. 0**
456. Ruzzo A, Canestrari E, Maltese P, Pizzagalli F, Graziano F, Santini D, Catalano V, Ficarelli R, Mari D, Bissoni R, Giordani P, Giustini L, Lippe P, Silva R, Mattioli R, Torresi U, Latini L, Magnani M. Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. *Clin Chem Lab Med* (**IF 3,556**) 2007;45(7):822-8. doi: 10.1515/CCLM.2007.143. PMID: 17617021. **Cit. 58**
457. Santini D, Fratto ME, Vincenzi B, Galluzzo S, Tonini G. Zoledronic acid in the management of metastatic bone disease. *Expert Opin Biol Ther* (**IF 3,974**). 2006 Dec;6(12):1333-48. doi: 10.1517/14712598.6.12.1333. PMID: 17223741. **Cit. 29**
458. Gentilucci UV, Santini D, Vincenzi B, Fiori E, Picardi A, Tonini G. Chemotherapy-induced steatohepatitis in colorectal cancer patients. *J Clin Oncol* (**IF 32,956**) 2006 Dec 1;24(34):5467; author reply 5467-8. doi: 10.1200/JCO.2006.08.1828. PMID: 17135651. **Cit. 17**
459. Abbate A, Morales C, De Falco M, Fedele V, Biondi Zoccai GG, Santini D, Palleiro J, Vasaturo F, Scarpa S, Liuzzo G, Severino A, Baldi F, Crea F, Biasucci LM, Vetovec GW, Gelpi RJ, Baldi A. Ischemia and apoptosis in an animal model of permanent infarct-related artery occlusion. *Int J Cardiol* (**IF 3,471**). 2007 Sep 14;121(1):109-11. doi: 10.1016/j.ijcard.2006.08.077. Epub 2006 Nov 15. PMID: 17112609. **Cit. 12**
460. Santini D, Schiavon G, Angeletti S, Vincenzi B, Gasparro S, Grilli C, La Cesa A, Virzì V, Leoni V, Budillon A, Addeo SR, Caraglia M, Dicuonzo G, Tonini G. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs? *Recent Pat Anticancer Drug Discov* (**IF 2,61**) 2006 Nov;1(3):383-96. doi: 10.2174/157489206778776989. PMID: 18221048. **Cit. 23**



461. Botev B, Casale M, Vincenzi B, D'Ascanio L, Santini D, Esposito V, Di Marino MP, Baldi A, Rinaldi V, Tonini G, Salvinelli F. A giant sarcoma of the parotid gland: a case report and review of the literature. *In Vivo* (**IF 1,541**) 2006 Nov- Dec;20(6B):907-10. PMID: 17203788. **Cit. 12**
462. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. *Expert Opin Emerg Drugs* (**IF 3,058**) 2006 Nov;11(4):665-83. doi: 10.1517/14728214.11.4.665. PMID: 17064225. **Cit. 3**
463. Santini D, Vincenzi B, Schiavon G, Di Seri M, Virzì V, Spalletta B, Caricato M, Coppola R, Tonini G. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. *Cancer Chemother Pharmacol* (**IF 2,737**) 2007 Apr;59(5):613-20. doi: 10.1007/s00280-006-0302-x. Epub 2006 Aug 31. PMID: 16944151. **Cit. 19**
464. Perrone G, Santini D, Zagami M, Vincenzi B, Verzì A, Morini S, Borzomati D, Coppola R, Antinori A, Magistrelli P, Tonini G, Rabitti C. COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters. *Virchows Arch* (**IF 2,848**) 2006 Sep;449(3):334-40. doi: 10.1007/s00428-006-0255-9. Epub 2006 Aug 12. PMID: 16906389. **Cit. 16**
465. Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, Tonini G. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. *Nat Clin Pract Oncol* (**NO IF**). 2006 Jun;3(6):325-38. doi: 10.1038/ncponc0520. PMID: 16757970. **Cit. 55**
466. Vincenzi B, Santini D, Tonini G. Taxanes in adjuvant chemotherapy for early breast cancer. *Womens Health (Lond)* (**IF 2,28**) 2006 May;2(3):323-5. doi: 10.2217/17455057.2.3.323. PMID: 19803903. **Cit. 0**
467. Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A, Caraglia M, Holen I. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. *Oncol Rep* (**IF 3,417**). 2006 May;15(5):1351-7. PMID: 16596210. **Cit. 46**
468. Vincenzi B, Santini D, Tonini G. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor. *J Clin Oncol* (**IF 32,956**). 2006 Apr 20;24(12):1957; author reply 1957-8. doi: 10.1200/JCO.2005.05.0450. PMID: 16622275. **Cit. 31**
469. Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bissoni R, Canestrari E, Ficarelli R, Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. *J Clin Oncol* (**IF 32,956**). 2006 Apr 20;24(12):1883-91. doi: 10.1200/JCO.2005.04.8322. PMID: 16622263. **Cit 123**
470. Zardi EM, Santini D, Vincenzi B, Galati G, Tonini G, Zobel BB, Afeltra A. Surgical complications after resection of adrenal carcinoma. *J Exp Clin Cancer Res* (**IF 5,646**) 2006 Sep;25(3):449-51. PMID: 17167987. **Cit. 2**
471. Tonini G, Vincenzi B, Santini D. Paraneoplastic syndromes: what we know and what we should know. *Clin Ter* (**IF 3,119**) 2006 Mar-Apr;157(2):93-4. PMID: 16817496. **Cit. 2**
472. Russo A, Terrasi M, Agnese V, Santini D, Bazan V. Apoptosis: a relevant tool for anticancer therapy. *Ann Oncol* (**IF 18,274**). 2006 Jun;17 Suppl 7:vii115-23. doi: 10.1093/annonc/mdl963. PMID: 16760273. **Cit. 79**

473. Santini D, Graziano F, Catalano V, Di Seri M, Testa E, Baldelli AM, Giordani P, La Cesa A, Spalletta B, Vincenzi B, Russo A, Caraglia M, Virzi V, Cascinu S, Tonini G. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. *BMC Cancer* (**IF 3,15**) 2006 May 10;6:125. doi: 10.1186/1471-2407-6-125. PMID: 16686939; PMCID: PMC1475875. **Cit. 33**
474. Abbate A, Limana F, Capogrossi MC, Santini D, Biondi-Zoccai GG, Scarpa S, Germani A, Straino S, Severino A, Vasaturo F, Campioni M, Liuzzo G, Crea F, Vetrovec GW, Biasucci LM, Baldi A. Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction. *Apoptosis* (**IF 4,543**) 2006 Jun;11(6):1061-3. doi: 10.1007/s10495-006-6306-5. PMID: 16544098. **Cit. 17**
475. Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. *Br J Cancer* (**IF 5,791**) 2006 Mar 27;94(6):792-7. doi: 10.1038/sj.bjc.6603018. PMID: 16508634; PMCID: PMC2361373. **Cit. 98**
476. Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L, Gebbia N, Tonini G. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. *Ann Oncol* (**IF 18,274**) 2006 May;17(5):835-41. doi: 10.1093/annonc/mdl031. Epub 2006 Feb 28. PMID: 16507564. **Cit. 25**
477. Perrone G, Santini D, Verzi A, Vincenzi B, Borzomati D, Vecchio F, Coppola R, Antinori A, Magistrelli P, Tonini G, Rabitti C. COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables. *J Clin Pathol* (**IF 2,894**) 2006 May;59(5):492-6. doi: 10.1136/jcp.2005.030098. Epub 2006 Feb 17. PMID: 16489179; PMCID: PMC1860297. **Cit. 11**
478. Vincenzi B, Schiavon G, Silletta M, Santini D, Perrone G, Di Marino M, Angeletti S, Baldi A, Tonini G. Cell cycle alterations and lung cancer. *Histol Histopathol* (**IF 2,025**) 2006 Apr;21(4):423-35. doi: 10.14670/HH-21.423. PMID: 16437388. **Cit. 37**
479. Vincenzi B, Santini D, Tonini G. Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan. *Ann Oncol* (**IF 18,274**) 2006 Mar;17(3):527-8. doi: 10.1093/annonc/mdj014. Epub 2005 Sep 21. PMID: 16176972. **Cit. 5**
480. Vincenzi B, Santini D, Tonini G. Renal-cell carcinoma. *N Engl J Med.* (**IF 74,699**) 2006 Mar 9;354(10):1095-6; author reply 1095-6. PMID: 16528812. **Cit. 2**
481. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. *Endocr Relat Cancer* (**IF 4,8**) 2006 Mar;13(1):7-26. doi: 10.1677/erc.1.01094. PMID: 16601276. **Cit 117**
482. Santini D, Vincenzi B, Schiavon G, La Cesa A, Gasparro S, Vincenzi A, Tonini G. Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. *BMC Cancer* (**IF 3,15**). 2006 Feb 24;6:42. doi: 10.1186/1471-2407-6-42. PMID: 16504126; PMCID: PMC1402306. **Cit. 4**
483. Graziano F, Kawakami K, Ruzzo A, Watanabe G, Santini D, Pizzagalli F, Bissoni R, Mari D, Floriani I, Catalano V, Silva R, Tonini G, Torri V, Giustini L, Magnani M. Methylene tetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. *Int J Cancer* (**IF 5,145**). 2006 Feb 1;118(3):628-32. doi: 10.1002/ijc.21397. PMID: 16094648. **Cit. 65**

484. Giorgio CG, Pappalardo A, Russo A, Giuffrida D, Santini D, Petralia G, Castorina S, Nunzio R, Failla G, Bordonaro R. A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). *Lung Cancer* (**IF 4,702**) 2006 Mar;51(3):357-62. doi: 10.1016/j.lungcan.2005.10.023. Epub 2006 Jan 9. PMID: 16406602. **Cit. 14**
485. Santini D, Vincenzi B, Tonini G. Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer? *Womens Health (Lond)* (**IF 2,28**) 2006 Jan;2(1):1-3. doi: 10.2217/17455057.2.1.1. PMID: 19803919. **Cit. 0**
486. Massacesi C, La Cesa A, Marcucci F, Pilone A, Rocchi MB, Zeponi L, Santini D, Tonini G, Burattini L. Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. *Oncology* (**IF 2,642**). 2006;70(4):294-300. doi: 10.1159/000096250. Epub 2006 Oct 12. PMID: 17047400. **Cit. 20**
487. Santini D, Altomare A, Vincenzi B, Perrone G, Bianchi A, Rabitti C, Montesarchio V, Esposito V, Baldi A, Tonini G. An increase of CA 19.9 as the first clinical sign of ileocecal valve metastasis from breast cancer. *In Vivo* (**IF 1,541**) 2006 Jan-Feb;20(1):165-8. PMID: 16433047. **Cit. 7**
488. Magistrelli P, Coppola R, Tonini G, Vincenzi B, Santini D, Borzomati D, Vecchio F, Valeri S, Castri F, Antinori A, Nuzzo G, Caraglia M, Picciocchi A. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. *J Cell Biochem* (**IF 3,448**) 2006 Jan 1;97(1):98-108. doi: 10.1002/jcb.20621. PMID: 16173075. **Cit. 30**
489. Campioni M, Santini D, Tonini G, Murace R, Dragonetti E, Spugnini EP, Baldi A. Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. *Exp Dermatol* (**IF 3,368**). 2005 Nov;14(11):811-8. doi: 10.1111/j.1600-0625.2005.00360.x. PMID: 16232302. **Cit. 45**
490. Abbate A, Scarpa S, Santini D, Palleiro J, Vasaturo F, Miller J, Morales C, Vetovec GW, Baldi A. Myocardial expression of survivin, an apoptosis inhibitor, in aging and heart failure. An experimental study in the spontaneously hypertensive rat. *Int J Cardiol* (**IF 3,471**). 2006 Aug 28;111(3):371-6. doi: 10.1016/j.ijcard.2005.07.061. Epub 2005 Oct 27. PMID: 16257070. **Cit. 48**
491. Giorgio CG, Giuffrida D, Pappalardo A, Russo A, Santini D, Salice P, Blanco G, Castorina S, Failla G, Bordonaro R. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. *Lung Cancer* (**IF 4,702**) 2005 Nov;50(2):247-54. doi: 10.1016/j.lungcan.2005.05.026. Epub 2005 Jul 20. PMID: 16039010. **Cit. 61**
492. Tonini G, Vincenzi B, Santini D. New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. *Expert Opin Drug Metab Toxicol* (**IF 3,487**) 2005 Jun;1(1):143-9. doi: 10.1517/17425255.1.1.143. PMID: 16922656. **Cit. 21**
493. Santini D, Vincenzi B, Tonini G, Scarpa S, Vasaturo F, Malacrino C, Vecchio F, Borzomati D, Valeri S, Coppola R, Magistrelli P, Nuzzo G, Picciocchi A. Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients. *Clin Cancer Res* (**IF 10,107**) 2005 May 15;11(10):3784-9. doi: 10.1158/1078-0432.CCR-04-2136. PMID: 15897577. **Cit. 17**
494. Cristi E, Perrone G, Toscano G, Verzì A, Nori S, Santini D, Tonini G, Vetrani A, Fabiano A, Rabitti C. Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. *J Clin Pathol* (**IF 2,894**) 2005 Nov;58(11):1170-4. doi: 10.1136/jcp.2004.025536. PMID: 16254106; PMCID: PMC1770760. **Cit. 21**
495. Abbate A, Bussani R, Biondi-Zoccai GG, Santini D, Petrolini A, De Giorgio F, Vasaturo F, Scarpa S, Severino A, Liuzzo G, Leone AM, Baldi F, Sinagra G, Silvestri F, Vetovec GW, Crea F, Biasucci LM, Baldi A. Infarct-related artery occlusion, tissue markers of ischaemia, and increased

- apoptosis in the peri-infarct viable myocardium. *Eur Heart J* (**IF 22,673**) 2005 Oct;26(19):2039-45. doi: 10.1093/eurheartj/ehi419. Epub 2005 Jul 19. PMID: 16030061. **Cit. 60**
496. Esposito V, Baldi A, De Luca A, Tonini G, Vincenzi B, Santini D, Persichetti P, Mancini A, Citro G, Baldi F, Groeger AM, Caputi M. Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer. *J Clin Pathol* (**IF 2,894**) 2005 Jul;58(7):734-9. doi: 10.1136/jcp.2004.023531. PMID: 15976342; PMCID: PMC1770708. **Cit. 29**
497. Santini D, Vincenzi B, Perrone G, Rabitti C, Borzomati D, Valeri S, Coppola R, Magistrelli P, Tonini G. Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma. *Ann Oncol* (**IF 18,274**) 2005 Nov;16(11):1847-8. doi: 10.1093/annonc/mdi353. Epub 2005 Jun 21. PMID: 15972277. **Cit. 2**
498. Tonini G, Vincenzi B, Santini D, Scarpa S, Vasaturo T, Malacrino C, Coppola R, Magistrelli P, Borzomati D, Baldi A, Antinori A, Caricato M, Nuzzo G, Picciocchi A. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. *Br J Cancer* (**IF 5,791**) 2005 Jun 20;92(12):2225-32. doi: 10.1038/sj.bjc.6602632. Erratum in: *Br J Cancer*. 2005 Oct 31;93(9):1084. PMID: 15928668; PMCID: PMC2361811. **Cit. 50**
499. Ruzzo A, Graziano F, Pizzagalli F, Santini D, Battistelli V, Panunzi S, Canestrari E, Catalano V, Humar B, Ficarelli R, Bearzi I, Cascinu S, Naldi N, Testa E, Magnani M. Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. *Ann Oncol* (**IF 18,274**) 2005 Jun;16(6):887-92. doi: 10.1093/annonc/mdi184. Epub 2005 Apr 25. PMID: 15851404. **Cit. 58**
500. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. *Histopathology* (**IF 3,626**) 2005 May;46(5):561-8. doi: 10.1111/j.1365-2559.2005.02132.x. PMID: 15842638. **Cit. 50**
501. Santini D, Tonini G, Vecchio FM, Borzomati D, Vincenzi B, Valeri S, Antinori A, Castri F, Coppola R, Magistrelli P, Nuzzo G, Picciocchi A. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. *J Clin Pathol* (**IF 2,894**) 2005 Feb;58(2):159-65. doi: 10.1136/jcp.2004.018887. PMID: 15677536; PMCID: PMC1770581. **Cit. 22**
502. Kawakami K, Graziano F, Watanabe G, Ruzzo A, Santini D, Catalano V, Bisonni R, Arduini F, Bearzi I, Cascinu S, Muretto P, Perrone G, Rabitti C, Giustini L, Tonini G, Pizzagalli F, Magnani M. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. *Clin Cancer Res* (**IF 10,107**) 2005 May 15;11(10):3778-83. doi: 10.1158/1078-0432.CCR-04-2428. PMID: 15897576. **Cit. 59**
503. Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, Baldi F, Rossiello L, Dell'Anna ML, Mastrofrancesco A, Maresca V, Flori E, Natali PG, Picardo M, Paggi MG. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. *Clin Cancer Res* (**IF 10,107**) 2005 May 1;11(9):3175-83. doi: 10.1158/1078-0432.CCR-04-0631. PMID: 15867210. **Cit. 49**
504. Tonini G, Vincenzi B, Santini D, Olzi D, Lambiase A, Bonini S. Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient. *J Natl Cancer Inst* (**IF 12,589**). 2005 Apr 20;97(8):606-7. doi: 10.1093/jnci/dji104. PMID: 15840884. **Cit. 15**
505. Graziano F, Ruzzo A, Santini D, Humar B, Tonini G, Catalano V, Berardi R, Pizzagalli F, Arduini F, Bearzi I, Scartozzi M, Cascinu S, Testa E, Ficarelli R, Magnani M. Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. *J Clin Oncol* (**IF 32,956**) 2005 Apr 1;23(10):2339-45. doi: 10.1200/JCO.2005.02.345. PMID: 15800325. **Cit. 42**

506. Vincenzi B, Santini D, Tonini G. Thymidylate synthase expression in colorectal cancer: the never-ending story. *J Clin Oncol* (**IF 32,956**). 2005 Mar 20;23(9):2108; author reply 2108-9. doi: 10.1200/JCO.2005.05.178. PMID: 15774806. **Cit. 2**
507. Parisi Q, Biondi-Zoccai GG, Abbate A, Santini D, Vasaturo F, Scarpa S, Bussani R, Leone AM, Petrolini A, Silvestri F, Biasucci LM, Baldi A. Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. *Int J Cardiol* (**IF 3,471**). 2005 Mar 18;99(2):337-9. doi: 10.1016/j.ijcard.2003.11.038. PMID: 15749199. **Cit. 25**
508. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, Grilli C, Virzi V, Gasparro S, Rocci L, Tonini G. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. *J Interferon Cytokine Res* (**IF 2,032**). 2005 Mar;25(3):144-51. doi: 10.1089/jir.2005.25.144. PMID: 15767788. **Cit. 123**
509. Santini D, Vincenzi B, La Cesa A, Caricato M, Schiavon G, Spalletta B, Di Seri M, Coppola R, Rocci L, Tonini G. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. *Oncology* (**IF 2,642**). 2005;69(1):27-34. doi: 10.1159/000087285. Epub 2005 Jul 28. PMID: 16088232. **Cit. 24**
510. Santini D, Vincenzi B, La Cesa A, Virzi V, Navajas F, Malafarina V, Dicuonzo G, Cassandro R, Esposito V, Montesarchio V, Groeger AM, Tonini G. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study. *Anticancer Res* (**IF 1,994**). 2005 Jan-Feb;25(1B):669-74. PMID: 15816644. **Cit. 9**
511. Graziano F, Kawakami K, Watanabe G, Ruzzo A, Humar B, Santini D, Catalano V, Ficarelli R, Merriman T, Panunzi S, Testa E, Cascinu S, Bearzi I, Tonini G, Magnani M. Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. *Int J Cancer* (**IF 5,145**). 2004 Dec 20;112(6):1010-4. doi: 10.1002/ijc.20489. PMID: 15386366. **Cit. 49**
512. Vincenzi B, Santini D, Grilli C, La Cesa A, Dianzani C, Tonini G. Complications of therapy in cancer patients: Case 3. Toxic epidermal necrolysis induced by oral phenobarbital and whole-brain radiotherapy in a breast cancer patient. *J Clin Oncol* (**IF 32,956**). 2004 Nov 15;22(22):4649-51. doi: 10.1200/JCO.2004.05.003. PMID: 15542817. **Cit. 12**
513. Vincenzi B, Cesa AL, Santini D, Schiavon G, Grilli C, Graziano F, Tonini G. Predictive factors for response to chemotherapy in colorectal cancer patients. *Crit Rev Oncol Hematol* (**IF 5,833**). 2004 Oct;52(1):45-60. doi: 10.1016/j.critrevonc.2004.05.005. PMID: 15363466. **Cit. 10**
514. Schiavon G, Vincenzi B, Santini D, Avvisati G, Tonini G. Recurrent thrombophlebitis in a colon cancer patient with C677T heterozygous genotype for MTHFR treated with 5-fluorouracil-based adjuvant chemotherapy. *Chemotherapy* (**IF 1,288**) 2004 Oct;50(4):194-5. doi: 10.1159/000081031. Epub 2004 Sep 23. PMID: 15452397. **Cit. 3**
515. Vincenzi B, Santini D, La Cesa A, Tonini G. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. *Cancer* (**5,742**) 2004 May 1;100(9):1987-8; author reply 1988. doi: 10.1002/cncr.20194. PMID: 15112281. **Cit. 3**
516. Santini D, Abbate A, Scarpa S, Vasaturo F, Biondi-Zoccai GG, Bussani R, De Giorgio F, Bassan F, Camilot D, Di Marino MP, Feroce F, Baldi F, Silvestri F, Crea F, Baldi A. Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction. *J Clin Pathol* (**IF 2,894**) 2004 Dec;57(12):1321-4. doi: 10.1136/jcp.2004.018986. PMID: 15563676; PMCID: PMC1770501. **Cit. 44**

517. Perrone G, Vincenzi B, Santini D, Verzi A, Tonini G, Vetrani A, Rabitti C. Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. *Cancer Lett* (**IF 7,36**) 2004 May 28;208(2):227-34. doi: 10.1016/j.canlet.2003.11.032. PMID: 15142682. **Cit. 48**
518. Baldi A, Santini D, Vasaturo F, Santini M, Vicidomini G, Di Marino MP, Esposito V, Groeger AM, Liuzzi G, Vincenzi B, Tonini G, Piccoli M, Baldi F, Scarpa S. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. *Thorax* (**IF 10,307**) 2004 May;59(5):428-33. doi: 10.1136/thx.2003.008912. Erratum in: *Thorax*. 2004 Jun;59(6):543. PMID: 15115874; PMCID: PMC1746992. **Cit. 44**
519. Abbate A, Santini D, Biondi-Zoccai GG, Scarpa S, Vasaturo F, Liuzzo G, Bussani R, Silvestri F, Baldi F, Crea F, Biasucci LM, Baldi A. Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe? *Heart* (**IF 5,213**) 2004 Apr;90(4):440-3. doi: 10.1136/hrt.2003.010280. PMID: 15020525; PMCID: PMC1768143. **Cit. 48**
520. Leoni V, Santini D, Vincenzi B, Grilli C, Onori N, Tonini G. Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions. *Allergy* (**IF 8,706**) 2004 Feb;59(2):241. doi: 10.1046/j.1398-9995.2003.00383.x. PMID: 14763950. **Cit. 3**
521. Biondi-Zoccai GG, Abbate A, Vasaturo F, Scarpa S, Santini D, Leone AM, Parisi Q, De Giorgio F, Bussani R, Silvestri F, Baldi F, Biasucci LM, Baldi A. Increased apoptosis in remote non-infarcted myocardium in multivessel coronary disease. *Int J Cardiol* (**IF 3,471**). 2004 Mar;94(1):105-10. doi: 10.1016/j.ijcard.2003.07.001. PMID: 14996483. **Cit. 21**
522. Baldi A, Santini D, Russo P, Catricalà C, Amantea A, Picardo M, Tatangelo F, Botti G, Dragonetti E, Murace R, Tonini G, Natali PG, Baldi F, Paggi MG. Analysis of APAF-1 expression in human cutaneous melanoma progression. *Exp Dermatol* (**IF 3,368**) 2004 Feb;13(2):93-7. doi: 10.1111/j.0906-6705.2004.00136.x. PMID: 15009102. **Cit. 54**
523. Santini D, Vincenzi B, Perrone G, Rabitti C, Borzomati D, Caricato M, La Cesa A, Grilli C, Verzi A, Coppola R, Tonini G. Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. *Oncology* (**IF 2,642**). 2004;67(2):135-42. doi: 10.1159/000081000. PMID: 15539918. **Cit. 17**
524. Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. *BioDrugs* (**IF 3,15**). 2004;18(4):269-78. doi: 10.2165/00063030-200418040-00004. PMID: 15244502. **Cit. 48**
525. Santini D, Massacesi C, D'Angelillo RM, Marcucci F, Campisi C, Vincenzi B, Pilone A, Bianco V, Bonsignori M, Tonini G. Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study. *Med Oncol* (**IF 2,834**) 2004;21(1):59-66. doi: 10.1385/MO:21:1:59. PMID: 15034215. **Cit. 16**
526. Santini D, Vincenzi B, Massacesi C, Picardi A, Gentilucci UV, Esposito V, Liuzzi G, La Cesa A, Rocci L, Marcucci F, Montesarchio V, Groeger AM, Bonsignori M, Tonini G. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. *Anticancer Res* (**IF 1,994**). 2003 Nov-Dec;23(6D):5173-9. PMID: 14981985. **Cit. 31**
527. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. *J Interferon Cytokine Res* (**IF 2,032**) 2003 Nov;23(11):649-54. doi: 10.1089/107999003322558782. PMID: 14651779. **Cit. 96**

528. Santini D, Vincenzi B, La Cesa A, Casale M, Salvinelli F, Tonini G. Recurrent episodes of involuntary masticatory spasms induced by continuous infusion of oxaliplatin. *J Natl Cancer Inst* (**IF 12,589**). 2003 Oct 15;95(20):1555-6. doi: 10.1093/jnci/djg087. PMID: 14559882. **Cit. 3**
529. De Luca A, De Falco M, Severino A, Campioni M, Santini D, Baldi F, Paggi MG, Baldi A. Distribution of the serine protease HtrA1 in normal human tissues. *J Histochem Cytochem* (**IF 2,187**) 2003 Oct;51(10):1279-84. doi: 10.1177/002215540305101004. PMID: 14500695. **Cit. 92**
530. Vincenzi B, Santini D, La Cesa A, Tonini G. Cancer chronotherapy: principles, applications, and perspectives. *Cancer* (**5,742**) 2003 Aug 15;98(4):881-2; author reply 882-3. doi: 10.1002/cncr.11600. PMID: 12910534. **Cit. 5**
531. Massacesi C, Santini D, Rocchi MB, La Cesa A, Marcucci F, Vincenzi B, Delprete S, Tonini G, Bonsignori M. Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. *Anticancers Drugs* (**IF 1,784**). 2003 Aug;14(7):533-41. doi: 10.1097/00001813-200308000-00005. PMID: 12960737. **Cit. 11**
532. Santini D, Vincenzi B, Tonini G, Scarpa S, Baldi A. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. *Clin Cancer Res* (**IF 10,107**) 2003 Aug 1;9(8):3215; author reply 3216. PMID: 12912976. **Cit. 11**
533. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. *Clin Cancer Res* (**IF 10,107**) 2003 Aug 1;9(8):2893-7. PMID: 12912933. **Cit 266**
534. Landi D, Santini D, Vincenzi B, La Cesa A, Dianzani C, Tonini G. Dramatic improvement of psoriasis with gemcitabine monotherapy. *Br J Dermatol* (**IF 7**) 2003 Dec;149(6):1306-7. doi: 10.1111/j.1365-2133.2003.05667.x. PMID: 14674923. **Cit. 4**
535. Graziano F, Santini D, Testa E, Catalano V, Beretta GD, Mosconi S, Tonini G, Lai V, Labianca R, Cascinu S. A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. *Br J Cancer* (**IF 5,791**) 2003 Oct 20;89(8):1428-32. doi: 10.1038/sj.bjc.6601280. PMID: 14562012; PMCID: PMC2394359. **Cit. 17**
536. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S, Tonini G. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. *Ann Oncol* (**IF 18,274**) 2003 Oct;14(10):1468-76. doi: 10.1093/annonc/mdg401. PMID: 14504045. **Cit 138**
537. De Luca A, De Falco M, Severino A, Campioni M, Santini D, Baldi F, Paggi MG, Baldi A. Distribution of the serine protease HtrA1 in normal human tissues. *J Histochem Cytochem* (**IF 2,37**) 2003 Oct;51(10):1279-84. doi: 10.1177/002215540305101004. PMID: 14500695.
538. Vincenzi B, Santini D, Avvisati G, Borzomati D, Tonini G. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients (*Br J Surg* 2003; 90: 547-548). *Br J Surg* (**IF 5,899**) 2003 Sep;90(9):1165-6. doi: 10.1002/bjs.4378. PMID: 12945089. **Cit. 0**
539. Tonini G, Vincenzi B, Di Cosimo S, Gravante G, Santini D, Ambrogi V, Micheletti E, Rocci L, D'Aprile M. Fatal thrombocytopenia and thrombocytopathia: an unusual onset of non-small cell lung cancer. *Onkologie* (**NO IF**) 2003 Jun;26(3):272-4. doi: 10.1159/000071624. PMID: 12845213. **Cit. 1**

540. Salvinelli F, Casale M, Vincenzi B, Santini D, Di Peco V, Firrisi L, Onori N, Greco F, Tonini G. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect. *J Exp Clin Cancer Res* (**IF 5,646**) 2003 Mar;22(1):155-8. PMID: 12725337. **Cit. 8**
541. Tonini G, Vincenzi B, Santini D, La Cesa A, Finolezzi E, Onori N, D'Angelillo R, Baldi A, Trodella L. Prevention of radiotherapy-induced emesis. *J Exp Clin Cancer Res* (**IF 5,646**) 2003 Mar;22(1):17-22. PMID: 12725317. **Cit. 12**
542. Vincenzi B, Santini D, Rocci L, Tonini G. Bisphosphonates: new antiangiogenic molecules in cancer treatment? *Ann Oncol* (**IF 18,274**) 2003 May;14(5):806-7. doi: 10.1093/annonc/mdg194. PMID: 12702541. **Cit. 23**
543. Santini D, Picardi A, Vincenzi B, Binetti P, Massacesi C, La Cesa A, Tonini G. Severe liver dysfunction after raltitrexed administration in an HCV-positive colorectal cancer patient. *Cancer Invest* (**IF 2,218**) 2003;21(1):162-3. doi: 10.1081/cnv-120016411. PMID: 12643018. **Cit. 9**
544. Baldi A, Santini D, De Luca A, Paggi MG. cDNA array technology in melanoma: an overview. *J Cell Physiol* (**IF 5,546**). 2003 Aug;196(2):219-23. doi: 10.1002/jcp.10255. PMID: 12811814. **Cit. 20**
545. Vincenzi B, Santini D, Avvisati G, Baldi A, Cesa AL, Tonini G. Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach? *Med Hypotheses* (**IF 1,322**) 2003 Jul;61(1):98-101. doi: 10.1016/s0306-9877(03)00124-5. PMID: 12781649. **Cit. 19**
546. Tonini G, Vincenzi B, Santini D, Avvisati G, La Cesa A, Baldi A. Unusual problems in breast cancer and a rare lung cancer case. Case 1. Clinical complete response of breast cancer metastases after trastuzumab-based immunotherapy. *J Clin Oncol* (**IF 32,956**) 2003 Jun 1;21(11):2215-6. doi: 10.1200/JCO.2003.04.195. PMID: 12775749. **Cit. 1**
547. Baldi A, Battista T, De Luca A, Santini D, Rossiello L, Baldi F, Natali PG, Lombardi D, Picardo M, Felsani A, Paggi MG. Identification of genes down-regulated during melanoma progression: a cDNA array study. *Exp Dermatol* (**IF 3,368**). 2003 Apr;12(2):213-8. doi: 10.1034/j.1600-0625.2003.00026.x. PMID: 12702151. **Cit. 46**
548. Esposito V, Groeger AM, De Luca L, Di Marino M, Santini D, Marchei P, Baldi F, Wolner E, Baldi A. Expression of surface protein receptors in lung cancer. *Anticancer Res* (**IF 1,994**). 2002 Nov-Dec;22(6C):4039-43. PMID: 12553029. **Cit. 14**
549. Romiti A, Tonini G, Santini D, Di Seri M, Masciangelo R, Mezi S, Veri A, Santuari L, Vincenzi B, Brescia A, Marchei P, Frati L, Tomao S. Tolerability of Raltitrexed ('Tomudex') in elderly patients with colorectal cancer. *Anticancer Res* (**IF 1,994**) 2002 Sep-Oct;22(5):3071-6. PMID: 12530045. **Cit. 9**
550. Bianco V, Rozzi A, Tonini G, Santini D, Magnolfi E, Vincenzi B, D'Angelillo R, Marchei P. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study. *Anticancer Res* (**IF 1,994**). 2002 Sep-Oct;22(5):3053-6. PMID: 12530041. **Cit. 25**
551. Vespasiani Gentilucci U, Santini D, Picardi A, Vincenzi B, Riva E, Bianchi A, Tonini G. Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor. *J Interferon Cytokine Res* (**IF 2,032**). 2002 Jun;22(6):683-8. doi: 10.1089/10799900260100178. PMID 12162879. **Cit. 4**



552. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. *Clin Cancer Res* (**IF 10,107**) 2002 May;8(5):1080-4. PMID: 12006522. **Cit 246**
553. Santini D, Tonini G, Vincenzi B, Murace R, Ferranti G, Baldi A. Skin lesions in melanoma and Kaposi's sarcoma. Case 1. Detection of circulating malignant cells by RT-PCR in a case of cutaneous melanoma in complete regression. *J Clin Oncol* (**IF 32,956**). 2002 Mar 1;20(5):1411-2. doi: 10.1200/JCO.2002.20.5.1411. PMID: 11870187. **Cit. 1**
554. Tonini G, Santini D, Vincenzi B, Dicuonzo G, Salerno A, Finolezzi E, Avvisati G. Raltitrexed as monochemotherapy induces a statistically significant increase in platelet count. *Acta Oncol* (**IF 3,298**). 2002;41(3):315-6. doi: 10.1080/02841860260088881. PMID: 12195753. **Cit. 0**
555. Vincenzi B, Santini D, Spoto S, Finolezzi E, D'Angelillo RM, La Cesa A, Tonini G. The antineoplastic treatment in the elderly. *Clin Ter* (**IF 3,119**) 2002 May-Jun;153(3):207-15. PMID: 12161983. **Cit. 2**
556. Tonini G, Santini D, Vincenzi B, Borzomati D, Dicuonzo G, La Cesa A, Onori N, Coppola R. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. *J Biol Regul Homeost Agents* (**IF 1,397**) 2002 Apr-Jun;16(2):105-9. PMID: 12144121. **Cit. 55**
557. Cascinu S, Graziano F, Ferrà F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). *Ann Oncol* (**IF 18,274**) 2002 May;13(5):716-20. doi: 10.1093/annonc/mdf091. PMID: 12075739. **Cit. 52**
558. Santini D, Vincenzi B, Fossati C, D'Angelillo RM, Patti G, Bianco V, Avvisati G, Tonini G. Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis: a pilot study with ACTH-Depot plus tropisetron. *Med Oncol* (**IF 2,834**) 2001;18(2):131-5. doi: 10.1385/MO:18:2:131. PMID: 11778758. **Cit. 2**
559. Dicuonzo G, Angeletti S, Garcia-Foncillas J, Brugarolas A, Okrouzhnov Y, Santini D, Tonini G, Lorino G, De Cesaris M, Baldi A. Colorectal carcinomas and PTEN/MMAC1 gene mutations. *Clin Cancer Res* (**IF 10,107**) 2001 Dec;7(12):4049-53. PMID: 11751500. **Cit. 51**
560. Vincenzi B, Finolezzi E, Fossati C, Verzi A, Santini D, Tonini G, Arullani A, Avvisati G. Unusual presentation of Hodgkin's disease mimicking inflammatory bowel disease. *Leuk Lymphoma* (**IF 3,093**) 2001 Jul;42(3):521-6. doi: 10.3109/10428190109064611. PMID: 11699419. **Cit. 4**
561. Baldi A, Santini D, Battista T, Dragonetti E, Ferranti G, Petitti T, Groeger AM, Angelini A, Rossiello R, Baldi F, Natali PG, Paggi MG. Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. *J Cell Biochem* (**IF 3,448**) 2001 Aug 21-Sep 5;83(3):364-72. doi: 10.1002/jcb.1235. PMID: 11596105. **Cit. 53**
562. Baldi A, Santini D, Paggi MG. Association for Molecular Pathology: Sixth annual meeting in Denver, November 9-12, 2000. *J Cell Physiol* (**IF 5,546**) 2001 Jul;188(1):139-42. doi: 10.1002/jcp.1096. PMID: 11382930. **Cit. 2**
563. Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Battistoni F, Dicuonzo G, Labianca R. Idiosyncratic reaction after oxaliplatin infusion. *Ann Oncol* (**IF 18,274**) 2001 Jan;12(1):132-3. doi: 10.1023/a:1008366223918. PMID: 11249043. **Cit. 54**
564. D'Aprile M, Santini D, Di Cosimo S, Gravante G, Vincenzi B, Spoto S, Costantino S, Rabitti C, Tonini G. Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man:

- clinical report and literature review. *Clin Ter* (**IF 3,119**) 2000 Sep-Oct;151(5):371-4. PMID: 11141722. **Cit. 8**
565. Dieli F, Singh M, Spallek R, Romano A, Titone L, Sireci G, Friscia G, Di Sano C, Santini D, Salerno A, Ivanyi J. Change of Th0 to Th1 cell-cytokine profile following tuberculosis chemotherapy. *Scand J Immunol* (**IF 2,717**) 2000 Jul;52(1):96-102. doi: 10.1046/j.1365-3083.2000.00744.x. PMID: 10886789. **Cit. 30**
566. Santini D, Binetti P. La dimensione tutoriale della formazione clinica dello studente [The tutorial dimension of clinical training of students]. *Clin Ter* (**IF 3,119**) 2000 Mar-Apr;151(2):97-101. Italian. PMID: 10876977. **Cit. 1**
567. Santini D, Tonini G, Abbate A, Di Cosimo S, Gravante G, Vincenzi B, Campisi C, Patti G, Di Sciascio G. Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. *Ann Oncol* (**IF 18,274**) 2000 Apr;11(4):479-81. doi: 10.1023/a:1008380208045. PMID: 10847470. **Cit. 35**
568. Baldi A, Rossiello R, Di Marino M, Ferrara N, Groeger AM, Esposito V, Santini D, Kaiser HE, Baldi F. Colonic type adenocarcinoma of male urethra. *In Vivo* (**IF 1,541**) 2000 Jul-Aug;14(4):487-92. PMID: 10945163. **Cit. 3**
569. Baldi A, Dragonetti E, Battista T, Groeger AM, Esposito V, Baldi G, Santini D. Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients. *Anticancer Res* (**IF 1,994**) 2000 Sep-Oct;20(5C):3923-8. PMID: 11268478. **Cit. 17**
570. Groeger AM, Baldi A, Caputi M, Esposito V, Russo P, Severino A, Santini D, Rossiello R, Kaiser HE, Baldi F. Intrapulmonary teratoma associated with thymic tissue. *Anticancer Res* (**IF 1,994**) 2000 Sep-Oct;20(5C):3919-22. PMID: 11268477. **Cit. 7**
571. Groeger AM, Caputi M, Esposito V, Baldi A, Rossiello R, Santini D, Mancini A, Kaiser HE, Baldi F. Expression of p21 in non small cell lung cancer relationship with PCNA. *Anticancer Res* (**IF 1,994**) 2000 Sep-Oct;20(5A):3301-5. PMID: 11062757. **Cit. 20**
572. Santini D, Vincenzi B, Finolezzi E, Di Cosimo S, Gravante G, Spoto S, Tonini G. Prevenzione dell'emesi da chemioterapia antineoplastica nel paziente oncologico anziano [The prevention of vomiting due to antineoplastic chemotherapy in the elderly cancer patient]. *Minerva Med* (**IF 1,202**) 1999 Jul-Aug;90(7-8):205-9. Italian. PMID: 10719419. **Cit. 0**
573. Baldi A, Groeger AM, Esposito V, Di Lieto E, Di Marino MP, Santini D, Baldi F. Lymphomatoid granulomatosis of the lung: a clinico-pathological study. *Anticancer Res* (**IF 1,994**) 1998 Nov-Dec;18(6B):4621-4. PMID: 9891529. **Cit. 5**
574. Marchei P, Lanza R, Poggi A, Santini D, Speranza I, Bianco V, Simeoni F. A rare case of primary lymphoma of the breast and metachronous breast primitive lobular carcinoma: case report. *Eur J Gynaecol Oncol* (**IF 0,215**) 1997;18(6):511-2. PMID: 9443024. **Cit. 3**
575. Marchei P, Simeoni F, Bianco V, Santini D, Balducci M, Vecchione A, Frati L. Assistenza extraospedaliera al paziente oncologico terminale. Aspetti clinico-organizzativi. Nostra esperienza [Out-of-the-hospital care for terminal cancer patients. Clinical and organizational features. Our experience] *Minerva Med* (**IF 1,202**) 1997 Jan-Feb;88(1-2):25-30. Italian. PMID: 9132628. **Cit. 0**
576. Marchei P, Bianco V, Pignatelli E, Chiadini S, Santini D, Carico E, Marchei M, Vecchione A. Adjuvant treatment for breast cancer in the elderly. *Anticancer Res* (**IF 1,994**) 1996 Mar-Apr;16(2):911-3. PMID: 8687150. **Cit. 3**

577. Marchei P, Santini D, Bianco V, Chiadini S, Reale MG, Simeoni F, Marchei GG, Vecchione A. Serum ostase in the follow-up of breast cancer patients. *Anticancer Res* (**IF 1,994**) 1995 Sep-Oct;15(5B):2217-22. PMID: 8572628. **Cit. 9**
578. Reale MG, Santini D, Marchei GG, Manna A, Del Nero A, Bianco V, Marchei P, Frati L. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer. *Int J Biol Markers* (**IF 1,9**) 1995 Jan-Mar;10(1):42-6. PMID: 7629426. **Cit. 10**
579. Santini D, Simeoni F, Bianco V, Chiadini S, Speranza I, Pignatelli E, Marchei P. Terapia del seminoma I stadio. Revisione critica [Treatment of stage-I seminoma. Critical review]. *Minerva Urol Nefrol* (**IF 3,548**) 1995 Mar;47(1):31-8. Italian. PMID: 7570258. **Cit. 0**
580. Santini D, Marchei GG, Trasatti L, Di Seri M, Reale MG, Frati I. Utilità del dosaggio del 5NU unitamente al CA 19-9 nella diagnostica e nel monitoraggio delle affezioni epatiche discariocinetiche [Usefulness of the determination of 5NU together with CA 19-9 in the diagnosis and monitoring of dyskaryokinetic liver diseases]. *J Nucl Med Allied Sci* (**NO IF**). 1990 Oct-Dec;34(4 Suppl):291. Italian. PMID: 2092138. **Cit. 0**
581. Marchei P, Cifaldi L, De Benedetto A, Santini D, Manna A, Trasatti L, Marchei GG, Reale MG. Valutazione clinica dell'efficacia dell'associazione dei markers sierici CEA, CA 19.9, CA 72.4 come indici di neoplasia del tratto gastro-intestinale [Clinical evaluation of the efficacy of the combined determination of serum markers CEA, CA 19.9, CA 72.4 as indexes of gastro-intestinal tract neoplasms]. *G Ital Oncol* (**NO IF**). 1990 Oct-Dec;10(4):121-4. Italian. PMID: 2093080. **Cit. 0**